Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.3.16 - protein-serine/threonine phosphatase and Organism(s) Homo sapiens and UniProt Accession O95278

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abducens Nerve Diseases
Isolated diplopia associated with calcineurin inhibitor therapy in a patient with idiopathic membranous nephropathy: a case report.
Acanthoma
Anogenital epidermolytic acanthomas: effective treatment of pruritus with 0.1% tacrolimus ointment.
Acidosis
A kinase-anchoring protein 150 and calcineurin are involved in regulation of acid-sensing ion channels ASIC1a and ASIC2a.
Acid-sensing ion channel 1a mediates acid-induced pyroptosis through calpain-2/calcineurin pathway in rat articular chondrocytes.
Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen.
Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients.
Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts.
Direct evidence for calcineurin binding to the exon-7 loop of the sodium-bicarbonate cotransporter NBCn1.
Extracellular presence of IL-8 in the astrocyte-rich cultured cerebellar granule cells under acidosis.
Fludrocortisone-a treatment for tubulopathy post-paediatric renal transplantation: A national paediatric nephrology unit experience.
Maximizing growth in children after renal transplantation.
Post-Renal Transplant Metabolic Acidosis: A Neglected Entity.
Posttransplant acidosis and associated disorders of mineral metabolism in patients with a renal graft.
Specific disruption of calcineurin-signaling in the distal convoluted tubule impacts the transcriptome and proteome, and causes hypomagnesemia and metabolic acidosis.
The Calcineurin inhibitor FK506 (Tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport.
Acidosis, Renal Tubular
Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients.
Direct evidence for calcineurin binding to the exon-7 loop of the sodium-bicarbonate cotransporter NBCn1.
Post-Renal Transplant Metabolic Acidosis: A Neglected Entity.
Acne Vulgaris
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Acquired Hyperostosis Syndrome
Exosomal proteome from the serum, bone marrow, and palm and toe pustular skin tissues of a single patient with SAPHO syndrome.
Acute Coronary Syndrome
Deconvoluting the Dual Antiplatelet Activity of a Plant Extract.
Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory.
Acute Kidney Injury
Acute Kidney Injury as a Complication of Cardiac Transplantation: Incidence, Risk Factors, and Impact on 1-year Mortality and Renal Function.
Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy.
Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection.
Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
Complications of Solid Organ Transplantation: Cardiovascular, Neurologic, Renal, and Gastrointestinal.
Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report.
End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation.
Growth failure associated with sirolimus: case report.
Identification of patients best suited for combined liver-kidney transplantation: part II.
Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.
Long-term results of liver transplantation.
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Mini-review of kidney disease following hematopoietic stem cell transplant?.
MiRNAs in kidney transplantation: potential role as new biomarkers.
Outcomes after liver transplantation: Chronic kidney disease.
Post transplant thrombotic microangiopathy causing acute renal failure.
Posttransplantation chronic renal damage in nonrenal transplant recipients.
Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation.
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Renal Biopsy in Children-Effect on Treatment Decisions: A Single-Center Experience.
Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience.
Rho GTPases in kidney physiology and diseases.
Tacrolimus Aggravated Tube Feeding Syndrome with Acute Renal Failure in a Pediatric Liver Transplant Recipient.
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Acute Lung Injury
miR-21-5p Suppresses Mitophagy to Alleviate Hyperoxia-Induced Acute Lung Injury by Directly Targeting PGAM5.
Adenocarcinoma
Abrogation of DUSP6 by hypermethylation in human pancreatic cancer.
Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
BH-protocadherin-c, a member of the cadherin superfamily, interacts with protein phosphatase 1 alpha through its intracellular domain.
Chemokine (C-C) motif ligand 20 is regulated by PGF(2?)-F-prostanoid receptor signalling in endometrial adenocarcinoma and promotes cell proliferation.
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17?-estrodial-induced cell growth in endometrial adenocarcinoma cell.
Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma.
Increased expression of calcineurin in human colorectal adenocarcinomas.
Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.
Key genes in lung cancer translational research: a meta-analysis.
Molecular mechanisms of pancreatic carcinogenesis.
Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma.
Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells.
Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.
Adenocarcinoma of Lung
APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.
Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways.
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.
miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma.
Overexpression of immunoglobulin (CD79a) binding protein1 (IGBP-1) in small lung adenocarcinomas and its clinicopathological significance.
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Survivin mediates self-protection through ROS/cdc25c/CDK1 signaling pathway during tumor cell apoptosis induced by high fluence low-power laser irradiation.
Adenocarcinoma, Clear Cell
Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Adenomatous Polyposis Coli
Adenomatous polyposis coli heterozygous knockout mice display hypoactivity and age-dependent working memory deficits.
Adenomatous Polyps
Premature chromosome condensation revisited: a novel chemical approach permits efficient cytogenetic analysis of cancers.
Adenomyosis
Loss of Expressions of Dusp6, Sprouty4, and Sef, Negative Regulators of FGF2/ERK1/2 Signaling, in the Endometrium of Women With Adenomyosis.
African Swine Fever
African swine fever virus A238L inhibitor of NF-kappaB and of calcineurin phosphatase is imported actively into the nucleus and exported by a CRM1-mediated pathway.
African swine fever virus protein A238L interacts with the cellular phosphatase calcineurin via a binding domain similar to that of NFAT.
Domains involved in calcineurin phosphatase inhibition and nuclear localisation in the African swine fever virus A238L protein.
Agammaglobulinemia
Evolution of immunoglobulin and mannose binding protein levels after renal transplantation: association with infectious complications.
Albuminuria
Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
aldehyde dehydrogenase (nad+) deficiency
Aldehyde dehydrogenase 2 knockout accentuates ethanol-induced cardiac depression: Role of protein phosphatases.
Alopecia
Frontal fibrosing alopecia demographics: a survey of 29 patients.
Immunosuppressive treatment for proliferative lupus nephritis.
Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials.
Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control.
alpha-Thalassemia
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Alzheimer Disease
A pool of beta-tubulin is hyperphosphorylated at serine residues in Alzheimer disease brain.
A role for calcineurin in Alzheimer's disease.
A zebrafish model for calcineurin-dependent brain function.
Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms.
Activation of Protein Phosphatase 2B and Hyperphosphorylation of Tau in Alzheimer's Disease.
Acute decrease in alkaline phosphatase after brain injury: A potential mechanism for tauopathy.
Altered expression of insulin-degrading enzyme and regulator of calcineurin in the rat intracerebral streptozotocin model and human apolipoprotein E-?4-associated Alzheimer's disease.
Alzheimer's Disease, Dendritic Spines, and Calcineurin Inhibitors: A New Approach?
Calcineurin (phosphatase 2B) is present in neurons containing neurofibrillary tangles and in a subset of senile plaques in Alzheimer's disease.
Calcineurin immunoreactivity in Alzheimer's disease.
Calcineurin inhibition rescues early synaptic plasticity deficits in a mouse model of Alzheimer's disease.
Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models.
Calcineurin: directing the damage in Alzheimer disease: An Editorial for 'Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain' on doi: 10.1111/jnc.14469.
Calpain activation in okadaic-acid-induced neurodegeneration.
Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder.
Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease.
Cognitive Decline in Alzheimer's Disease Is Associated with Selective Changes in Calcineurin/NFAT Signaling.
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme.
Cytoskeletal changes in the brains of mice lacking calcineurin A alpha.
Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways.
Dehydroevodiamine attenuates calyculin A-induced tau hyperphosphorylation in rat brain slices.
Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A.
Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease.
Deprotonation states of the two active site water molecules regulate the binding of protein phosphatase 5 with its substrate: A molecular dynamics study.
Differential activation of caspase-3 at two maturational stages during okadaic acid-induced rat neuronal death.
Dimethyl Fumarate Exerts Neuroprotection by Modulating Calcineurin/NFAT1 and NF?B Dependent BACE1 Activity in a Neuronal Model of Alzheimer's Disease.
DSCR1(Adapt78)--a Janus gene providing stress protection but causing Alzheimer's disease?
Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat.
Elevated protein levels of protein phosphatases PP-2A and PP-2B in astrocytes of Alzheimer's disease temporal cortex.
Enhanced expression of protein phosphatase 2A associated with hyper-phosphorylation of histone H1 in Alzheimer's disease brain.
Evidence for colocalization of calcineurin and calcium channels in dorsal root ganglion neurons.
Expression of calcipressin1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer's disease.
Expression of protein phosphatases (PP-1, PP-2A, PP-2B and PTP-1B) and protein kinases (MAP kinase and P34cdc2) in the hippocampus of patients with Alzheimer disease and normal aged individuals.
Fecal corticosterone levels in RCAN1 mutant mice.
Fine mapping of calcineurin (PPP3CA) gene reveals novel alternative splicing patterns, association of 5'UTR trinucleotide repeat with addiction vulnerability, and differential isoform expression in Alzheimer's disease.
Genetic variation in the tau protein phosphatase-2A pathway is not associated with Alzheimer's disease risk.
Glycogen synthase kinase-3? regulates leucine-309 demethylation of protein phosphatase-2A via PPMT1 and PME-1.
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.
Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts.
Increased production of paired helical filament epitopes in a cell culture system reduces the turnover of tau.
Inhibition of calcineurin by infusion of CsA causes hyperphosphorylation of tau and is accompanied by abnormal behavior in mice.
Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices.
Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats.
Inhibition of protein phosphatases induces transport deficits and axonopathy.
Inhibition of the NFAT pathway alleviates amyloid Beta neurotoxicity in a mouse model of Alzheimer's disease.
Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine.
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Knockdown of microRNA-195 contributes to protein phosphatase-2A inactivation in rats with chronic brain hypoperfusion.
Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I(2)(PP2A)/SET.
Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment.
Memantine mediates astrocytic activity in response to excitotoxicity induced by PP2A inhibition.
Mitophagy in degenerative joint diseases.
Neuroimmunomodulation by calcineurin in aging and Alzheimer's disease.
Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain.
Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.
Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease.
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease [corrected]
Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain.
Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease.
Phosphoprotein phosphatase activities in Alzheimer disease brain.
Protein kinase A phosphorylates Down syndrome critical region 1 (RCAN1).
Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta.
PTPA activates protein phosphatase-2A through reducing its phosphorylation at tyrosine-307 with upregulation of protein tyrosine phosphatase 1B.
Q134R: Small chemical compound with NFAT inhibitory properties improves behavioral performance and synapse function in mouse models of amyloid pathology.
RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration.
Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors.
Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes.
Reduction of mint-1, mint-2, and APP overexpression in okadaic acid-treated neurons.
Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis.
Regulator of Calcineurin (RCAN-1) Regulates Thermotaxis Behavior in Caenorhabditis elegans.
Regulator of calcineurin 1 is a novel RNA-binding protein to regulate neuronal apoptosis.
Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain.
Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex.
Ser9 phosphorylation causes cytoplasmic detention of I(2)(PP2A)/SET in Alzheimer disease.
Silencing PP2A Inhibitor by Lenti-shRNA Interference Ameliorates Neuropathologies and Memory Deficits in tg2576 Mice.
Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3? Signaling in Human Tau Transgenic Mice.
Site-specific regulation of Alzheimer-like tau phosphorylation in living neurons.
Substituent effect of N-benzylated gramine derivatives that prevent the PP2A inhibition and dissipate the neuronal Ca2+ overload, as a multitarget strategy for the treatment of Alzheimer's disease.
Tacrolimus Protects against Age-Associated Microstructural Changes in the Beagle Brain.
The calcineurin inhibitor Sarah (Nebula) exacerbates A?42 phenotypes in a Drosophila model of Alzheimer's disease.
The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
The Neuroprotective Effects of Ginsenosides on Calcineurin Activity and Tau Phosphorylation in SY5Y Cells.
The new indirubin derivative inhibitors of glycogen synthase kinase-3, 6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons.
The polarity of the amino acid residue 118 of calcineurin B is closely linked to calcineurin enzyme activity.
The regulator of calcineurin 1 increases adenine nucleotide translocator 1 and leads to mitochondrial dysfunctions.
Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain.
Two polymorphisms of RCAN1 gene associated with Alzheimer's disease in the Chinese Han population.
Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray.
Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease.
Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study.
Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation.
[Expression of protein phosphatase 2AC in the brain of mice and Alzheimer's patients].
Amnesia
Differential expression of molecular markers of synaptic plasticity in the hippocampus, prefrontal cortex, and amygdala in response to spatial learning, predator exposure, and stress-induced amnesia.
Amyloidosis
Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.
Amyotrophic Lateral Sclerosis
Calcineurin A and calbindin immunoreactivity in the spinal cord of G93A superoxide dismutase transgenic mice.
Impaired Cu-Zn Superoxide Dismutase (SOD1) and Calcineurin (Cn) Interaction in ALS: A Presumed Consequence for TDP-43 and Zinc Aggregation in Tg SOD1
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Overexpressed mutant G93A superoxide dismutase protects calcineurin from inactivation.
Oxidative inactivation of calcineurin by Cu,Zn superoxide dismutase G93A, a mutant typical of familial amyotrophic lateral sclerosis.
Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord.
Superoxide dismutase mutations of familial amyotrophic lateral sclerosis and the oxidative inactivation of calcineurin.
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Wild-type p53-induced phosphatase 1 down-regulation promotes apoptosis by activating the DNA damage-response pathway in amyotrophic lateral sclerosis.
Anaphylaxis
Endothelial Regulator of Calcineurin 1 Promotes Barrier Integrity and Modulates Histamine-Induced Barrier Dysfunction in Anaphylaxis.
Successful switch to oral tacrolimus in a patient with hypersensitivity reaction to parenteral vitamin K, cyclosporine, and tacrolimus: A case report.
Anemia
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state.
Early non-immunological post transplant complications: a single center experience.
Evolution of glomerular filtration rate, renal injury markers, anemia, and Angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Impact of donor-related arteriosclerosis in pretransplant biopsy on long-term outcome of living-kidney transplantation: A propensity score-matched cohort study.
Increasing incidence of post-kidney transplant anemia in children.
Microcytic anemia associated with mTOR or calcineurin inhibition: An unusual situation after allogeneic hematopoietic stem cell transplantation.
Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis.
Mutation of chicken anemia virus VP2 differentially affects serine/threonine and tyrosine protein phosphatase activities.
Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil.
Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report.
Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report.
Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
[Chronic renal failure after heart, lung, liver, or intestine transplantation]
Anemia, Aplastic
Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia.
Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation.
Anemia, Hemolytic, Autoimmune
Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor.
Anemia, Hypochromic
NH4+ Toxicity, Which Is Mainly Determined by the High NH4+/K+ Ratio, Is Alleviated by CIPK23 in Arabidopsis.
Aneurysm
The elevated serum levels of calcineurin and nuclear factor of activated T-cells 1 in children with Kawasaki disease.
Angina, Stable
Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma.
Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?
Angina, Unstable
Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.
Angioedema
Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient.
Ankylosis
The intracellular protein phosphatase magnesium-dependent 1A negatively regulates osteoclast commitment.
Anthrax
Calyculin A sensitive protein phosphatase is required for Bacillus anthracis lethal toxin induced cytotoxicity.
Regulatory interactions of a virulence-associated serine/threonine phosphatase-kinase pair in Bacillus anthracis.
Aortic Coarctation
Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: involvement of calcineurin and mitogen-activated protein kinase signalings.
Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: Involvement of calcineurin and mitogen-activated protein kinase signalings.
Aortic Valve Stenosis
Calcineurin in human heart hypertrophy.
Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin.
Upregulation of myocardial estrogen receptors in human aortic stenosis.
Arrhythmias, Cardiac
Aberrant sialylation causes dilated cardiomyopathy and stress-induced heart failure.
Drug-induced alterations in Mg2+ homoeostasis.
Heart-specific deletion of CnB1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function.
Arteriolosclerosis
A case of de novo focal segmental glomerulosclerosis occurred one and half years after kidney transplantation supposed to be caused by calcineurin inhibitor.
Arteriosclerosis
Differential impact of belatacept and cyclosporine A on central aortic blood pressure and arterial stiffness after renal transplantation.
Impact of donor-related arteriosclerosis in pretransplant biopsy on long-term outcome of living-kidney transplantation: A propensity score-matched cohort study.
Influence of preservation method on histopathological lesions of kidney allografts.
Arteritis
Calcineurin inhibitors exacerbate coronary arteritis via the MyD88 signalling pathway in a murine model of Kawasaki disease.
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Arthritis
Acid-sensing ion channel 1a mediates acid-induced pyroptosis through calpain-2/calcineurin pathway in rat articular chondrocytes.
Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISA(TX)247.
Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis.
Calcineurin is expressed and plays a critical role in inflammatory arthritis.
Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-? Transgenic Mice.
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
Dual-specificity phosphatase 5 attenuates autoimmune arthritis in mice via reciprocal regulation of the Th17/Treg cell balance and inhibition of osteoclastogenesis.
Regulator of Calcineurin 3 Ameliorates Autoimmune Arthritis by Suppressing Th17 Cell Differentiation.
Specific calcineurin targeting in macrophages confers resistance to inflammation via MKP-1 and p38.
Arthritis, Experimental
Calcineurin is expressed and plays a critical role in inflammatory arthritis.
Arthritis, Rheumatoid
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Cabin1 regulates inflammatory responses and fibroblast-like synoviocytes apoptosis in mice with collagen-induced arthritis.
Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis.
Calcineurin is expressed and plays a critical role in inflammatory arthritis.
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus.
Midterm clinico-radiologic findings of an open label observation study of add-on tacrolimus with biologics or non-biologic DMARDs.
Overexpression of miR-101 May Target DUSP1 to Promote the Cartilage Degradation in Rheumatoid Arthritis.
Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study.
Protein phosphatase magnesium-dependent 1A induces inflammation in rheumatoid arthritis.
Tacrolimus treatment increases bone formation in patients with rheumatoid arthritis.
Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.
The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases.
Aspergillosis
Calcineurin-dependent dephosphorylation of the transcription factor CrzA at specific sites controls conidiation, stress tolerance, and virulence of Aspergillus fumigatus.
Identification and mutational analyses of phosphorylation sites of the calcineurin-binding protein CbpA and the identification of domains required for calcineurin binding in Aspergillus fumigatus.
Impaired calcineurin signaling in myeloid cells results in downregulation of pentraxin-3 and increased susceptibility to aspergillosis.
Newer combination antifungal therapies for invasive aspergillosis.
Asthma
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects.
Allergic disease after pediatric liver transplantation with systemic tacrolimus and cyclosporine a therapy.
Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma.
Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients.
Effects of variations in access to care for children with atopic dermatitis.
Epigenome-wide effects of vitamin D on asthma bronchial epithelial cells.
Mast cells as targets of pimecrolimus.
MiR-1165-3p Suppresses Th2 Differentiation via Targeting IL-13 and PPM1A in a Mouse Model of Allergic Airway Inflammation.
Protein phosphatase 5 mediates corticosteroid insensitivity in airway smooth muscle in patients with severe asthma.
Regulator of calcineurin 1 (rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice.
Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma.
The GPx1-PTP1B-PP2A Axis: A Key Determinant of Airway Inflammation and Alveolar Destruction.
[Cross-talk between calcineurin and protein kinases in airway remodeling in asthma]
Astrocytoma
Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
Ataxia
An autosomal recessive cerebellar ataxia syndrome with upward gaze palsy, neuropathy, and seizures.
PLS3 Overexpression Delays Ataxia in Chp1 Mutant Mice.
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Ataxia Telangiectasia
Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
Absence of Wip1 partially rescues Atm deficiency phenotypes in mice.
Activation of NRF2 by dexamethasone in ataxia telangiectasia cells involves KEAP1 inhibition but not the inhibition of p38.
Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition.
Mice lacking protein phosphatase 5 are defective in ataxia telangiectasia mutated (ATM)-mediated cell cycle arrest.
P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Phosphoglycerate mutase 1 (PGAM1) overexpression promotes radio- and chemoresistance in gliomas by activating the DNA damage response.
r-Tocotrienol inhibits cell proliferation of human gastric cancer by regulating nuclear factor-kB activity.
The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Utilizing protein phosphatase inhibitors to define PP2A as a regulator of ataxia-telangiectasia mutated.
Wild-type p53-induced phosphatase 1 down-regulation promotes apoptosis by activating the DNA damage-response pathway in amyotrophic lateral sclerosis.
Atherosclerosis
Association of astragaloside IV-inhibited autophagy and mineralization in vascular smooth muscle cells with lncRNA H19 and DUSP5-mediated ERK signaling.
Association of CnB 5I/5D promoter gene polymorphism and serum calcineurin levels in early onset of coronary artery disease of south Indian cohort.
Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway.
Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity.
Protein Phosphatase 5 Contributes to the Overexpression of Epigenetically Regulated T-Lymphocyte Genes in Patients with Lupus.
RCAN1 in cardiovascular diseases: molecular mechanisms and a potential therapeutic target.
Regulation of gene expression by cyclic GMP.
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
Unsaturated fatty acids isolated from human lipoproteins activate protein phosphatase type 2Cbeta and induce apoptosis in endothelial cells.
Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5'-monophosphate-activated protein kinase/mammalian target of rapamycin complex 1 pathway.
WIP-ing out atherosclerosis with autophagy.
[Current trends in renal transplant immunosuppression]
Atrial Fibrillation
Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation.
Calcium- and integrin-binding protein-1 and calcineurin are upregulated in the right atrial myocardium of patients with atrial fibrillation.
Calpain-Calcineurin-Nuclear Factor Signaling and the Development of Atrial Fibrillation in Patients with Valvular Heart Disease and Diabetes.
Mechanisms underlying pathological Ca2+ handling in diseases of the heart.
Serine-threonine protein phosphatase regulation of Cx43 dephosphorylation in arrhythmogenic disorders.
[Calpain-2 and calcineurin protein expression in right atrial appendages from patients underwent valve replacement with or without atrial fibrillation].
Atrioventricular Block
Heart block in mice overexpressing calcineurin but not NF-AT3.
Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog.
Atypical Hemolytic Uremic Syndrome
Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen.
Autoimmune Diseases
A new cell-permeable peptide allows successful allogeneic islet transplantation in mice.
A review and update on orphan drugs for the treatment of noninfectious uveitis.
Calcineurin inhibitors: status quo and perspectives.
CD44-Positive Glomerular Parietal Epithelial Cells in a Mouse Model of Calcineurin Inhibitors-Induced Nephrotoxicity.
Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.
Cyclosporine A disposition, hepatic and renal tolerance in Wistar rat.
Fibrosis caused by loss of PTEN expression by fibroblasts is crucially dependent on CCN2.
Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus.
Improvement of irregularity of brain vessel walls in systemic lupus erythematosus by tacrolimus.
MAP4K Family Kinases and DUSP Family Phosphatases in T-Cell Signaling and Systemic Lupus Erythematosus.
New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.
Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.
The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.
The novel calcineurin inhibitor CN585 has potent immunosuppressive properties in stimulated human T cells.
The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases.
To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.
Transplantation of the islets of Langerhans: new hope for treatment of type 1 diabetes mellitus.
Use of three-carbon chain compounds as biosynthesis precursors to enhance tacrolimus production in Streptomyces tsukubaensis.
USP16-mediated deubiquitination of calcineurin A controls peripheral T cell maintenance.
YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy.
[Novel action of aldosterone in CsA nephrotoxicity]
[Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice].
Azoospermia
DNA damage in round spermatids of mice with a targeted disruption of the Pp1cgamma gene and in testicular biopsies of patients with non-obstructive azoospermia.
Bacterial Infections
Characterization of calcineurin A and B genes in the abalone, Haliotis diversicolor, and their immune response role during bacterial infection.
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.1 Differential diagnosis of chronic graft dysfunction.
Immunosuppression reduction in kidney transplant recipients during bacterial infection-A retrospective study.
In vivo modulation of innate resistance to Edwardsiella ictaluri with a phosphatase inhibitor.
Balanitis
Anti-inflammatory treatment.
Discordant results with pimecrolimus 1% cream in the treatment of plasma cell balanitis.
Successful treatment of plasma cell cheilitis with topical tacrolimus: Report of two cases.
Tacrolimus 0.1% ointment: is it really effective in plasma cell vulvitis? Report of four cases.
Therapeutic efficacy of topical calcineurin inhibitors in plasma cell balanitis: case series and review of the literature.
beta-Thalassemia
Graft Versus Host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta Thalassemia Major with Busulfan, Fludarabine, and Thiotepa.
Imaging findings in a child with calcineurin inhibitor-induced pain syndrome after bone marrow transplant for beta thalassemia major.
The relation between mitogen activated protein kinase (MAPK) pathway and different genes expression in patients with beta Thalassemia.
Blindness
Prevalence and associated phenotypes of DUSP6, IL17RD and SPRY4 variants in a large Chinese cohort with isolated hypogonadotropic hypogonadism.
Blister
Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
Identification and biochemical characterization of protein phosphatase 5 from the cantharidin-producing blister beetle, Epicauta chinensis.
Morphological changes and reorganization of actinfilaments in human myeloid leukemia cells induced by a novel protein phosphatase inhibitor, tautomycin.
Bone Diseases
Calcium-Phosphate Crystals Promote RANKL Expression via the Downregulation of DUSP1.
CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health.
Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet.
Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients.
[Effects of kidney transplantation on bone: osteoporosis or other?]
Bone Diseases, Metabolic
Egyptian clinical practice guideline for kidney transplantation.
Hepatitis C: liver transplantation.
Bone Resorption
Cellular and molecular consequences of calcineurin A alpha gene deletion.
Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption.
Effects of cyclosporine on osteoclast activity: inhibition of calcineurin activity with minimal effects on bone resorption and acid transport activity.
Finely-Tuned Calcium Oscillations in Osteoclast Differentiation and Bone Resorption.
Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients.
Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease.
Inhibitory effect of okadaic acid on bone resorption in neonatal mouse calvaria in vitro. Protein dephosphorylation as an important regulatory mechanism in the bone resorption process.
Molecular cloning, expression, and function of osteoclastic calcineurin Aalpha.
Protein phosphatase inhibitors and bone resorption: inhibition by okadaic acid and biphasic actions of calyculin-A.
Bradycardia
Heart block in mice overexpressing calcineurin but not NF-AT3.
Brain Death
Oral Preconditioning of Donors After Brain Death With Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation.
PP2Ac upregulates PI3K-Akt signaling and induces hepatocyte apoptosis in liver donor after brain death.
The effects of brain death and ischemia on tolerance induction are organ-specific.
Brain Diseases
Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation.
Basiliximab for posterior reversible encephalopathy syndrome after lung transplantation.
Brain MR imaging abnormalities in kidney transplant recipients.
Calcineurin inhibitor encephalopathy can develop years post lung transplantation.
Calcineurin inhibitor encephalopathy.
Calcineurin inhibitor-free strategies for prophylaxis and treatment of GVHD in children with posterior reversible encephalopathy syndrome after stem cell transplantation.
Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review.
Clinical and Genetic Study on a Chinese Patient with Infantile Onset Epileptic Encephalopathy carrying a PPP3CA Null Variant: a case report.
Early-onset infant epileptic encephalopathy associated with a de novo PPP3CA gene mutation.
Evidence for colocalization of calcineurin and calcium channels in dorsal root ganglion neurons.
MiR-363-3p attenuates neonatal hypoxic-ischemia encephalopathy by targeting DUSP5.
Neurologic complications after liver transplantation.
Neurologic complications in renal transplantation.
Neurologic Complications of Transplantation.
Neurotoxicity including posterior reversible encephalopathy syndrome after initiation of calcineurin inhibitors in transplanted methylmalonic acidemia patients: Two case reports and review of the literature.
Novel calcineurin A (PPP3CA) variant associated with epilepsy, constitutive enzyme activation and downregulation of protein expression.
Persistent accumulation of unrepaired DNA damage in rat cortical neurons: nuclear organization and ChIP-seq analysis of damaged DNA.
Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Posterior reversible encephalopathy syndrome after liver transplantation in children: a rare complication related to calcineurin inhibitor effects.
Posterior Reversible Encephalopathy Syndrome After Orthotopic Heart Transplantation: A Case Report.
Posterior reversible encephalopathy syndrome due to immunosuppressant after living-donor lobar lung transplantation: report of a case.
Posterior reversible encephalopathy syndrome in children with kidney disease.
Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.
Reversible leukoencephalopathy syndrome associated to leukopenia in a chronic hemodialysis patient.
Risk Factor and Long-Term Outcome Analyses for Acute Limbic Encephalitis and Calcineurin Inhibitor-Induced Encephalopathy in Adults following Allogeneic Hematopoietic Cell Transplantation.
Seizure treatment in transplant patients.
Structure of the gene coding for calcineurin B (PPP3R1) and mapping to D2S358-D2S1778 (chromosomal region 2p15).
Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.
Tacrolimus-Induced Vision Loss in a Renal Transplant Patient: Posterior Reversible Encephalopathy Syndrome.
[Retrospective analysis of posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation]
Brain Edema
A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke.
Brain Infarction
Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury.
Brain Injuries
A Combined Proteomics and Bioinformatics Approach Reveals Novel Signaling Pathways and Molecular Targets After Intracerebral Hemorrhage.
A significant increase in both basal and maximal calcineurin activity following fluid percussion injury in the rat.
Butylphthalide ameliorates experimental autoimmune encephalomyelitis by suppressing PGAM5-induced necroptosis and inflammation in microglia.
Calcium/calcineurin signaling in primary cortical astrocyte cultures: Rcan1-4 and cyclooxygenase-2 as NFAT target genes.
MEK/ERK- and calcineurin/NFAT-mediated mechanism of cerebral hyperemia and brain injury following NMDA receptor activation.
Proteomic analysis of alterations induced by perinatal hypoxic-ischemic brain injury.
Quercetin protects against cerebral ischemia/reperfusion and oxygen glucose deprivation/reoxygenation neurotoxicity.
Search for novel gene markers of traumatic brain injury by time differential microarray analysis.
TRPM7 Mediates Neuronal Cell Death Upstream of Calcium/Calmodulin-Dependent Protein Kinase II and Calcineurin Mechanism in Neonatal Hypoxic-Ischemic Brain Injury.
Variation in PPP3CC Genotype Is Associated with Long-Term Recovery after Severe Brain Injury.
WIP1 Phosphatase Plays a Critical Neuroprotective Role in Brain Injury Induced by High-Altitude Hypoxic Inflammation.
Brain Injuries, Traumatic
A persistent change in subcellular distribution of calcineurin following fluid percussion injury in the rat.
A significant increase in both basal and maximal calcineurin activity following fluid percussion injury in the rat.
EXPRESSION OF PROTEIN PHOSPHATASE 2B (CALCINEURIN) SUBUNIT A ISOFORMS IN RAT HIPPOCAMPUS FOLLOWING A TRAUMATIC BRAIN INJURY.
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
Regional calcineurin subunit B isoform expression in rat hippocampus following a traumatic brain injury.
The combination of either tempol or FK506 with delayed hypothermia: implications for traumatically induced microvascular and axonal protection.
Variation in PPP3CC Genotype Is Associated with Long-Term Recovery after Severe Brain Injury.
Brain Ischemia
Calcineurin activity in children with Mental handicap.
Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder.
Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia.
Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia.
Ginkgo biloba extract (EGb761) and FK506 preserve energy metabolites in the striatum during focal cerebral ischemia and reperfusion in gerbils monitored by microdialysis.
Interplay between the gamma isoform of PKC and calcineurin in regulation of vulnerability to focal cerebral ischemia.
miR-330 regulates Drp-1 mediated mitophagy by targeting PGAM5 in a rat model of permanent focal cerebral ischemia.
Neuroprotection of gamma-aminobutyric acid receptor agonists via enhancing neuronal nitric oxide synthase (Ser847) phosphorylation through increased neuronal nitric oxide synthase and PSD95 interaction and inhibited protein phosphatase activity in cerebral ischemia.
Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism.
Pathophysiological relevance of forkhead transcription factors in brain ischemia.
Potential role of calcineurin for brain ischemia and traumatic injury.
Protein phosphatase 2A-negative regulation of the protective signaling pathway of Ca2+/CaM-dependent ERK activation in cerebral ischemia.
Protein phosphatase-2A is activated in pig brain following cardiac arrest and resuscitation.
Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology.
[Effects of 3-N-butylphthalide on cortical calcineurin and calpain activities in focal cerebral ischemia rats]
[Involvement of calcineurin A alpha and A beta in neuronal death in a gerbil model of cerebral ischemia]
Brain Neoplasms
Calcineurin as a neuronal marker of human brain tumors.
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1.
Reversible hyperphosphorylation and reorganization of vimentin intermediate filaments by okadaic acid in 9L rat brain tumor cells.
Breast Neoplasms
A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells.
A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors.
Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells.
Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Cloning of a cDNA encoding an isoform of human protein phosphatase inhibitor 2 from vascularized breast tumor.
Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
Delayed mammary gland involution in MMTV-AKT1 transgenic mice.
Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.
Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720.
Detectible mosaic truncating PPM1D mutations, age and breast cancer risk.
Differential Roles for DUSP Family Members in Epithelial-to-Mesenchymal Transition and Cancer Stem Cell Regulation in Breast Cancer.
Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester.
Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells.
Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk.
Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer.
Erratum: Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.
Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line.
Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.
Hereditary breast cancer; Genetic penetrance and current status with BRCA.
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1.
Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively.
Identification of differentially expressed genes after PPM1D silencing in breast cancer.
IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells.
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Integrative transcriptome and proteome study to identify the signaling network regulated by POPX2 phosphatase.
Investigation of POPX2 phosphatase functions by comparative phosphoproteomic analysis.
Investigation of two Wnt signalling pathway single nucleotide polymorphisms in a breast cancer-affected Australian population.
KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
Knockdown of protein phosphatase 5 (PPP5C) suppresses the growth of leukemic cell line U937.
Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.
Micro-RNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1): New Signaling Route Through Which Transforming Growth Factor-Beta Mediates the Migration and Actin Dynamics of Breast Cancer Cells.
MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
Mouse 4T1 Breast Cancer Cell-Derived Exosomes Induce Proinflammatory Cytokine Production in Macrophages via miR-183.
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase.
Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase.
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Older breast cancer survivors may harbor hereditary cancer predisposition pathogenic variants and are at risk for clonal hematopoiesis.
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23.
Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
Plasma membrane calcium ATPase isoform 4 inhibits vascular endothelial growth factor-mediated angiogenesis through interaction with calcineurin.
POPX2 is a novel LATS phosphatase that regulates the Hippo pathway.
POPX2 phosphatase regulates apoptosis through the TAK1-IKK-NF-?B pathway.
PPM1B depletion in U2OS cells supresses cell growth through RB1-E2F1 pathway and stimulates bleomycin-induced cell death.
PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
Pro-necrotic molecules impact local immunosurveillance in human breast cancer.
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.
Protein phosphatase magnesium-dependent 1? (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma.
Protein phosphatase Mg2+/Mn2+ dependent 1F promotes smoking-induced breast cancer by inactivating phosphorylated-p53-induced signals.
Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks.
PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model.
Puerarin promotes DUSP1 expression by regulating miR?133a?3p in breast cancer.
Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer.
Ras and TGF-? signaling enhance cancer progression by promoting the ?Np63 transcriptional program.
Reduced expression of the regulatory A subunit of serine/threonine protein phosphatase 2A in human breast cancer MCF-7 cells.
Requirement of protein phosphatase 2A for recruitment of IQGAP1 to Rac-bound beta1 integrin.
Retraction note to: Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.
SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment.
Silencing of DUSP6 gene by RNAi-mediation inhibits proliferation and growth in MDA-MB-231 breast cancer cells: an in vitro study.
Small Intestine Posttransplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report.
Sodium cantharidate induces apoptosis in breast cancer cells by regulating energy metabolism via the protein phosphatase 5-p53 axis.
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
The 17q23 amplicon and breast cancer.
The catalytic subunit of protein phosphatase 2A is carboxyl-methylated in vivo.
The Clinical Significance of PPEF1 as a Promising Biomarker and Its Potential Mechanism in Breast Cancer.
The Discodermia calyx Toxin Calyculin A Enhances Cyclin D1 Phosphorylation and Degradation, and Arrests Cell Cycle Progression in Human Breast Cancer Cells.
The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
The interaction between endogenous calcineurin and the plasma membrane calcium-dependent ATPase is isoform specific in breast cancer cells.
The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.
The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression.
The POPX2 phosphatase regulates cancer cell motility and invasiveness.
The protein phosphatase 4 - PEA15 axis regulates the survival of breast cancer cells.
The retinoid anticancer signal: mechanisms of target gene regulation.
The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus.
The role of dual?specificity phosphatase 1 and protein phosphatase 1 in ?2?adrenergic receptor?mediated inhibition of extracellular signal regulated kinase 1/2 in triple negative breast cancer cell lines.
The role of PPM1D in cancer and advances in studies of its inhibitors.
The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer.
Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells.
Up-regulation of eukaryotic elongation factor-1 subunits in breast carcinoma.
Wip1-deficient mice are resistant to common cancer genes.
Bronchiolitis Obliterans
Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation.
Everolimus Use for Intolerance or Failure of Baseline Immunosuppression in Adult Heart and Lung Transplantation.
Immunosuppression: what's standard and what's new?
Long-term use of everolimus in lung transplant patients.
Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
Bronchitis
Upregulation of DUSP6 impairs infectious bronchitis virus replication by negatively regulating ERK pathway and promoting apoptosis.
Bronchitis, Chronic
Hypothalamic digoxin, hemispheric chemical dominance, and chronic bronchitis emphysema.
Bulbo-Spinal Atrophy, X-Linked
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Burkitt Lymphoma
Caspase-8-mediated cleavage of Bid and protein phosphatase 2A-mediated activation of Bax are necessary for Verotoxin-1-induced apoptosis in Burkitt's lymphoma cells.
Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
Expression of platelet parameters and platelet membrane glycoproteins in childhood Burkitt lymphoma.
Caliciviridae Infections
Inhibition of calcineurin or IMPDH exerts moderate to potent antiviral activity against norovirus replication.
Candidiasis
Calcineurin is essential for virulence in Candida albicans.
Comparative analysis of calcineurin signaling between Candida dubliniensis and Candida albicans.
Ppg1, a PP2A-type protein phosphatase, controls filament extension and virulence in Candida albicans.
Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain.
Carcinogenesis
A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A.
A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.
Alterations of the PPP1R3 gene in human cancer.
An unusual cause of cancer mimicry following liver transplantation.
AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer.
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Calcineurin signaling as a negative determinant of keratinocyte cancer stem cell potential and carcinogenesis.
Chemopreventive sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3? pathway in colon cancer.
Chromosomal aberrations in UVB-induced tumors of immunosuppressed mice.
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Colorectal cancer: Calcineurin drives CRC tumorigenesis.
Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.
Delivery of the VIVIT Peptide to Human Glioma Cells to Interfere with Calcineurin-NFAT Signaling.
Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Digital RNA Sequencing of Human Epidermal Keratinocytes Carrying Human Papillomavirus Type 16 E7.
Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells.
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis.
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.
DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Dynamic Regulation of ME1 Phosphorylation and Acetylation Affects Lipid Metabolism and Colorectal Tumorigenesis.
Epithelial Calcineurin Promotes Microbiota-Dependent Colorectal Cancer.
Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.
Functional Roles of Protein Phosphatase 4 in Multiple Aspects of Cellular Physiology: A Friend and A Foe.
Gene amplification and overexpression of protein phosphatase 1alpha in oral squamous cell carcinoma cell lines.
Genetic alterations and expression of the protein phosphatase 1 genes in human cancers.
Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer.
Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.
iASPP is important for bladder cancer cell proliferation.
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype.
Loss of endogenous Nfatc1 reduces the rate of DMBA/TPA-induced skin tumorigenesis.
Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D -driven tumor promotion.
Loss of protein phosphatase 6 in mouse keratinocytes increases susceptibility to ultraviolet-B-induced carcinogenesis.
m6A methyltransferase Wilms' tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation.
Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing.
Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics.
Molecular mechanisms of pancreatic carcinogenesis.
NF-?B gene signature predicts prostate cancer progression.
Okadaic acid activates Wnt/?-catenin-signaling in human HepaRG cells.
Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration.
Phosphatase magnesium-dependent 1 ? (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer.
PP-1? and PP-1? display antagonism and differential roles in tumorigenicity of lung cancer cells.
PP2C? inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.
PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
PPM1D is a prognostic marker and therapeutic target in colorectal cancer.
PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia.
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
PPM1H is an independent prognostic biomarker of non-small cell lung cancer.
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
PRL-3 activates NF-?B signaling pathway by interacting with RAP1.
PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.
Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients.
Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53.
Protein phosphatase Mg2+/Mn2+ dependent 1F promotes smoking-induced breast cancer by inactivating phosphorylated-p53-induced signals.
PTEN signaling pathways in melanoma.
PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1.
Redox inhibition of protein phosphatase PP2A: Potential implications in oncogenesis and its progression.
Role of lncRNA-ENST00000412010 in regulating nasopharyngeal cancer cell survival.
Role of PP2C-alpha in cell growth, in radio- and chemosensitivity, and in tumorigenicity.
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management.
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
The Clinical Significance of PPEF1 as a Promising Biomarker and Its Potential Mechanism in Breast Cancer.
The mechanism of action of the tumour suppressor gene PTEN.
The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis.
Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice.
Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway.
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.
Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.
Type-2A protein phosphatase activity is required to maintain death receptor responsiveness.
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5'-monophosphate-activated protein kinase/mammalian target of rapamycin complex 1 pathway.
Wip1 abrogation decreases intestinal tumor frequency in APC(Min/+) mice irrespective of radiation quality.
WIP1 deficiency inhibits HTLV-1 Tax oncogenesis: novel therapeutic prospects for treatment of ATL?
Carcinoma
Absence of PPP2R1A mutations in Wilms tumor.
Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1.
Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin.
Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Correction: Liu, Y.-S.; et al. Inhibition of Protein Phosphatase 1 Stimulates Noncanonical ER Stress eIF2? Activation to Enhance Fisetin-Induced Chemosensitivity in HDAC Inhibitor-Resistant Hepatocellular Carcinoma Cells. Cancers 2019, 11, 918.
Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway.
Differences in association of the serine/threonine protein phosphatase PP-2A with microtubules of metastatic and nonmetastatic tumor cells.
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma.
Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells.
Downregulation of calcineurin activity in cervical carcinoma.
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
DUSP1 is involved in the progression of small cell carcinoma of the prostate.
DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma.
DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma.
Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2.
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Expression of Wip1 in Kidney Carcinoma and its Correlation with Tumor Metastasis and Clinical Significance.
Gene amplification and overexpression of protein phosphatase 1alpha in oral squamous cell carcinoma cell lines.
Identification and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes.
ILKAP regulates ILK signaling and inhibits anchorage-independent growth.
Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line.
Inhibition of protein phosphatase PPM1D enhances retinoic acid-induced differentiation in human embryonic carcinoma cell line.
Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma.
Key genes in lung cancer translational research: a meta-analysis.
Knockdown of Protein Phosphatase Magnesium-dependent 1 (PPM1D) through Lentivirus-mediated RNA Silencing Inhibits Colorectal Carcinoma Cell Proliferation.
Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy.
Loss of endogenous Nfatc1 reduces the rate of DMBA/TPA-induced skin tumorigenesis.
MicroRNA-527 Induces Proliferation and Cell Cycle in Esophageal Squamous Cell Carcinoma Cells by Repressing PH Domain Leucine-Rich-Repeats Protein Phosphatase 2.
Mitochondria-to-nucleus stress signaling in mammalian cells: nature of nuclear gene targets, transcription regulation, and induced resistance to apoptosis.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Multidrug-resistant human KB carcinoma cells are highly resistant to the protein phosphatase inhibitors okadaic acid and calyculin A. Analysis of potential mechanisms involved in toxin resistance.
Okadaic acid, a phosphatase inhibitor, induces activation and phosphorylation of the Na+/H+ antiport.
Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric Carcinomas.
Oxidized S100A4 inhibits the activation of protein phosphatase 5 through S100A1 in MKN?45 gastric carcinoma cells.
PPM1D controls nucleolar formation by up-regulating phosphorylation of nucleophosmin.
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
PPP1CA contributes to the senescence program induced by oncogenic Ras.
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
Protein phosphatase 2Cbetal regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
Protein phosphatase-2A associates with the cytoskeleton to maintain cell spreading and reduced motility of nonmetastatic Lewis lung carcinoma cells: the loss of this regulatory control in metastatic cells.
Protein phosphatase-2A association with microtubules and its role in restricting the invasiveness of human head and neck squamous cell carcinoma cells.
Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma.
Protein phosphatase-2A maintains focal adhesion complexes in keratinocytes and the loss of this regulation in squamous cell carcinomas.
Protein phosphatase-2A modulates the serine and tyrosine phosphorylation of paxillin in Lewis lung carcinoma tumor variants.
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Protein phosphatase-2A restricts migration of Lewis lung carcinoma cells by modulating the phosphorylation of focal adhesion proteins.
Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma.
Rapamycin instead of mycophenolate mofetil or azathioprine in treatment of post-renal transplantation urothelial carcinoma.
Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants.
Role of the phosphatase PP4 in the activation of JNK-1 in prostate carcinoma cell lines PC-3 and LNCaP resulting in increased AP-1 and EGR-1 activity.
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Small Molecules Alter VEGFR and PTEN Expression in HPV-positive and -negative SCC: New Hope for Targeted-therapy.
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
Squamous cell carcinoma on the lower lip after using topical calcineurin inhibitor.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway.
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma.
The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis.
Therapeutic Effect of ?-Secretase Inhibition in Kras(G12V)-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK.
Tissue-specific gene therapy directed to tumor angiogenesis.
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Urothelial carcinoma in kidney transplant recipients: conversion from calcineurin inhibitor to proliferation signal inhibitor?
Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A.
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma.
[Effect of inhibitor-1 of protein phosphatase I on apoptosis of human cervical carcinoma cell line HeLa]
[Ultraviolet A-induced DNA damage: role in skin cancer].
Carcinoma in Situ
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
Carcinoma, Basal Cell
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Carcinoma, Ductal
Clinicopathological significance of dual-specificity protein phosphatase 4 expression in invasive ductal carcinoma of the breast.
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Enhanced expression of PP1 gamma 1, a catalytic subunit isoform of protein phosphatase type 1, in invasive ductal carcinoma of the breast.
Carcinoma, Ehrlich Tumor
Dephosphorylation of the small heat shock protein hsp25 by calcium/calmodulin-dependent (type 2B) protein phosphatase.
Dexamethasone induced expression of phosphatase inhibits generation of reactive oxygen species in Ehrlich ascites tumor cells.
Purification and characterization of butyrate-induced protein phosphatase involved in apoptosis of Ehrlich ascites tumor cells.
Carcinoma, Embryonal
Effects of protein phosphatase inhibition by okadaic acid on the differentiation of F9 embryonal carcinoma cells.
Carcinoma, Hepatocellular
A Genetic Variant of PPP1CB Influences Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma in Han Chinese: A Pathway Based Analysis.
A protein phosphatase is involved in the inhibition of histone deacetylation by sodium butyrate.
Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma.
Activation of protein phosphatase 1alpha promoter in ascites hepatoma cells.
Calcineurin A versus NS5A-TP2/HD domain containing 2: a case study of site-directed low-frequency random mutagenesis for dissecting target specificity of peptide aptamers.
CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression.
Combination of calcineurin B subunit (CnB) and 5-fluorouracil reverses 5-fluorouracil-induced immunosuppressive effect and enhances the antitumor activity in hepatocellular carcinoma.
Correction: Liu, Y.-S.; et al. Inhibition of Protein Phosphatase 1 Stimulates Noncanonical ER Stress eIF2? Activation to Enhance Fisetin-Induced Chemosensitivity in HDAC Inhibitor-Resistant Hepatocellular Carcinoma Cells. Cancers 2019, 11, 918.
Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth.
Cytosolic protein phosphatases of rat ascites hepatoma AH-13 as compared with those of rat liver: isolation and characterization of a novel protein phosphatase.
Deficiency in calcineurin activity in liver transplantation candidates with alcoholic cirrhosis or hepatocellular carcinoma.
Descriptive Analysis of Everolimus Conversion in Liver Transplant Recipients With Malignant Neoplastic Disease.
Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma.
Dual-specificity phosphatases are targets of the Wnt/?-catenin pathway and candidate mediators of ?-catenin/Ras signaling interactions.
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update.
Expression in hepatomas and chromosomal localization of rat protein phosphatase 5 gene.
Genetically engineered drug rhCNB induces apoptosis and cell cycle arrest in both gastric cancer cells and hepatoma cells.
Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital-treated rats. Characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor.
Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation.
High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients.
Higher intratumor than peritumor expression of DUSP6/MKP-3 is associated with recurrence after curative resection of hepatocellular carcinoma.
Immunosuppressive treatment with everolimus in patients after orthotopic liver transplantation: 4 years of experience.
Impact of recipient age and preoperative fasting blood glucose level as the risk factors of living donor liver transplantation in cirrhotic patients in the recent comprehensive era with knowledge of indications: Recent status in a Japanese single center.
Increases in intracellular calcium dephosphorylate histone H3 at serine 10 in human hepatoma cells: potential role of protein phosphatase 2A-protein kinase CbetaII complex.
Indications and management of everolimus after liver transplantation.
Insulin activates a 70-kDa S6 kinase through serine/threonine-specific phosphorylation of the enzyme polypeptide.
Insulin activation of protein kinase C: a reassessment.
Knockdown of PPP5C inhibits growth of hepatocellular carcinoma cells in vitro.
Knockdown of protein phosphatase 5 (PPP5C) suppresses the growth of leukemic cell line U937.
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Lipin-1 is a novel substrate of protein phosphatase PGAM5.
Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase.
miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F.
mRNA levels and enzyme activities of protein phosphatases in drug-resistant rat ascites hepatomas.
Neoplastic alterations in subcellular distribution of type 1 alpha protein phosphatase in rat ascites hepatoma cells.
Overexpression of Protein Phosphatase 1? (PP1?) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Particulate-associated protein phosphatases of rat hepatomas as compared with the enzymes of rat liver.
PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3.
Protein phosphatase 2A alpha involvement in granulocytic differentiation of HL-60 cells.
Protein phosphatase 2A-B55? enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Protein phosphatase inhibitor-1 mRNA expression correlates with neoplastic transformation of epithelial liver cells and progression of hepatocellular carcinomas.
Protein phosphatase magnesium-dependent 1? (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma.
Protein phosphatase magnesium-dependent 1? is a novel tumor marker and target in hepatocellular carcinoma.
PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells.
Reconstitution of human hepatoma endosome-endosome fusion in vitro: potential roles for an endoprotease and a phosphoprotein phosphatase.
Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
Regulation of tumor necrosis factor cytotoxicity by calcineurin.
Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Risk factors of recipient receiving living donor liver transplantation in the comprehensive era of indication and perioperative managements.
Selective high expression of protein phosphatase pp1-alpha messenger-RNA in rat poorly differentiated ascites hepatomas.
Selective increases in isoform PP1 alpha of type-1 protein phosphatase in ascites hepatoma cells.
Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria.
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
Suppression of Plasminogen Activators and the MMP-2/-9 Pathway by a Zanthoxylum avicennae Extract to Inhibit the HA22T Human Hepatocellular Carcinoma Cell Migration and Invasion Effects in Vitro and in Vivo via Phosphatase 2A Activation.
Ten years of sirolimus therapy in orthotopic liver transplant recipients.
The competing endogenous circular RNA ADAMTS14 suppressed hepatocellular carcinoma progression through regulating microRNA-572/regulator of calcineurin 1.
Up-regulation of nuclear PP1alpha and PP1delta in hepatoma cells.
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
Zanthoxylum avicennae extract enhances GSK-3? to attenuate ?-catenin via phosphatase 2A to block metastatic effects of HA22T cells and hepatocellular carcinoma xenografted nude mice.
[Overexpression of protein phosphatase 2 regulatory subunit B''? gene effect on proliferation and invasion of hepatoma cells].
Carcinoma, Intraductal, Noninfiltrating
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells.
Carcinoma, Lewis Lung
Differences in association of the serine/threonine protein phosphatase PP-2A with microtubules of metastatic and nonmetastatic tumor cells.
Protein phosphatase-2A associates with the cytoskeleton to maintain cell spreading and reduced motility of nonmetastatic Lewis lung carcinoma cells: the loss of this regulatory control in metastatic cells.
Protein phosphatase-2A modulates the serine and tyrosine phosphorylation of paxillin in Lewis lung carcinoma tumor variants.
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Protein phosphatase-2A restricts migration of Lewis lung carcinoma cells by modulating the phosphorylation of focal adhesion proteins.
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
Tissue-specific gene therapy directed to tumor angiogenesis.
Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A.
Carcinoma, Non-Small-Cell Lung
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
An okadaic acid fragment analogue prevents nicotine-induced resistance to cisplatin by recovering PP2A activity in non-small cell lung cancer cells.
APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.
Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Corrigendum to "APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP" [EBioMedicine (2019)].
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
Involvement of CHP2 in the Development of Non-Small Cell Lung Cancer and Patients' Poor Prognosis.
MicroRNA-365b-3p represses the proliferation and promotes the apoptosis of non-small cell lung cancer cells by targeting PPP5C.
miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation.
PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer.
Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.
Therapeutic Effect of ?-Secretase Inhibition in Kras(G12V)-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK.
Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.
Carcinoma, Ovarian Epithelial
Association of metastin/a G-protein-coupled receptor signaling and Down syndrome critical region 1 in epithelial ovarian cancer.
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes.
Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway.
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
Carcinoma, Renal Cell
Current approaches to the use of sirolimus in renal transplantation.
Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma.
Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Carcinoma, Small Cell
DUSP1 is involved in the progression of small cell carcinoma of the prostate.
Carcinoma, Squamous Cell
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Characterization of a membrane-associated phosphotyrosyl protein phosphatase from the A431 human epidermoid carcinoma cell line.
Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin.
Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Downregulation of calcineurin activity in cervical carcinoma.
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.
DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma.
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Induction of apoptosis in human oral squamous carcinoma cell lines by protein phosphatase inhibitors.
Key genes in lung cancer translational research: a meta-analysis.
Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy.
Loss of endogenous Nfatc1 reduces the rate of DMBA/TPA-induced skin tumorigenesis.
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
Protein phosphatase-2A association with microtubules and its role in restricting the invasiveness of human head and neck squamous cell carcinoma cells.
Protein phosphatase-2A maintains focal adhesion complexes in keratinocytes and the loss of this regulation in squamous cell carcinomas.
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Small Molecules Alter VEGFR and PTEN Expression in HPV-positive and -negative SCC: New Hope for Targeted-therapy.
Squamous cell carcinoma on the lower lip after using topical calcineurin inhibitor.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis.
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Carcinoma, Transitional Cell
Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line.
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma.
Carcinosarcoma
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Cardiac Output, Low
[Intracellular disorders in the dog myocardium in low cardiac output syndrome caused by massive hemorrhage, approaches to correction]
Cardiomegaly
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.
A proteomic interrogation of Cryptococcus neoformans: interaction networks for calcineurin in a heated environment.
A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway.
Activation of calcineurin expression in ischemia-reperfused rat heart and in human ischemic myocardium.
Activation of Serine One-Carbon Metabolism by Calcineurin A?1 Reduces Myocardial Hypertrophy and Improves Ventricular Function.
Activation of transient receptor potential vanilloid 3 channel (TRPV3) aggravated pathological cardiac hypertrophy via calcineurin/NFATc3 pathway in rats.
Adrenergic receptor blockade-induced regression of pressure-overload cardiac hypertrophy is associated with inhibition of the calcineurin/NFAT3/GATA4 pathway.
Analysis of calcineurin activity by capillary electrophoresis with laser-induced fluorescence detection using peptide substrate.
Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats.
Angiotensin-converting enzyme inhibitor suppresses activation of calcineurin in renovascular hypertensive rats.
Are calcineurin genes associated with endurance phenotype traits?
AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats.
Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins.
Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.
Blockade of calcineurin reverses cardiac hypertrophy and induces the down-regulation of JNK mRNA expression in renovascular hypertensive rats.
BMP TYPE I RECEPTOR ALK2 IS REQUIRED FOR ANGIOTENSIN II-INDUCED CARDIAC HYPERTROPHY.
c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling.
Ca(2+) fluxes involvement in gene expression during cardiac hypertrophy.
Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway.
Calcineurin activity in children with Mental handicap.
Calcineurin activity is required for cardiac remodeling in pregnancy.
Calcineurin anchoring and cell signaling.
Calcineurin and cardiac hypertrophy: where have we been? Where are we going?
Calcineurin and electrical remodeling in pathologic cardiac hypertrophy.
Calcineurin and hypertrophic heart disease: novel insights and remaining questions.
Calcineurin and matrix protein expression in cardiac hypertrophy : Evidence for calcineurin B to control excessive hypertrophic signaling.
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension.
Calcineurin enhances MAPK phosphatase-1 expression and p38 MAPK inactivation in cardiac myocytes.
Calcineurin in human heart hypertrophy.
Calcineurin increases cardiac transient outward K+ currents via transcriptional up-regulation of Kv4.2 channel subunits.
Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse renin gene, TGR(mREN2)27.
Calcineurin inhibition and cardiac hypertrophy: a matter of balance.
Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: requiescat in pace?
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Calcineurin inhibitor attenuates cardiac hypertrophy due to energy metabolic disorder.
Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension.
Calcineurin inhibitors and cardiac hypertrophy.
Calcineurin inhibits Na+/Ca2+ exchange in phenylephrine-treated hypertrophic cardiomyocytes.
Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training.
Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy.
Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy.
Calcineurin signaling in human cardiac hypertrophy.
Calcineurin splicing variant calcineurin A?1 improves cardiac function after myocardial infarction without inducing hypertrophy.
Calcineurin-AKAP interactions: therapeutic targeting of a pleiotropic enzyme with a little help from its friends.
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure.
Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.
Calcium signaling regulates ventricular hypertrophy during development independent of contraction or blood flow.
Calcium-calcineurin signaling in the regulation of cardiac hypertrophy.
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.
Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins.
CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.
Carabin Protects Against Cardiac Hypertrophy by Blocking Calcineurin, Ras, and Ca2+/Calmodulin-Dependent Protein Kinase II Signaling.
Carabin: Endogenous calcineurin inhibitor, a potential diagnostic and therapeutic target for cardiac hypertrophy in heart failure.
Cardiac CaM Kinase II genes ? and ? contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy.
Cardiac CaMKII? and Wenxin Keli Prevents Ang II-Induced Cardiomyocyte Hypertrophy by Modulating CnA-NFATc4 and Inflammatory Signaling Pathways in H9c2 Cells.
Cardiac hypertrophy and thyroid hormone signaling.
Cardiac hypertrophy induced by prostaglandin F(2alpha) may be mediated by calcineurin signal transduction pathway in rats.
Cardiac-Specific EPI64C Blunts Pressure Overload-Induced Cardiac Hypertrophy.
Cardiomyocyte calcineurin is required for the onset and progression of cardiac hypertrophy and fibrosis in adult mice.
Cardiovascular effects of an immunosuppressive agent cyclosporin A.
Changes in Cx43 and NaV1.5 expression precede the occurrence of substantial fibrosis in calcineurin-induced murine cardiac hypertrophy.
Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway.
Choline Protects Against Cardiac Hypertrophy Induced by Increased After-load.
CIB1 is a regulator of pathological cardiac hypertrophy.
Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
Cissampelos pareira Linn. ameliorates thyroxin-induced cardiac hypertrophy in rats.
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Compensatory renal hypertrophy following uninephrectomy is calcineurin-independent.
Constitutively active calcineurin induces cardiac endoplasmic reticulum stress and protects against apoptosis that is mediated by alpha-crystallin-B.
Continuous blockade of L-type Ca2+ channels suppresses activation of calcineurin and development of cardiac hypertrophy in spontaneously hypertensive rats.
Control of cardiac myosin heavy chain gene expression.
Cooperative autoinhibition and multi-level activation mechanisms of calcineurin.
Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Facilitates the Development of Cardiac Hypertrophy.
Cyclosporin A regulates sodium-calcium exchanger (NCX1) gene expression in vitro and cardiac hypertrophy in NCX1 transgenic mice.
Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
Danshen (Salvia miltiorhiza) inhibits Leu27 IGF-II-induced hypertrophy in H9c2 cells.
Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.
Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism.
Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes.
Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy.
Downregulation of Ca2+ signalling proteins in cardiac hypertrophy.
Downregulation of calcineurin activity in cervical carcinoma.
Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy.
Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy.
E2/ER ? Enhances Calcineurin Protein Degradation and PI3K/Akt/MDM2 Signal Transduction to Inhibit ISO-Induced Myocardial Cell Apoptosis.
Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca(2+)-ATPase activity in rat cardiac pressure-overload hypertrophy.
Effects of omega-3 fatty acids and metformin combination on diabetic cardiomyopathy in rats through autophagic pathway.
Electrical remodeling in pressure-overload cardiac hypertrophy: role of calcineurin.
Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice.
Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure.
Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin.
Expression of an active LKB1 complex in cardiac myocytes results in decreased protein synthesis associated with phenylephrine-induced hypertrophy.
Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling.
Functional and phenotypic relevance of differentially expressed proteins in calcineurin mutants of Caenorhabditis elegans.
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
GATA4-mediated cardiac hypertrophy induced by d-myo-inositol 1,4,5-tris-phosphate.
Heart block in mice overexpressing calcineurin but not NF-AT3.
High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes.
Human Molecular Genetic and Functional Studies Identify TRIM63, Encoding Muscle RING Finger Protein 1, as a Novel Gene for Human Hypertrophic Cardiomyopathy.
In vivo cardiac gene transfer of Kv4.3 abrogates the hypertrophic response in rats after aortic stenosis.
Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles.
Induction of the calcineurin variant CnA?1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization.
Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality.
Inhibitory molecules in signal transduction pathways of cardiac hypertrophy.
Inorganic arsenic induces sex-dependent pathological hypertrophy in the heart.
iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin.
Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes.
Intermedin alleviates pathological cardiac remodeling by upregulating klotho.
Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis.
Into the heart: The emerging role of the ubiquitin-proteasome system.
Involvement of calcineurin in angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibroblast hyperplasia of rats.
Involvement of calcium-sensing receptor in cardiac hypertrophy-induced by angiotensinII through calcineurin pathway in cultured neonatal rat cardiomyocytes.
Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin.
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Loaded wheel running and muscle adaptation in the mouse.
Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signalling.
Loss of ?-adrenergic-stimulated phosphorylation of CaV1.2 channels on Ser1700 leads to heart failure.
LPS-enhanced IGF-IIR pathway to induce H9c2 cardiomyoblast cell hypertrophy was attenuated by Carthamus tinctorius extract via IGF-IR activation.
Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway.
Methionine oxidation in the calmodulin-binding domain of calcineurin disrupts calmodulin binding and calcineurin activation.
MicroRNA-22 Regulates Cardiac Hypertrophy and Remodeling in Response to Stress.
MicroRNA-328 as a regulator of cardiac hypertrophy.
miR-155 functions downstream of angiotensin II receptor subtype 1 and calcineurin to regulate cardiac hypertrophy.
Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo.
Molecular and cellular mechanisms of mechanical stress-induced cardiac hypertrophy.
Molecular mechanisms regarding potassium bromate?induced cardiac hypertrophy without apoptosis in H9c2 cells.
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Multiple domains of MCIP1 contribute to inhibition of calcineurin activity.
Multiple signaling pathways coordinately mediate reactive oxygen species dependent cardiomyocyte hypertrophy.
MuRF1 Negatively Regulates Pathological Cardiac Hypertrophy Through Downregulation of Calcineurin A.
Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.
Neurally-mediated increase in calcineurin activity regulates cardiac contractile function in absence of hypertrophy.
NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro.
O-GlcNAc Signaling is Essential for NFAT-Mediated Transcriptional Reprogramming During Cardiomyocyte Hypertrophy.
Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy.
Olmesartan attenuates cardiac hypertrophy and improves cardiac diastolic function in spontaneously hypertensive rats through inhibition of calcineurin pathway.
Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels.
Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway.
Overexpression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heart.
Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy.
PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) regulates G-protein-coupled receptor kinase 5 (GRK5)-induced cardiac hypertrophy in vitro.
Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway.
Physical and functional interaction between calcineurin and the cardiac L-type Ca2+ channel.
Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure.
Plasma membrane Ca2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents.
Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy.
Positive correlations between serum calcineurin activity and left ventricular hypertrophy.
Positive Role for a Negative Calcineurin Regulator in Cardiac Hypertrophy.
Positive Transcription Elongation Factor b Activity in Compensatory Myocardial Hypertrophy is Regulated by Cardiac Lineage Protein-1.
Possible involvement of calcineurin, protein kinase C, and Src-family kinases in angiotensin II-induced tyrosine phosphorylation of p130cas in rat cardiac muscle.
PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart.
Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype?
Prevention of cardiac hypertrophy in mice by calcineurin inhibition.
Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant.
Protein kinase-mediated regulation of calcineurin through the phosphorylation of modulatory calcineurin-interacting protein 1.
Re: Regulation of protein kinase C isozyme and calcineurin expression in isoproterenol-induced cardiac hypertrophy.
Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy.
Recognition of ?-calcineurin by the domains of calmodulin: Thermodynamic and structural evidence for distinct roles.
Recognition of ?-calcineurin by the domains of calmodulin: thermodynamic and structural evidence for distinct roles.
Regulation of gene expression by cyclic GMP.
Regulation of protein kinase C isozyme and calcineurin expression in isoproterenol induced cardiac hypertrophy.
Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition.
Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient.
Reversibility of adverse, calcineurin-dependent cardiac remodeling.
Role of calcineurin in striated muscle: development, adaptation, and disease.
Role of heterotrimeric G protein and calcium in cardiomyocyte hypertrophy induced by IGF-1.
Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy.
Rutaecarpine Ameliorates Pressure Overload Cardiac Hypertrophy by Suppression of Calcineurin and Angiotensin II.
Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy.
Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation.
Separating the good and evil of cardiac growth by CIB1 and calcineurin.
Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.
Stachydrine hydrochloride suppresses phenylephrine-induced pathological cardiac hypertrophy by inhibiting the calcineurin/nuclear factor of activated T-cell signalling pathway.
Stretch-modulation of second messengers: effects on cardiomyocyte ion transport.
Structures of calcineurin and its complexes with immunophilins-immunosuppressants.
TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NF?B, and Bnip3 Pathways.
Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth.
Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo.
Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function.
Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.
Targeting calcineurin and associated pathways in cardiac hypertrophy and failure.
The ability of phosphodiesterase-5 inhibitors sildenafil and ordonafil to reverse L-NAME induced cardiac hypertrophy in the rabbit: possible role of calcineurin and p38.
The combined inhibition of the CaMKII? and calcineurin signaling cascade attenuates IGF-IIR-induced cardiac hypertrophy.
The essential role of MEKK3 signaling in angiotensin II-induced calcineurin/nuclear factor of activated T-cells activation.
The function of calcineurin and ERK1/2 signal in the antihypertrophic effects of kappa-opioid receptor stimulation on myocardial hypertrophy induced by isoprenaline.
The Nlrp3 Inflammasome promotes myocardial dysfunction in structural cardiomyopathy through IL-1?
The other side of cardiac Ca(2+) signaling: transcriptional control.
The proteasome activator REG? accelerates cardiac hypertrophy by declining PP2Ac?-SOD2 pathway.
The role of modulatory calcineurin-interacting proteins in calcineurin signaling.
Transcriptional upregulation of calcineurin Abeta by endothelin-1 is partially mediated by calcium/calmodulin-dependent protein kinase IIdelta3 in rat cardiomyocytes.
Transient outward potassium channel: a heart failure mediator.
TRPA1 inhibition ameliorates pressure overload-induced cardiac hypertrophy and fibrosis in mice.
TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.
Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac hypertrophy in cell models.
Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension.
Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways.
Zebrafish hhatla is involved in cardiac hypertrophy.
Zinc inhibits doxorubicin-activated calcineurin signal transduction pathway in H9c2 embryonic rat cardiac cells.
[Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension]
[Cardiac hypertrophy and calcium signaling]
[Functional analysis of calcineurin-mediated signalling pathway using fission yeast as a model system]
[Role of Ca2+/calmodulin-dependent calcineurin signaling pathway in neuropeptide Y-induced cardiac hypertrophy in rats]
[Role of calcineurin in the progression of cardiac hypertrophy in renovascular hypertensive rats]
[Role of valsartan on myocardial Calpain I, calcineurin and Ca/calmodulin-dependent protein kinase II? expression of renovascular hypertensive rats].
[The mutants of calcineurin transgenic mice]
Cardiomyopathies
Aberrant sialylation causes dilated cardiomyopathy and stress-induced heart failure.
ASK1 Regulates Cardiomyocyte Death but Not Hypertrophy in Transgenic Mice.
Calcineurin and beyond: cardiac hypertrophic signaling.
Calcineurin in human heart hypertrophy.
Cell surface and gene expression regulation molecules in dystrophinopathy: mdx vs. Duchenne.
Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy.
Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure.
Direct and Indirect Involvement of MicroRNA-499 in Clinical and Experimental Cardiomyopathy.
Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival.
Erratum to: High throughput phenotyping of left and right ventricular cardiomyopathy in calcineurin transgene mice.
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
High throughput phenotyping of left and right ventricular cardiomyopathy in calcineurin transgene mice.
Impaired contractile function and calcium handling in hearts of cardiac-specific calcineurin b1-deficient mice.
Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.
Isoproterenol-Induced Cardiomyopathy in Rats: Influence of Acorus calamus Linn. : A. calamus Attenuates Cardiomyopathy.
Mechanisms underlying pathological Ca2+ handling in diseases of the heart.
Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress.
Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy.
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition.
The combined inhibition of the CaMKII? and calcineurin signaling cascade attenuates IGF-IIR-induced cardiac hypertrophy.
The long-term effect of simultaneous heart and kidney transplantation on native renal function.
Cardiomyopathy, Dilated
Activation of calcineurin and stress activated protein kinase/p38-mitogen activated protein kinase in hearts of utrophin-dystrophin knockout mice.
Calcineurin Protects the Heart in a Murine Model of Dilated Cardiomyopathy.
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
Increased COUP-TFII expression in adult hearts induces mitochondrial dysfunction resulting in heart failure.
Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.
Molecular mechanisms of reduced sarcoplasmic reticulum Ca(2+) uptake in human failing left ventricular myocardium.
Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.
Pathogenesis of dilated cardiomyopathy: molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice.
Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy.
Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice.
The CnB1 p.D102A variant is linked to dilated cardiomyopathy via impaired Calcineurin activity.
Cardiomyopathy, Hypertrophic
Calcineurin in human heart hypertrophy.
Pathogenesis of Hypertrophic Cardiomyopathy Caused by Myozenin 2 Mutations Is Independent of Calcineurin Activity.
Progressive Left Ventricular Hypertrophy after Heart Transplantation: Insights and Mechanisms Suggested by Multimodal Images.
Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart.
Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.
Cardiotoxicity
Aldehyde dehydrogenase 2 ameliorates acute cardiac toxicity of ethanol: role of protein phosphatase and forkhead transcription factor.
Cissampelos pareira Linn. ameliorates thyroxin-induced cardiac hypertrophy in rats.
Current methods of the analysis of immunosuppressive agents in clinical materials: A review.
Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation.
Phloretin Alleviates Arsenic Trioxide-Induced Apoptosis of H9c2 Cardiomyoblasts via Downregulation in Ca2+/Calcineurin/NFATc Pathway and Inflammatory Cytokine Release.
Protection against tacrolimus-induced cardiotoxicity in rats by olmesartan and aliskiren.
[The Role of Laboratory Medicine in Hematopoietic Stem Cell Transplantation "Echocardiogram"].
Cardiovascular Diseases
Aortic valve replacement performed twice through ministernotomy 15 years after lung transplantation.
Association of a Change in Immunosuppressive Regimen with Hemodynamic and Inflammatory Markers of Cardiovascular Disease After Kidney Transplantation.
Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies).
Calcineurin suppresses AMPK-dependent cytoprotective autophagy in cardiomyocytes under oxidative stress.
Clinical application of mTORi based immunosuppression for renal transplantation in India.
DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases.
Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Effects of Calcineurin Inhibitors on Paraoxonase and Arylesterase Activity After a Kidney Transplant.
Enhanced platelet responsiveness due to chilling and its relation to CD40 ligand level and platelet-leukocyte aggregate formation.
Extracellular vesicles from patients with Acute Coronary Syndrome impact on ischemia-reperfusion injury.
From cyclosporine to the future.
Influence of dual-specificity protein phosphatase 5 on mechanical properties of rat cerebral and renal arterioles.
Is a flavonoid-rich diet with steamer cooking safe during calcineurin inhibitors therapy?
Massive Analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease MACE and miRNA profiling in CKD.
Neutrophil Gelatinase-Associated Lipocalin: Ready for Routine Clinical Use? An International Perspective.
PHACTR1 Gene Polymorphism Is Associated with Increased Risk of Developing Premature Coronary Artery Disease in Mexican Population.
Prolonged Subcutaneous Administration of Oxytocin Accelerates Angiotensin II-Induced Hypertension and Renal Damage in Male Rats.
Scutellarin exerts its anti-hypertrophic effects via suppressing the Ca2+-mediated calcineurin and CaMKII signaling pathways.
The evolving role of alemtuzumab (Campath-1H) in renal transplantation.
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
Therapeutic potential of VIVIT, a selective peptide inhibitor of nuclear factor of activated T cells, in cardiovascular disorders.
Cataract
Human Aqueous Humor Phosphatase Activity in Cataract and Glaucoma.
Ocular complications in a young pediatric population following bone marrow transplantation.
Spectrum and range of oxidative stress responses of human lens epithelial cells to H2O2 insult.
Strategies to reduce toxicities and improve outcomes in renal transplant recipients.
Catatonia
Catatonia After Liver Transplantation.
Celiac Disease
A possible mechanism behind autoimmune disorders discovered by genome-wide linkage and association analysis in celiac disease.
Central Nervous System Diseases
Seizure treatment in transplant patients.
Central Nervous System Infections
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
Cerebellar Ataxia
Cerebellar ataxia in a patient receiving calcineurin inhibitors after living donor liver transplantation: a case report.
Cerebellar Diseases
Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity.
Unusual cerebral white matter change in a Chinese family with Spinocerebellar ataxia type 12.
Cerebral Infarction
[Effect of electro-needling at acupoints of the yangming meridian on the expression of PAC-1 and lower limb functions in acute cerebral infarction patients].
Cerebrovascular Disorders
Neuroimaging and neurologic complications after organ transplantation.
Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.
Chagas Disease
A preliminary study of platelet hyperactivity in the chronic indeterminate phase of Chagas' disease.
Cheilitis
Plasma cell cheilitis successfully treated with topical calcineurin inhibitors.
Successful treatment of plasma cell cheilitis with topical calcineurin inhibitors.
Successful treatment of plasma cell cheilitis with topical tacrolimus: Report of two cases.
Cherubism
SH3BP2 mutations potentiate osteoclastogenesis via PLC?.
The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism.
Cholangiocarcinoma
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Cholangitis, Sclerosing
Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants.
Cholelithiasis
Prevalence of cholecystolithiasis and its management among kidney/pancreas-transplanted type 1 (insulin-dependent) diabetic patients.
Cholera
Calcineurin mediates calcium-induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach. Further evidence for cross-talk between signal transduction pathways that regulate pepsinogen secretion.
Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate - A controlled trial.
Regulation of the transmodulated epidermal growth factor receptor by cholera toxin and the protein phosphatase inhibitor okadaic acid.
Cholestasis
Calcineurin inhibitor-related cholestasis complicating lung transplantation.
Plasma miR-218a-5p as a biomarker for acute cholestatic liver injury in rats and investigation of its pathophysiological roles.
Cholestasis, Intrahepatic
Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.
Chondroma
Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
Chondrosarcoma
Enhanced expression of PP1gamma1, a catalytic subunit isoform of protein phosphatase type1 and expression of telomerase activity in Ewing's sarcoma cells.
Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
Choriocarcinoma
A protein kinase C-independent pathway leading to c-Jun-dependent expression of 100-kDa Ras GTPase-activating protein in JEG-3 human choriocarcinoma cells.
Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma.
Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis.
Chronic Traumatic Encephalopathy
Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy.
Chronic Urticaria
Calcineurin inhibitors in chronic urticaria.
Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria.
Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria.
Clostridium Infections
Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
Coccidiosis
A novel serine/threonine protein phosphatase type 5 from second-generation merozoite of Eimeria tenella is associated with diclazuril-induced apoptosis.
Coinfection
Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways.
Reduction of I(to) causes hypertrophy in neonatal rat ventricular myocytes.
Colitis
An approach to acute severe ulcerative colitis.
Calcineurin inhibition by polaprezinc in rats with experimentally-induced colitis.
Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune checkpoint inhibitor colitis.
Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome.
Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis.
Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice.
DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis.
FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression.
Hyperosmotic stress contributes to mouse colonic inflammation through the methylation of protein phosphatase 2A.
Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion.
Tacrolimus ameliorates dextran sulfate sodium-induced colitis in mice: implication of interferon-? and interleukin-1? suppression.
Where are we going with ulcerative colitis management?
Colitis, Ulcerative
A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis.
Amelioration of murine experimental colitis using biocompatible cyclosporine A lipid carriers.
Calcineurin inhibition in severe ulcerative colitis: Lost in translation?
Calcineurin inhibitors or anti-TNF-? agents in severe ulcerative colitis: available options and limitations.
Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study.
Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy.
Comparing guidelines for the treatment of inflammatory bowel disease.
Current surgical practice in pediatric ulcerative colitis: A systematic review.
Editorial: calcineurin inhibitors as a bridge to vedolizumab for severe ulcerative colitis.
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination with Vedolizumab in Patients With Refractory Ulcerative Colitis.
EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients.
Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus.
Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis.
Optimizing conventional therapy for inflammatory bowel disease.
Pediatric ulcerative colitis: current treatment approaches including role of infliximab.
Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery.
Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors.
Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors.
Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis.
Readministration of calcineurin inhibitors for ulcerative colitis.
Recent trends and future directions for the medical treatment of ulcerative colitis.
Risk Factors of Colectomy in Patients With Refractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab.
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.
Tacrolimus for the Treatment of Ulcerative Colitis.
Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review.
The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis.
The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy.
Therapy of ulcerative colitis.
Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
[Current management of toxic megacolon].
Colonic Neoplasms
Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway.
DUSP1 is controlled by p53 during the cellular response to oxidative stress.
Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth.
Elevated expression of the cdc25A protein phosphatase in colon cancer.
Fibroblast-derived CXCL12 regulates PTEN expression and is associated with the proliferation and invasion of colon cancer cells via PI3k/Akt signaling.
INPP4B is an oncogenic regulator in human colon cancer.
Ligand modulates VDR-Ser/Thr protein phosphatase interaction and p70S6 kinase phosphorylation in a cell-context-dependent manner.
LncRNA ROR1-AS1 promotes colon cancer cell proliferation by suppressing the expression of DUSP5/CDKN1A.
New Acetohydrazides Incorporating 2-Oxoindoline and 4-Oxoquinazoline: Synthesis and Evaluation of Cytotoxicity and Caspase Activation Activity.
Protein expression profiles that underpin the preventive and therapeutic potential of Moringa oleifera Lam against azoxymethane and dextran sodium sulfate-induced mouse colon carcinogenesis.
Protein phosphatase 1H, overexpressed in colon adenocarcinoma, is associated with CSE1L.
Silencing of PPMD1 inhibits proliferation of human colon cancer cells via induction of apoptosis and cell cycle arrest.
Synergistic cytotoxic effect between serine-threonine phosphatase inhibitors and 5-fluorouracil: a novel concept for modulation of cytotoxic effect.
The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 Inhibition.
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
[Effects of phosphatase of regenerating liver cell-3 gene silence by RNA interference on the expression of matrix metalloproteinases-2,-9 in human colon cancer cells]
Colorectal Neoplasms
Association between PPP2CA expression and colorectal cancer prognosis Tumour Marker Prognostic Study.
Autocrine BMP-4 Signaling Is a Therapeutic Target in Colorectal Cancer.
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
Calmodulin-binding proteins: A journey of 40 years.
Colorectal cancer: Calcineurin drives CRC tumorigenesis.
Correlation of PRL3 expression with colorectal cancer progression.
Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21(WAF1/CIP1) and proliferating cell nuclear antigen.
Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis.
DUSP10 gene polymorphism and risk of colorectal cancer in the Han Chinese population.
DUSP10 Is a Regulator of YAP1 Activity Promoting Cell Proliferation and Colorectal Cancer Progression.
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Epithelial Calcineurin Promotes Microbiota-Dependent Colorectal Cancer.
Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Increased Calcineurin A Expression Is Associated with a Lower Relapse-Free Survival Rate after Colorectal Cancer Surgery.
Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Inhibition of protein phosphatase 5 (PP5) suppresses survival and growth of colorectal cancer cells.
Knockdown of Protein Phosphatase Magnesium-dependent 1 (PPM1D) through Lentivirus-mediated RNA Silencing Inhibits Colorectal Carcinoma Cell Proliferation.
KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer.
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells.
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Polymorphisms in the DUSP10 gene are associated with sex-specific colorectal cancer risk in a Han population.
PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer.
PP4C facilitates lung cancer proliferation and inhibits apoptosis via activating MAPK/ERK pathway.
PPM1D is a prognostic marker and therapeutic target in colorectal cancer.
PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers.
Premature chromosome condensation revisited: a novel chemical approach permits efficient cytogenetic analysis of cancers.
The Comparison Between Molecular Tumour Profiling in Microdissected and Surgical Tissue Samples.
The critical role of calcineurin/NFAT (C/N) pathways and effective antitumor prospect for colorectal cancers.
The phosphatase of regenerating liver 3 (PRL-3) promotes cell migration via Arf-activity dependent stimulation of integrin alpha5 recycling.
The ratio of thioredoxin/Keap1 protein level is a predictor of distant metastasis in colorectal cancer.
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner.
[Expression of cancerous inhibitor of protein phosphatase 2A in tissue microarray of colorectal cancer and its clinical significance].
Common Cold
DUSP10 Negatively Regulates the Inflammatory Response to Rhinovirus through Interleukin-1? Signaling.
Communicable Diseases
CD28 confers CD4+ T cells with resistance to cyclosporin A and tacrolimus but to different degrees.
Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings.
Interactions between anti-infective agents and immunosuppressants-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Confusion
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
Conjunctivitis
Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.
Conjunctivitis, Allergic
Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.
Phase II drugs under investigation for allergic conjunctivitis.
[New strategy in the treatment of vernal keratoconjunctivitis by calcineurin inhibitor eye drops].
Connective Tissue Diseases
The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases.
Corneal Neovascularization
Loss of Down Syndrome Critical Region-1 Mediated-Hypercholesterolemia Accelerates Corneal Opacity Via Pathological Neovessel Formation.
Corneal Opacity
Loss of Down Syndrome Critical Region-1 Mediated-Hypercholesterolemia Accelerates Corneal Opacity Via Pathological Neovessel Formation.
Coronary Artery Disease
ACP1 Genetic Polymorphism and Coronary Artery Disease: Evidence of Effects on Clinical Parameters of Cardiac Function.
Association of CnB 5I/5D promoter gene polymorphism and serum calcineurin levels in early onset of coronary artery disease of south Indian cohort.
Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma.
Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab.
Coronary Disease
[Changes and significance of P-selectin and PAC-1 in coronary heart disease before and after stenting].
[Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans].
Coronary Vasospasm
Detection of platelets activated during acetylcholine-induced coronary vasospasm.
COVID-19
Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.
Calcineurin Inhibitors and COVID-19.
Calcineurin inhibitors revisited: A new paradigm for COVID-19?
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).
COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?
COVID-19 infection in a kidney transplant recipient-special emphasis on pharmacokinetic interactions: A case report.
Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection.
Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.
Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.
Immunosuppression practices during the COVID-19 pandemic: A multinational survey study of transplant programs.
Kidney transplantation and COVID-19 renal and patient prognosis.
Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19.
Resurgence of BK virus following Covid-19 in kidney transplant recipients.
SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway.
Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options.
Craniosynostoses
Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development.
Crohn Disease
Comparing guidelines for the treatment of inflammatory bowel disease.
Differences between treatment guidelines--Germany.
Newer Therapies for Inflammatory Bowel Disease.
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Cryptococcosis
A Mechanosensitive Channel Governs Lipid Flippase-Mediated Echinocandin Resistance in Cryptococcus neoformans.
Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis.
Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans calcineurin A mutant strain.
Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression.
Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent.
T11TS immunotherapy potentiates the repressed Calcineurin-NFAT signaling pathway of T cells in Cryptococcus neoformans infected rats: A cue towards T cell activation for antifungal immunity.
Cryptogenic Organizing Pneumonia
BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus.
Cryptorchidism
Prevalence and associated phenotypes of DUSP6, IL17RD and SPRY4 variants in a large Chinese cohort with isolated hypogonadotropic hypogonadism.
Cystic Fibrosis
Association of cystic fibrosis transmembrane conductance regulator and protein phosphatase 2C.
Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis.
Protein phosphatase 2C dephosphorylates and inactivates cystic fibrosis transmembrane conductance regulator.
Regulation of CFTR by protein phosphatase 2B and protein kinase C.
The molecular basis of chloride channel dysregulation in cystic fibrosis.
Cystinosis
Excellent long-term outcome of renal transplantation in cystinosis patients.
Cystinuria
A recessive contiguous gene deletion of chromosome 2p16 associated with cystinuria and a mitochondrial disease.
Cystitis
Effects of herpes simplex virus vectors encoding poreless TRPV1 or protein phosphatase 1? in a rat cystitis model induced by hydrogen peroxide.
The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.
Cysts
Protein phosphatase 1ß limits ring canal constriction during Drosophila germline cyst formation.
Protein phosphatase 2A, a potential regulator of actin dynamics and actin-based organelle motility in the green alga Acetabularia.
Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma.
Cytomegalovirus Infections
A single-center experience of overseas kidney transplant for immunologically high-risk patients.
A single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport(®) or Prograf(®) preparations of tacrolimus.
Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Cellular serine/threonine phosphatase activity during human cytomegalovirus infection.
Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
Cyclosporine Versus Tacrolimus: Which Calcineurin Inhibitor Has Influence on Cytomegalovirus Infection in Cardiac Transplantation?
Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem.
Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation?
High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients.
Incidence, Risk Factors, and Outcomes of Stroke Following Cardiac Transplantation.
New-Onset Diabetes after Kidney Transplantation.
New-onset diabetes mellitus after kidney transplantation: Current status and future directions.
Outcomes of kidney transplantation over a 16-year period in Korea: An analysis of the National Health Information Database.
RECENT ADVANCES IN MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR USE IN HEART AND LUNG TRANSPLANTATION.
Sirolimus-based therapy for kidney transplantation from expanded criteria donors.
The aetiology and pathogenesis of chronic allograft nephropathy.
Urinary granzyme A mRNA is a biomarker to diagnose subclinical and acute cellular rejection in kidney transplant recipients.
De Lange Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Deafness
Mutations in CDC14A, Encoding a Protein Phosphatase Involved in Hair Cell Ciliogenesis, Cause Autosomal-Recessive Severe to Profound Deafness.
Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1?) docking protein.
Death, Sudden, Cardiac
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels.
Deglutition Disorders
Eosinophilic esophagitis in children following cardiac transplantation: association with post-transplant lymphoproliferative disorder and other transplant outcomes.
Dehydration
An abscisic acid-AtNAP transcription factor-SAG113 protein phosphatase 2C regulatory chain for controlling dehydration in senescing Arabidopsis leaves.
Chronic interstitial nephritis in agricultural communities is a toxin-induced proximal tubular nephropathy.
Intra-specific variations in expression of stress-related genes in beech progenies are stronger than drought-induced responses.
Physiological and molecular responses for long term salinity stress in common fig (Ficus carica L.).
The root-colonizing endophyte Pirifomospora indica confers drought tolerance in Arabidopsis by stimulating the expression of drought stress-related genes in leaves.
Delirium
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
Dementia
Calcineurin Inhibition and Protein Kinase A Activation Limits Cognitive Dysfunction and Histopathological Damage in a Model of Dementia of the Alzheimer's Type.
Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia.
Calcium phosphatase calcineurin influences tau metabolism.
Generation and characterization of a laforin nanobody inhibitor.
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.
Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors.
The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure.
Dementia, Vascular
Knockdown of microRNA-195 contributes to protein phosphatase-2A inactivation in rats with chronic brain hypoperfusion.
Demyelinating Diseases
Calcineurin Activity Is Increased in Charcot-Marie-Tooth 1B Demyelinating Neuropathy.
In vivo and in vitro models of demyelinating disease: a phosphoprotein phosphatase in host cell endosomes dephosphorylating the nucleocapsid protein of coronavirus JHM.
Dental Plaque
Characterization of a small plasmid determining resistance to erythromycin, lincomycin, and vernamycin Balpha in a strain of Streptococcus sanguis isolated from dental plaque.
Dermatitis
A Practical Guide to Patch Testing.
Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis.
Calcineurin inhibitors in the treatment of allergic dermatitis.
Diagnosis and management of common dermatoses in children: atopic, seborrheic, and contact dermatitis.
Evidence-based Danish Guidelines for the Treatment of Malassezia-related Skin Diseases.
Granuloma Glutaeale Infantum: A Re-emerging Complication of Diaper Dermatitis.
JAAD Game Changers: Topical calcineurin inhibitors for pediatric periorificial dermatitis.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Port-wine-stain-associated dermatitis: implications for cutaneous vascular laser therapy.
Red Ginseng Inhibits Scratching Behavior Associated With Atopic Dermatitis in Experimental Animal Models.
Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
Tacrolimus ointment in the treatment of hormone-dependent dermatitis: A protocol of systematic review.
Tacrolimus-induced rosacea-like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application.
The IKK-2/Ikappa Balpha /NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice.
Topical calcineurin inhibitors for pediatric periorificial dermatitis.
Treatment of pediatric periorificial dermatitis with topical calcineurin inhibitor and topical/oral metronidazole.
[Allergic contact eczema].
[Cutaneous Malassezia infections and Malassezia associated dermatoses: An update].
Dermatitis, Allergic Contact
Discovery of Topical Calcineurin Inhibitors and Pharmacological Profile of Pimecrolimus.
Human skin safety test of green tea cell extracts in condition of allergic contact dermatitis.
Successful treatment of nodular actinic reticuloid with tacrolimus ointment.
Tacrolimus modulates dendritic cell activation in the sensitization phase of allergic contact dermatitis.
Dermatitis, Atopic
-
A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.
A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.
A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis.
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects.
Advances in allergic skin diseases.
Allergy in patients under fourteen years of age in Alergológica 2005.
Association Between Malignancy and Topical Use of Pimecrolimus.
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns.
Atopic dermatitis in children, part 2: treatment options.
Atopic dermatitis: a review of topical nonsteroid therapy.
Atopic dermatitis: a review of topical treatment options.
Atopic dermatitis: an overview.
Atopic Dermatitis: Managing the Itch.
Atopic dermatitis: understanding the disease and its management.
Atopic eczema.
Attrition of topical calcineurin inhibitor use over time in patients with atopic dermatitis.
Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate.
Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.
Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis.
Breaking the Itch-Scratch Cycle: Topical Options for the Management of Chronic Cutaneous Itch in Atopic Dermatitis.
Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.
Calcineurin inhibitors for the treatment of atopic dermatitis.
Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence.
Calcineurin inhibitors in the treatment of allergic dermatitis.
Calcineurin inhibitors: a novel approach to canine atopic dermatitis.
Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis
Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults.
Cutaneous nocardiosis in two dogs receiving ciclosporin therapy for the management of canine atopic dermatitis.
Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunisation.
Differences in therapeutic effects of topically applied corticosteroid and tacrolimus on atopic dermatitis-like symptoms in NC/Nga mice.
Differential effects of topical corticosteroid and calcineurin inhibitor on the epidermal tight junction.
Editorial comments on this issue of the Journal.
Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes.
Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials.
Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.
Efficacy of topical calcineurin inhibitors in psoriasis.
Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents.
Evaluation of Cancer Risk Related to Atopic Dermatitis and Use of Topical Calcineurin Inhibitors.
Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis.
Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
Glucocorticoids Inhibit Double-Stranded RNA-Induced Thymic Stromal Lymphopoietin Release from Keratinocytes in an Atopic Cytokine Milieu More Effectively than Tacrolimus.
Guidelines for the Management of Atopic Dermatitis in Singapore.
Health plan budget impact analysis for pimecrolimus.
How clinically relevant are treatment comparisons of topical calcineurin inhibitor trials for atopic eczema?
Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis.
Improving the management of atopic eczema in primary care.
Inhibition of calcineurin by cyclosporine A exerts multiple effects on human melanoma cell lines HT168 and WM35.
Innovative therapeutics in pediatric dermatology.
Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle.
Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults.
Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.
Long-Term Treatment of Atopic Dermatitis.
Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo-Controlled Study.
Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Management of atopic dermatitis in the pediatric population.
Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema.
Management of patients with atopic dermatitis: the role of emollient therapy.
Mechanism of action and clinical benefits of colloidal oatmeal for dermatologic practice.
Mechanisms of action of topical therapies and the rationale for combination therapy.
Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis.
Modulation of Lymphocyte Function In Vivo via Inhibition of Calcineurin or Purine Synthesis in Patients with Atopic Dermatitis.
Monitoring of therapy in atopic dermatitis - observations with the use of high-frequency ultrasonography.
New and emerging trends in the treatment of atopic dermatitis.
Off-label Uses of Topical Pimecrolimus.
Pediatric atopic dermatitis: a review of the medical management.
Periorbital dermatitis: Causes, differential diagnoses and therapy.
Personalized Immunomodulatory Therapy for Atopic Dermatitis: An Allergist's View.
Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
Phosphodiesterase 4 inhibitors.
Pimecrolimus , a topical calcineurin inhibitor used in the treatment of atopic eczema.
Pimecrolimus in dermatology: atopic dermatitis and beyond.
Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Pimecrolimus reduces eosinophil activation associated with calcium mobilization.
Pimecrolimus: a review of its use in atopic dermatitis.
Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro.
Position statement: topical calcineurin inhibitors in atopic dermatitis.
Potential new indications of topical calcineurin inhibitors.
Practical algorithm to inform clinical decision-making in the topical treatment of atopic dermatitis.
Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace.
Recent advances in treatment strategies for atopic dermatitis.
Recent developments in the treatment of adult atopic dermatitis.
Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment.
Research Waste in Atopic Eczema Trials-Just the Tip of the Iceberg.
Review of Atopic Dermatitis and Topical Therapies.
Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.
Role of the epidermal barrier in atopic dermatitis.
Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy.
Role of topical calcineurin inhibitors on atopic dermatitis of children.
Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.
Sclareol attenuates the development of atopic dermatitis induced by 2,4-dinitrochlorobenzene in mice.
Sdz asm 981.
Short-term efficacy of tacrolimus ointment and impact on quality of life.
Steroids versus other immune modulators in the management of allergic dermatoses.
Successful treatment of nodular actinic reticuloid with tacrolimus ointment.
Suppression of T cell activation by Hirsutenone, isolated from the bark of Alnus japonica, and its therapeutic advantages for atopic dermatitis.
Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis.
Systemic therapy of atopic dermatitis.
Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.
Tacrolimus for the management of psoriasis: clinical utility and place in therapy.
Tacrolimus ointment: a new therapy for atopic dermatitis--review of the literature.
Tacrolimus suppresses atopic dermatitis-associated cytokines and chemokines in monocytes.
The diagnosis and graded therapy of atopic dermatitis.
The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes.
The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis.
The ins and outs of an 'outside-in' view of allergies: atopic dermatitis and allergy prevention.
The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis.
The role of topical calcineurin inhibitors in atopic dermatitis.
The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review.
The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis.
The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
The US FDA 'Black Box' Warning for Topical Calcineurin Inhibitors : An Ongoing Controversy.
Therapeutic Perspectives in Atopic Dermatitis.
Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.
Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function.
Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations.
Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis.
Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use.
Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.
Topical calcineurin inhibitors in systemic lupus erythematosus.
Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues.
Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence.
Topical Corticosteroids and Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis: Focus on Percutaneous Absorption.
TOPICAL CORTICOSTEROIDS BUT NOT CALCINEURIN INHIBITORS INDUCED ATROPHY AFTER FOUR WEEKS.
Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation.
Topical pimecrolimus in the treatment of vitiligo.
Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
Treatment of pruritic diseases with topical calcineurin inhibitors.
Treatment strategies for atopic dermatitis: optimizing the available therapeutic options.
Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial.
Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.
Use of a home-visit nursing service to manage severe atopic dermatitis in a child with difficult family environment.
Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas.
What Is the Risk of Harm Associated With Topical Calcineurin Inhibitors?
What's new in the topical treatment of allergic skin diseases.
[Allergic contact eczema].
[Antipruritic effects of pimecrolimus and tacrolimus]
[Basis for the treatment of eczematous diseases in otorhinolaryngology].
[Calcineurin inhibitors in treatment of atopic dermatitis. Topical corticoids now only in severe outbreaks? ]
[Current aspects of the therapy with topical calcineurin inhibitors]
[How I treat ... atopic dermatitis by topical pimecrolimus (Elidel). The emerging paradigm of calcineurin inhibitors]
[Local treatment of atopic dermatitis with calcineurin inhibitors]
[Long term management of childhood atopic dermatitis with calcineurin inhibitors]
[New immune suppressants: topical immunomodulatory agents]
[Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life]
[Safety of topical tacrolimus and pimecrolimus in children with atopic dermatitis]
[The treatment of atopic dermatitis in adults with topical calcineurin inhibitors]
[Therapy of atopic dermatitis.]
[Therapy of atopic eczema with calcineurin inhibitors]
[Topical calcineurin inhibitors in atopic eczema -- contra]
[Topical calcineurin inhibitors in atopic eczema -- pro]
Dermatitis, Contact
Abnormal epidermal barrier in the pathogenesis of contact dermatitis.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Pimecrolimus and tacrolimus differ in their inhibition of lymphocyte activation during the sensitization phase of contact hypersensitivity.
Signal transducer and activator of transcription 1 decoy oligodeoxynucleotide suppression of contact hypersensitivity.
Specific calcineurin targeting in macrophages confers resistance to inflammation via MKP-1 and p38.
Dermatitis, Exfoliative
Omenn syndrome: therapeutic effects of cyclosporin.
Dermatitis, Seborrheic
Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: a comparative study.
Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Optimizing treatment approaches in seborrheic dermatitis.
Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy.
Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults.
Topical Anti-inflammatory Agents for Seborrheic Dermatitis of the Face or Scalp: Summary of a Cochrane Review.
Dermatomycoses
Clinical and mycological analysis of twenty-one cases of tinea incognita in the aegean region of Turkey: a retrospective study.
Tinea Incognita following the Use of an Antipsoriatic Gel.
[A tinea incognito case caused by Trichophyton rubrum with clinical and mycological cure and review of the literature]
Dermatomyositis
Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis.
Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Diabetes Insipidus, Nephrogenic
Loss of calcineurin Aalpha results in altered trafficking of AQP2 and in nephrogenic diabetes insipidus.
Diabetes Mellitus
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
A Rationale for Age-Adapted Immunosuppression in Organ Transplantation.
Adiponectin and leptin gene polymorphisms in patients with post-transplant diabetes mellitus.
Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Atorvastatin Alleviates Experimental Diabetic Cardiomyopathy by Regulating the GSK-3?-PP2Ac-NF-?B Signaling Axis.
Axillary Artery Dissection After Ultrasound-Guided Infraclavicular Brachial Plexus Block: A Case Report.
Benefit-risk assessment of sirolimus in renal transplantation.
Calcineurin inhibition and new-onset diabetes mellitus after transplantation.
Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation.
Calcineurin inhibitor-associated new-onset diabetes mellitus in chronic kidney disease treatment: a 4-year single-center cross-sectional study in China.
Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.
Calcineurin inhibitors in renal transplantation: what is the best option?
Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus.
Calcineurin/NFAT signaling in the beta-cell: From diabetes to new therapeutics.
CCL2 gene polymorphism is associated with post-transplant diabetes mellitus.
Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.
Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus.
Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.
Deciphering Tacrolimus-Induced Toxicity in Pancreatic ? Cells.
Early non-immunological post transplant complications: a single center experience.
Early-Onset Pneumonia After Liver Transplant: Microbial Causes, Risk Factors, and Outcomes, Mansoura University, Egypt, Experience.
Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia.
Excellent long-term outcome of renal transplantation in cystinosis patients.
Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
Glucocorticoids use in kidney transplant setting.
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy.
Impaired glucose transport and protein kinase B activation by insulin, but not okadaic acid, in adipocytes from subjects with Type II diabetes mellitus.
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients.
Influence of long chain polyunsaturated fatty acids and ornithine concentrations on complications after renal transplant.
KCNJ11 and KCNQ1 Gene Polymorphisms Are Not Associated with Post-Transplant Diabetes Mellitus in Kidney Allograft Recipients Treated with Tacrolimus.
Necrobiosis lipoidica with rapid response to doxycycline.
New onset diabetes after transplantation (NODAT): an overview.
New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.
New-onset diabetes mellitus after solid organ transplantation.
Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study.
Post-transplant diabetic ketoacidosis--a possible consequence of immunosuppression with calcineurin inhibiting agents: a case series.
Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Predictors of decline in renal function after lung transplantation.
Proteasomal degradation of IRS-2, but not IRS-1 by calcineurin inhibition: attenuation of insulin-like growth factor-I-induced GSK-3beta and ERK pathways in adrenal chromaffin cells.
Regulation of dual leucine zipper kinase activity through its interaction with calcineurin.
Risk factors for acute renal injury in living donor liver transplantation: evaluation of the RIFLE criteria.
Serum calcineurin activity in relation to oxidative stress and glycemic control in type II diabetes mellitus.
The defective protein level of myosin light chain phosphatase (MLCP) in the isolated saphenous vein, as a vascular conduit in coronary artery bypass grafting (CABG), harvested from patients with diabetes mellitus (DM).
The role and value of sirolimus administration in kidney and liver transplantation.
The year in review--ATC 2002.
Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases.
[Calcineurin inhibitors and mechanisms that are responsible for the appearance of post-transplant diabetes mellitus]
[Chronic renal failure after heart, lung, liver, or intestine transplantation]
[Late complications following renal transplantation]
[New immunosuppressive drugs and diabetes]
Diabetes Mellitus, Experimental
[Effect of trihydroxyoctadecadiene acids from Bryonia alba L. on the activity of glycogen metabolism enzymes in alloxan diabetes]
Diabetes Mellitus, Type 1
Atorvastatin Alleviates Experimental Diabetic Cardiomyopathy by Regulating the GSK-3?-PP2Ac-NF-?B Signaling Axis.
Calcineurin Inhibitor-Free Immunosuppressive Regimen in Type 1 Diabetes Patients Receiving Islet Transplantation: Single-Group Phase 1/2 Trial.
Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients.
Diabetes Mellitus, Type 2
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Abnormal myosin phosphatase targeting subunit 1 phosphorylation and actin polymerization contribute to impaired myogenic regulation of cerebral arterial diameter in the type 2 diabetic Goto-Kakizaki rat.
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Cytoprotective regulation of the mitochondrial permeability transition pore is impaired in type 2 diabetic Goto-Kakizaki rat hearts.
Dysfunction of insulin mediator protein kinase FA in lymphocytes of patients with NIDDM.
Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes.
Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus.
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Exendin-4 stimulates autophagy in pancreatic ?-cells via the RAPGEF/EPAC-Ca2+-PPP3/calcineurin-TFEB axis.
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Hypomethylation of the promoter of the catalytic subunit of protein phosphatase 2A in response to hyperglycemia.
Insulin Requirement After a Renal Transplant in Patients With Type 2 Diabetes: The Choice of Calcineurin Inhibitors.
Is a flavonoid-rich diet with steamer cooking safe during calcineurin inhibitors therapy?
Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes.
Mutational analysis of the coding regions of the genes encoding protein kinase B-alpha and -beta, phosphoinositide-dependent protein kinase-1, phosphatase targeting to glycogen, protein phosphatase inhibitor-1, and glycogenin: lessons from a search for genetic variability of the insulin-stimulated glycogen synthesis pathway of skeletal muscle in NIDDM patients.
New-Onset Diabetes after Kidney Transplantation.
New-onset diabetes after renal transplantation.
The B55alpha-containing PP2A holoenzyme dephosphorylates FOXO1 in islet beta cells under oxidative stress.
Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus.
Diabetic Angiopathies
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Diabetic Cardiomyopathies
Leukocytic toll-like receptor 2 knockout protects against diabetes-induced cardiac dysfunction.
Diabetic Nephropathies
Calcineurin is activated in diabetes and is required for glomerular hypertrophy and ECM accumulation.
Cluster analysis and phylogenetic relationship in biomarker identification of type 2 diabetes and nephropathy.
Differential expression of calcineurin A isoforms in the diabetic kidney.
DUSP1 overexpression attenuates renal tubular mitochondrial dysfunction by restoring Parkin-mediated mitophagy in diabetic nephropathy.
DUSP1 recuses diabetic nephropathy via repressing JNK-Mff-mitochondrial fission pathways.
DUSP26 regulates podocyte oxidative stress and fibrosis in a mouse model with diabetic nephropathy through the mediation of ROS.
FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin.
FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats.
Inhibition of calcineurin/NFAT pathway plays an essential role in renoprotective effect of tropisetron in early stage of diabetic nephropathy.
Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Diabetic Neuropathies
Downregulation of calcineurin activity in cervical carcinoma.
Diabetic Retinopathy
Expression of wild-type p53-induced phosphatase 1 in diabetic epiretinal membranes.
Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation.
Diffuse Intrinsic Pontine Glioma
Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Diplopia
Isolated diplopia associated with calcineurin inhibitor therapy in a patient with idiopathic membranous nephropathy: a case report.
DNA Virus Infections
Dephosphorylation of cGAS by PPP6C impairs its substrate binding activity and innate antiviral response.
Down Syndrome
A calcineurin inhibitory protein overexpressed in Down's syndrome interacts with the product of a ubiquitously expressed transcript.
A conserved family of calcineurin regulators.
A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion.
A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling.
A single extra copy of Down syndrome critical region 1-4 results in impaired hepatic glucose homeostasis.
A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
A zebrafish model for calcineurin-dependent brain function.
Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling.
Association Between Sequence Variations in RCAN1 Promoter and the Risk of Sporadic Congenital Heart Disease in a Chinese Population.
c-Jun Inhibits Thapsigargin-Induced ER Stress Through Up-Regulation of DSCR1/Adapt78.
Calcineurin activity in children with Mental handicap.
Confirmed rare copy number variants implicate novel genes in schizophrenia.
Covalent NEDD8 conjugation increases RCAN1 protein stability and potentiates its inhibitory action on calcineurin.
Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1).
CREB activates proteasomal degradation of DSCR1/RCAN1.
CREB-mediated Bcl-2 expression contributes to RCAN1 protection from hydrogen peroxide-induced neuronal death.
Cyclosporin A Promotes Tumor Angiogenesis in a Calcineurin-Independent Manner by Increasing Mitochondrial Reactive Oxygen Species.
Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways.
Differential expression of members of the RCAN family of calcineurin regulators suggests selective functions for these proteins in the brain.
Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes.
Division of labor in the growth cone by DSCR1.
Down syndrome candidate region 1 increases the stability of the IkappaBalpha protein: implications for its anti-inflammatory effects.
Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesis.
Down syndrome critical region 1 enhances the proteolytic cleavage of calcineurin.
Down syndrome critical region-1 is a transcriptional target of nuclear factor of activated T cells-c1 within the endocardium during heart development.
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.
DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways.
Fecal corticosterone levels in RCAN1 mutant mice.
Histone deacetylase 3 promotes RCAN1 stability and nuclear translocation.
Identification and analysis of human RCAN3 (DSCR1L2) mRNA and protein isoforms.
Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans.
Interaction of calcineurin with substrates and targeting proteins.
Lycopene inhibits regulator of calcineurin 1-mediated apoptosis by reducing oxidative stress and down-regulating Nucling in neuronal cells.
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Targets Down Syndrome Candidate Region 1 (DSCR1/RCAN1) to control Neuronal Differentiation.
Protein kinase A phosphorylates Down syndrome critical region 1 (RCAN1).
Raf-1 is a binding partner of DSCR1.
RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration.
RCAN1 links impaired neurotrophin trafficking to aberrant development of the sympathetic nervous system in Down syndrome.
RCAN1 Mutation and Functional Characterization in Children with Sporadic Congenital Heart Disease.
RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer's disease.
Regulation of Down Syndrome Critical Region 1 expression by Nuclear Factor of Activated T cells in megakaryocytes.
Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis.
Regulator of Calcineurin (RCAN): Beyond Down Syndrome Critical Region.
Regulator of Calcineurin (RCAN-1) Regulates Thermotaxis Behavior in Caenorhabditis elegans.
Regulator of calcineurin 1 is a novel RNA-binding protein to regulate neuronal apoptosis.
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
The Caenorhabditis elegans homologue of Down syndrome critical region 1, RCN-1, inhibits multiple functions of the phosphatase calcineurin.
The calcineurin inhibitor Sarah (Nebula) exacerbates A?42 phenotypes in a Drosophila model of Alzheimer's disease.
The neuronal and endocrine roles of RCAN1 in health and disease.
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
The regulator of calcineurin 1 (RCAN1/DSCR1) activates the cAMP response element-binding protein (CREB) pathway.
The transcription factor STAT2 enhances proteasomal degradation of RCAN1 through the ubiquitin E3 ligase FBW7.
Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras.
VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis?
Drug Resistant Epilepsy
A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease.
De Novo Mutations in PPP3CA Cause Severe Neurodevelopmental Disease with Seizures.
Early-onset infant epileptic encephalopathy associated with a de novo PPP3CA gene mutation.
Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.
PPP3CA truncating variants clustered in the regulatory domain cause early-onset refractory epilepsy.
Drug-Related Side Effects and Adverse Reactions
A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms.
Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling.
Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
Idiosyncratic drug reactions and membranous glomerulopathy.
Immunosuppressive agents in organ transplantation: past, present, and future.
Liver transplantation and liver cell transplantation.
Mycophenolate sodium: tolerability and efficacy in transplantation in the rat.
Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies.
The influence of immunomodulatory diets on transplant success and complications.
Dry Eye Syndromes
Calcineurin Inhibitor Voclosporin Preserves Corneal Barrier and Conjunctival Goblet Cells in Experimental Dry Eye.
Ductus Arteriosus, Patent
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Dwarfism
Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development.
Dysautonomia, Familial
Calcineurin and synaptophysin in the human spinal cord of normal individuals and patients with familial dysautonomia.
Dyslexia
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Dyslipidemias
A retrospective analysis of ezetimibe treatment in renal transplant recipients.
Calcineurin Antagonizes AMPK to Regulate Lipolysis in Caenorhabditis elegans.
Characteristics and Outcomes of Kidney Transplant Recipients with a Functioning Graft for More than 25 Years.
Cyclosporin A inhibits apolipoprotein AI gene expression.
mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
New onset diabetes after transplantation (NODAT): an overview.
Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia.
[Chronic renal failure after heart, lung, liver, or intestine transplantation]
Dyspnea
Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.
Eclampsia
Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.
Elucidating the mechanism of posterior reversible encephalopathy syndrome: a case of transient blindness after central venous catheterization.
Eczema
A multi-centre, parallel group superiority trial of silk therapeutic clothing compared to standard care for the management of eczema in children (CLOTHES Trial): study protocol for a randomised controlled trial.
A Practical Guide to Patch Testing.
Atopic dermatitis: skin care and topical therapies.
Atopic dermatitis: the updated practice parameter and beyond.
Challenges in assessing rare risks associated with topical calcineurin inhibitors for the treatment of eczema.
Common Skin Conditions in Children: Noninfectious Rashes.
Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness.
Health plan budget impact analysis for pimecrolimus.
Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway.
Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema.
National Eczema Association and topical calcineurin inhibitor labeling.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Potential new indications of topical calcineurin inhibitors.
Predictors of Basal Cell Carcinoma in High-Risk Patients in the VATTC (VA Topical Tretinoin Chemoprevention) Trial.
Skin conditions: new drugs for managing skin disorders.
Topical calcineurin inhibitors in eczema and cancer association: A cohort study.
Treatment of childhood eczema.
Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders.
Use of Complementary and Alternative Therapies in Outpatients with Atopic Dermatitis from a Dermatological University Department.
[Development of calcineurin blocking non-steroid topical immunosuppressants for effective management of eczema]
[Evidence-based treatment options for allergic diseases in otolaryngology: an update].
[New and rarley used treatment options for refractory hand eczema: local UVA-1 phototherapy, retinoids, calcineurin inhibitors]
[Off-label indications for topical tacrolimus].
[The treatment of atopic dermatitis in adults with topical calcineurin inhibitors]
Eczema, Dyshidrotic
Pompholyx: what's new?
Edema, Cardiac
VEGF-C/VEGFR-3 axis protects against pressure-overload induced cardiac dysfunction through regulation of lymphangiogenesis.
Embolic Stroke
Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury.
Embolism
Comparison of denovo sirolimus vs. Calcineurin inhibitor immunosuppression regarding incidence of deep venous thrombosis and pulmonary embolism following renal transplantation.
Encephalitis
Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Posterior reversible encephalopathy syndrome concurrent with human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation.
Encephalomyelitis
Butylphthalide ameliorates experimental autoimmune encephalomyelitis by suppressing PGAM5-induced necroptosis and inflammation in microglia.
Encephalomyelitis, Autoimmune, Experimental
Butylphthalide ameliorates experimental autoimmune encephalomyelitis by suppressing PGAM5-induced necroptosis and inflammation in microglia.
Encephalomyelitis, Venezuelan Equine
Protein Phosphatase 1? Interacts with Venezuelan Equine Encephalitis Virus Capsid Protein and Regulates Viral Replication through Modulation of Capsid Phosphorylation.
End Stage Liver Disease
A comprehensive review of immunosuppression used for liver transplantation.
Endometrial Hyperplasia
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Endometrial Neoplasms
Analysis of methylation profiling data of hyperplasia and primary and metastatic endometrial cancers.
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.
Identification and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes.
Infrequent methylation of the DUSP6 phosphatase in endometrial cancer.
Membrane-associated serine/threonine protein phosphatase in endometrial cancer.
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
[MicroRNA-145-5p over-expression suppresses proliferation, migration and invasion and promotes apoptosis of human endometrial cancer cells by targeting dual specific phosphatase 6].
Endometriosis
Administration of betaHCG leads to dose-dependent changes of gene expression signature of endometriotic stromal cells.
Elevated phosphatase of regenerating liver 3 (PRL-3) promotes cytoskeleton reorganization, cell migration and invasion in endometrial stromal cells from endometrioma.
Endometrial ILKAP expression among patients with endometriosis and its association with clinical characteristics.
Endotoxemia
Calcineurin regulates myocardial function during acute endotoxemia.
Eosinophilia
Regulator of calcineurin 1 (rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice.
Epilepsies, Myoclonic
A novel nonsense mutation of the EPM2A gene in Northwest Greece causing myoclonic epilepsy.
A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.
Are there errors in glycogen biosynthesis and is laforin a repair enzyme?
Biophysical characterization of laforin-carbohydrate interaction.
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Epilepsy
A bioassay for Lafora disease and laforin glucan phosphatase activity.
A chloroplast-localized dual-specificity protein phosphatase in Arabidopsis contains a phylogenetically dispersed and ancient carbohydrate-binding domain, which binds the polysaccharide starch.
Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
Altered patterns of Ca2+/calmodulin-dependent protein kinase II and calcineurin immunoreactivity in the hippocampus of patients with temporal lobe epilepsy.
Assessing the Biological Activity of the Glucan Phosphatase Laforin.
Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease.
Burden analysis of rare microdeletions suggests a strong impact of neurodevelopmental genes in genetic generalised epilepsies.
Calmodulin-binding proteins: A journey of 40 years.
De Novo Mutations in PPP3CA Cause Severe Neurodevelopmental Disease with Seizures.
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Glycogen phosphorylation and Lafora disease.
High level calcineurin activity predisposes neuronal cells to apoptosis.
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.
Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease.
Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product.
Incorporation of phosphate into glycogen by glycogen synthase.
Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.
Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
Mutations in NHLRC1 cause progressive myoclonus epilepsy.
Myristoyltransferase and calcineurin: novel molecular therapeutic target for epilepsy.
Novel calcineurin A (PPP3CA) variant associated with epilepsy, constitutive enzyme activation and downregulation of protein expression.
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Polyglucosan body structure in Lafora disease.
Prolonged infusion of inhibitors of calcineurin or L-type calcium channels does not block mossy fiber sprouting in a model of temporal lobe epilepsy.
Similar protein phosphatases control starch metabolism in plants and glycogen metabolism in mammals.
Spatiotemporal expression of RCAN1 and its isoform RCAN1-4 in the mouse hippocampus after pilocarpine-induced status epilepticus.
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.
The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure.
The Emerging Roles of the Calcineurin-Nuclear Factor of Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases.
Traumatic Brain Injury Causes a Tacrolimus-Sensitive Increase in Non-Convulsive Seizures in a Rat Model of Post-Traumatic Epilepsy.
Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex.
Epilepsy, Frontal Lobe
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Epilepsy, Post-Traumatic
Traumatic Brain Injury Causes a Tacrolimus-Sensitive Increase in Non-Convulsive Seizures in a Rat Model of Post-Traumatic Epilepsy.
Epilepsy, Temporal Lobe
Altered patterns of Ca2+/calmodulin-dependent protein kinase II and calcineurin immunoreactivity in the hippocampus of patients with temporal lobe epilepsy.
Prolonged infusion of inhibitors of calcineurin or L-type calcium channels does not block mossy fiber sprouting in a model of temporal lobe epilepsy.
Spatiotemporal expression of RCAN1 and its isoform RCAN1-4 in the mouse hippocampus after pilocarpine-induced status epilepticus.
Epiretinal Membrane
Expression of wild-type p53-induced phosphatase 1 in diabetic epiretinal membranes.
Erectile Dysfunction
[Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction]
Erythema
Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
The UV erythema test as a model to investigate the anti-inflammatory potency of topical preparations--reevaluation and optimization of the method.
Esophageal Achalasia
Chest pain in a heart transplant recipient: A case report.
Esophageal Neoplasms
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma.
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
MicroRNA-527 Induces Proliferation and Cell Cycle in Esophageal Squamous Cell Carcinoma Cells by Repressing PH Domain Leucine-Rich-Repeats Protein Phosphatase 2.
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Esthesioneuroblastoma, Olfactory
Calcineurin, a calcium/calmodulin-regulated protein phosphatase, in mammalian neuroendocrine cells and neoplasms.
Eye Diseases
Immunosuppression for the Uveitides.
Eye Infections
Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.
Facial Dermatoses
[Steroid-aggravated rosacea: successful therapy with pimecrolimus]
Fanconi Anemia
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Fatty Liver
Calcineurin inhibitor attenuates cardiac hypertrophy due to energy metabolic disorder.
Pediatric post-transplant metabolic syndrome: New clouds on the horizon.
Fibroadenoma
Effect of Converting From Calcineurin Inhibitor- to Sirolimus-Based Immunosuppressant Regimen on Breast Fibroadenoma Among Kidney Transplant Patients.
Enhanced expression of PP1 gamma 1, a catalytic subunit isoform of protein phosphatase type 1, in invasive ductal carcinoma of the breast.
Fibrocystic Breast Disease
Enhanced expression of PP1 gamma 1, a catalytic subunit isoform of protein phosphatase type 1, in invasive ductal carcinoma of the breast.
Fibroma
Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides.
Food Hypersensitivity
Allergic disease after pediatric liver transplantation with systemic tacrolimus and cyclosporine a therapy.
Management of tacrolimus-associated food allergy after liver transplantation.
Frontotemporal Dementia
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Tau pathology in Alzheimer disease and other tauopathies.
The phosphatase calcineurin regulates pathological TDP-43 phosphorylation.
Fungemia
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.
Gallbladder Neoplasms
DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system.
DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer.
Protein phosphatase PHLPP induces cell apoptosis and exerts anticancer activity by inhibiting Survivin phosphorylation and nuclear export in gallbladder cancer.
Gastrointestinal Stromal Tumors
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Gastroparesis
Impaired contractile responses and altered expression and phosphorylation of Ca(2+) sensitization proteins in gastric antrum smooth muscles from ob/ob mice.
Genetic Diseases, Inborn
Calcineurin A alpha (PPP3CA), calcineurin A beta (PPP3CB) and calcineurin B (PPP3R1) are located on human chromosomes 4, 10q21-->q22 and 2p16-->p15 respectively.
Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles.
NHLRC1 homozygous dodecamer expansion in a Newfoundland dog with Lafora disease.
Gestational Trophoblastic Disease
[Expression and significance of LMP2 and PPM1A in gestational trophoblastic disease].
Giant Cell Arteritis
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Gingival Overgrowth
Gingival overgrowth in renal transplant recipients: a study concerning prevalence, severity, periodontal, and predisposing factors.
Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis.
Periodontal Microbiological Status Influences the Occurrence of Cyclosporine-A and Tacrolimus-Induced Gingival Overgrowth.
Poor oral hygiene enhances gingival overgrowth caused by calcineurin inhibitors.
Gitelman Syndrome
Transplantation of a Gitelman Syndrome Kidney Ameliorates Hypertension: A Case Report.
Glaucoma
Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma.
Calpain activation in experimental glaucoma.
Human Aqueous Humor Phosphatase Activity in Cataract and Glaucoma.
Glaucoma, Open-Angle
Human Aqueous Humor Phosphatase Activity in Cataract and Glaucoma.
Glioblastoma
Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma.
Activation of DNA-PK by ionizing radiation is mediated by protein phosphatase 6.
Adding perphenazine to increase effectiveness of standard glioblastoma chemoirradiation.
AEG-1 expression correlates with CD133 and PPP6c levels in human glioma tissues.
Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.
Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma.
Cordycepin inhibits migration of human glioblastoma cells by affecting lysosomal degradation and protein phosphatase activation.
Corrigendum: Decreased DUSP26 Expression Promotes Malignant Behavior in Glioblastoma Cells via Deregulation of MAPK and Akt Signaling Pathway.
Cyclosporin A attenuating morphine tolerance through inhibiting NO/ERK signaling pathway in human glioblastoma cell line: the involvement of calcineurin.
Decreased DUSP26 Expression Promotes Malignant Behavior in Glioblastoma Cells via Deregulation of MAPK and Akt Signaling Pathway.
Dual-specificity phosphatase (DUSP6) in human glioblastoma: epithelial-to-mesenchymal transition (EMT) involvement.
Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53.
Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.
Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche.
Glioblastomas on the move.
ILKAP, ILK and PINCH1 control cell survival of p53-wildtype glioblastoma cells after irradiation.
Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
Inhibitory effects of cyclosporin A on calcium mobilization-dependent interleukin-8 expression and invasive potential of human glioblastoma U251MG cells.
Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion.
Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells.
Serine/threonine protein phosphatase 6 modulates the radiation sensitivity of glioblastoma.
STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation.
Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.
Glioma
AEG-1 expression correlates with CD133 and PPP6c levels in human glioma tissues.
Calcineurin involvement in the regulation of high-threshold Ca2+ channels in NG108-15 (rodent neuroblastoma x glioma hybrid) cells.
Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.
Calmodulin-dependent phosphatases of PC12, GH3, and C6 cells: physical, kinetic, and immunochemical properties.
Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity.
Ceramide activates heterotrimeric protein phosphatase 2A.
Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3.
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Cyclic AMP induces activity increase of kinase FA (a transmembrane signal of insulin) during NG108-15 hybrid cell differentiation.
Cyclosporin A-sensitive signaling pathway involving calcineurin regulates survival of reactive astrocytes.
Decreased DUSP26 Expression Promotes Malignant Behavior in Glioblastoma Cells via Deregulation of MAPK and Akt Signaling Pathway.
Disease relevance of T11TS-induced T-cell signal transduction through the CD2-mediated calcineurin-NFAT pathway: Perspectives in glioma immunotherapy.
Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
Glucose deprivation affects the expression of genes encoding cAMP-activated protein kinase and related proteins in U87 glioma cells in ERN1 dependent manner.
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
Impact of calcineurin inhibitors on rat glioma cells viability.
Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Inhibitory effects of cyclosporin A on calcium mobilization-dependent interleukin-8 expression and invasive potential of human glioblastoma U251MG cells.
Mechanisms of hypoosmotic volume regulation in glioma cells.
MicroRNA?216b inhibits cell proliferation and invasion in glioma by directly targeting metadherin.
Modulation by calcineurin of 5-HT3 receptor function in NG108-15 neuroblastoma x glioma cells.
MTDH promotes glioma invasion through regulating miR-130b-ceRNAs.
Nuclear factor of activated T cells (NFAT) as a new component of the signal transduction pathway in glioma cells.
Open Data for Differential Network Analysis in Glioma.
Over-expression of Wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas.
P68 RNA helicase promotes invasion of glioma cells through negatively regulating DUSP5.
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma.
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
PPM1D silencing by lentiviral-mediated RNA interference inhibits proliferation and invasion of human glioma cells.
Protein phosphatase 1? regulates the proliferation of human glioma via the NF-?B pathway.
Protein phosphatase 4 catalytic subunit is overexpressed in glioma and promotes glioma cell proliferation and invasion.
Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression.
Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion.
Protein Phosphatase Magnesium-Dependent 1? (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors.
Proteomics reveals protein phosphatase 1? as a biomarker associated with Hippo signal pathway in glioma.
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
Retraction Note to: uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma.
Serine/Threonine Protein Phosphatase-5 Accelerates Cell Growth and Migration in Human Glioma.
Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma.
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth.
uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma.
Glomerulonephritis
Accompanying renal injuries did not impact graft survival in patients with transplant glomerulopathy.
Acute transplant glomerulopathy is associated with antibody-mediated rejection and poor graft outcome.
Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus.
Change in glomerular volume and its clinicopathological impact after kidney transplantation.
Chronic allograft nephropathy: current concepts and future directions.
Clinical Significance of Renal Allograft Protocol Biopsies: A Single Tertiary Center Experience in Malaysia.
Egyptian clinical practice guideline for kidney transplantation.
Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Kidney Complications of Hematopoietic Stem Cell Transplantation.
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Posterior Reversible Encephalopathy Syndrome in Henoch-Schonlein Purpura and Hemolytic Uremic Syndrome.
Protein Phosphatase 2A Enables Expression of Interleukin 17 (IL-17) through Chromatin Remodeling.
Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy.
Synergistic impact of pre-diabetes and immunosuppressants on the risk of diabetes mellitus during treatment of glomerulonephritis and renal vasculitis.
The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging.
The serine/threonine protein phosphatase 2A controls autoimmunity.
The value of long-term protocol biopsies after kidney transplantation.
[Late complications following renal transplantation]
[Use of rituximab in primary and secondary glomerulonephritis].
Glomerulonephritis, IGA
Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis.
The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA).
Glomerulonephritis, Membranoproliferative
Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.
Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation.
Glomerulonephritis, Membranous
Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy.
Calcineurin B1 subunit in human peripheral blood mononuclear cells and its role in idiopathic membranous nephropathy.
Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials.
Chronic renal failure and end-stage renal disease are associated with a high rate of mortality after heart transplantation.
Endoplasmic Reticulum Stress Predicts Clinical Response to Cyclosporine Treatment in Primary Membranous Nephropathy.
Immunosuppressive regimens based on Cyclophospamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy.
Isolated diplopia associated with calcineurin inhibitor therapy in a patient with idiopathic membranous nephropathy: a case report.
Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.
Kidney Pathology after Hematologic Cell Transplantation-A Single-Center Observation Study of Indication Biopsies and Autopsies.
Membranous Nephropathy: Core Curriculum 2021.
Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer?
Response Predictors to Calcineurin Inhibitors in Patients with Primary Membranous Nephropathy.
Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients.
Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes.
The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4.
The calcineurin regulatory subunit polymorphism and the treatment efficacy of tacrolimus for idiopathic membranous nephropathy.
The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.
Glomerulosclerosis, Focal Segmental
A case of de novo focal segmental glomerulosclerosis occurred one and half years after kidney transplantation supposed to be caused by calcineurin inhibitor.
A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis.
Calcineurin inhibitors in the treatment of primary focal segmental glomerulosclerosis: A protocol of systematic review and meta-analysis of randomized controlled trials.
Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis of the Literature.
Calcineurin Inhibitors With Reduced-Dose Steroids as First-Line Therapy for Focal Segmental Glomerulosclerosis.
Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.
Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial.
Influence of preservation method on histopathological lesions of kidney allografts.
Loss of Subpodocytic Space Predicts Poor Response to Tacrolimus in Steroid-Resistant Calcineurin Inhibitor-Naïve Adult-Onset Primary Focal Segmental Glomerulosclerosis.
Persistent CD-19 Depletion by Rituximab is Cost-effective in Maintaining Remission in Calcineurin-inhibitor Dependent Podocytopathy.
Renal transplantation: basic concepts and evolution of therapy.
Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.
Standard immunosuppresive therapy of immune-mediated glomerular diseases.
Successful treatment of recurrent focal segmental glomerulosclerosis combined with calcineurin inhibitor nephrotoxicity four yr after kidney transplantation.
Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors.
Glucose Intolerance
Conversion to sirolimus in solid organ transplantation: a single-center experience.
Dual specificity phosphatase 6 deficiency is associated with impaired systemic glucose tolerance and reversible weight retardation in mice.
Glucocorticoids use in kidney transplant setting.
How to assess for impaired glucose tolerance before transplantation and should these results influence the choice of calcineurin inhibitors?
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Involvement of AMPK in alcohol dehydrogenase accentuated myocardial dysfunction following acute ethanol challenge in mice.
New onset diabetes after transplantation (NODAT): an overview.
Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Glucose Metabolism Disorders
DUSP1 recuses diabetic nephropathy via repressing JNK-Mff-mitochondrial fission pathways.
Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation.
Glucose metabolism disorders in children with refractory nephrotic syndrome.
Glycogen Storage Disease
The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure.
Glycosuria
Increase in liver protein phosphatase-1 in spontaneously diabetic Chinese hamsters.
Gout
Gout Due to Tacrolimus in a Liver Transplant Recipient.
Hyperuricemia and gout in solid-organ transplant: update in pharmacological management.
Managing new-onset gout in pediatric renal transplant recipients: when, how, to what extent.
Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature.
[A case of gout secondary to primary myelofibrosis].
[Research on relationship of syndrome type and parameters of hemorheology and platelet activation in patients with acute gout arthritis of dampness-heat blockage type and stasis-heat accumulate type]
Graft vs Host Disease
A BMT CTN phase II trial of unrelated donor marrow transplantation for children with severe sickle cell disease.
A gut feeling about murine syngeneic GVHD.
A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
Achalasia in a Patient Undergoing Hematologic Stem Cell Transplant After Exposure to Tacrolimus.
Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation.
Advances in immune regulation in transplantation.
Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma.
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
Allogeneic Hematopoietic Cell Transplantation with Full-Intensity Conditioning for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1998-2006.
Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.
Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.
Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.
Calcineurin and mTOR Inhibitor-Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study.
Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Calcineurin inhibitor-associated oral inflammatory polyps after transplantation.
Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation.
Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Calcineurin inhibitors suppress acute graft-versus-host disease via NFAT-independent inhibition of T cell receptor signaling.
Calcineurin inhibitors target Lck activation in graft-versus-host disease.
Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
Chronic Kidney Disease, Thrombotic Microangiopathy and Hypertension Following T-cell Depleted Hematopoietic Stem Cell Transplantation.
Chronic liver graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients during tapering or after stopping calcineurin inhibitors.
Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature.
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations.
Comparative Study of Tacrolimus and Short-Term Methotrexate: 2-Day versus 3-Day Methotrexate as Graft-versus-Host-Disease Prophylaxis after Umbilical Cord Blood Transplantation in Adults.
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.
Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation.
Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.
DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.
Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease.
Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
Haploidentical Peripheral Stem Cell Transplantation for Young Patients with Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide and Methotrexate.
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.
Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report.
Hematopoietic Stem Cell Transplantation in Children with Inborn Errors of Immunity: a Multi-center Experience in Colombia.
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome.
High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults.
Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Human Leukocyte Antigen-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis.
Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.
Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults.
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation.
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.
Inhibition of Calcineurin Abrogates While Inhibition of mTOR Promotes Regulatory T Cell Expansion and Graft-Versus-Host Disease Protection by IL-2 in Allogeneic Bone Marrow Transplantation.
Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A.
Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation.
Midostaurin and cyclosporine drug interaction: A case report.
Mini-review of kidney disease following hematopoietic stem cell transplant?.
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.
Novel Insights Into the Mechanism of GVHD-Induced Tissue Damage.
Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study.
Oral Pyogenic Granuloma After Bone Marrow Transplant in the Pediatric/Adolescent Population: Report of 5 Cases.
Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease.
Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors.
Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation.
Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation.
Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?
Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation.
Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Safety and interactions of new antifungals in stem cell transplant recipients.
Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at >1 year after undergoing allogeneic hematopoietic stem cell transplantation.
Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation.
Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.
Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease.
Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.
Successful switch to oral tacrolimus in a patient with hypersensitivity reaction to parenteral vitamin K, cyclosporine, and tacrolimus: A case report.
Successful treatment of calcineurin inhibitor-induced pain syndrome with acute graft versus host disease by switching calcineurin inhibitors followed by pregabalin.
Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors.
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.
Tacrolimus induced pseudogout following allogeneic hematopoietic cell transplant.
Thrombotic microangiopathy in transplantation and malignancy.
Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation.
Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.
Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.
[Retrospective analysis of posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation]
[The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant/steroid-dependent extensive cGVHD].
Granuloma
Successful Treatment of Recalcitrant Granuloma Gluteale Infantum with Topical Tacrolimus 0.03% Ointment.
Granuloma Annulare
[Granuloma annulare.]
Hamartoma Syndrome, Multiple
Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
Head and Neck Neoplasms
Interrelationship between protein phosphatase-2A and cytoskeletal architecture during the endothelial cell response to soluble products produced by human head and neck cancer.
Headache Disorders
Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms.
Hearing Loss
Deficit of mitogen-activated protein kinase phosphatase 1 (DUSP1) accelerates progressive hearing loss.
Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development.
SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96?hours.
Hearing Loss, Noise-Induced
An experimental comparative study of dexamethasone, melatonin and tacrolimus in noise-induced hearing loss.
Calcineurin activation contributes to noise-induced hearing loss.
Treatment With Calcineurin Inhibitor FK506 Attenuates Noise-Induced Hearing Loss.
Hearing Loss, Sensorineural
Prostaglandin E1 effects on CD62p and PAC-1 in patients with sudden sensorineural hearing loss.
Heart Arrest
Heart block in mice overexpressing calcineurin but not NF-AT3.
Protein phosphatase-2A is activated in pig brain following cardiac arrest and resuscitation.
Heart Block
Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.
Heart block in mice overexpressing calcineurin but not NF-AT3.
iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin.
Heart Defects, Congenital
De novo missense variants in PPP1CB are associated with intellectual disability and congenital heart disease.
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Diseases
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.
C. sinensis ablates allograft vasculopathy when used as an adjuvant therapy with cyclosporin A.
Calcineurin and hypertrophic heart disease: novel insights and remaining questions.
Calcineurin increases cardiac transient outward K+ currents via transcriptional up-regulation of Kv4.2 channel subunits.
Calcineurin-AKAP interactions: therapeutic targeting of a pleiotropic enzyme with a little help from its friends.
Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder.
Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy.
Inhibition of calcineurin and sarcolemmal Ca2+ influx protects cardiac morphology and ventricular function in K(v)4.2N transgenic mice.
Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes.
Phenylephrine promotes cardiac fibroblast proliferation through calcineurin-NFAT pathway.
Prevention of cardiac hypertrophy in mice by calcineurin inhibition.
Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.
[Upstream therapy for atrial fibrillation].
Heart Failure
A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.
A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development.
Acute cellular transplant rejection following laparoscopic adjustable gastric banding in a morbidly obese patient post heart transplantation.
Age-Dependent Protein Expression of Serine/Threonine Phosphatases and Their Inhibitors in the Human Cardiac Atrium.
Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways.
Ca2+-dependent modulation of single human cardiac L-type calcium channels by the calcineurin inhibitor cyclosporine.
Calcineurin and human heart failure.
Calcineurin in human heart hypertrophy.
Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: requiescat in pace?
Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats.
Calcineurin signaling in the heart: The importance of time and place.
Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production.
Calcineurin-induced energy wasting in a transgenic mouse model of heart failure.
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure.
Calcium-calcineurin signaling in the regulation of cardiac hypertrophy.
Carabin: Endogenous calcineurin inhibitor, a potential diagnostic and therapeutic target for cardiac hypertrophy in heart failure.
Cardiac calcineurin during transition from hypertrophy to heart failure in rats.
Cardiac CaM Kinase II genes ? and ? contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy.
Cardiac hypertrophy and thyroid hormone signaling.
Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1? in heart failure.
Changes in metabolic profile and population of skeletal muscle fibers of mice overexpressing calsequestrin: Influence of losartan.
Chronic ?-adrenergic stimulation reverses depressed Ca handling in mice overexpressing inhibitor-2 of protein phosphatase 1.
Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A.
Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats.
Cyclosporin A regulates sodium-calcium exchanger (NCX1) gene expression in vitro and cardiac hypertrophy in NCX1 transgenic mice.
Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
End-stage renal disease after orthotopic heart transplantation: a single-institute experience.
Enhanced activation of p21-activated kinase 1 in heart failure contributes to dephosphorylation of connexin 43.
Enhanced Ca2+ channel currents in cardiac hypertrophy induced by activation of calcineurin-dependent pathway.
Enhanced myocyte contractility and Ca2+ handling in a calcineurin transgenic model of heart failure.
Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia.
Evidence for calcineurin-mediated regulation of SERCA 2a activity in human myocardium.
Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.
Ginseng Inhibits Cardiomyocyte Hypertrophy and Heart Failure via NHE-1 Inhibition and Attenuation of Calcineurin Activation.
High throughput phenotyping of left and right ventricular cardiomyopathy in calcineurin transgene mice.
HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.
Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function.
Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure.
Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.
Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality.
Isoform- and tissue-specific regulation of the Ca2+-sensitive transcription factor NFAT in cardiac myocytes and in heart failure.
Isoform-specific roles of protein phosphatase 1 catalytic subunits in sarcoplasmic reticulum-mediated Ca2+ cycling.
Losartan decreases p42/44 MAPK signaling and preserves LZ+ MYPT1 expression.
Mechanisms underlying pathological Ca2+ handling in diseases of the heart.
Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.
Neutrophil Gelatinase-Associated Lipocalin: Ready for Routine Clinical Use? An International Perspective.
NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure.
Overexpression of heart-specific small subunit of myosin light chain phosphatase results in heart failure and conduction disturbance.
Peroxynitrite Increases Protein Phosphatase Activity and Promotes the Interaction of Phospholamban with Protein Phosphatase 2a in the Myocardium.
Possible therapeutic targets in cardiac myocyte apoptosis.
Protective effect of the endothelin antagonist CPU0213 against isoprenaline-induced heart failure by suppressing abnormal expression of leptin, calcineurin and SERCA2a in rats.
Reply to revisiting calcineurin and human heart failure
Reversibility of adverse, calcineurin-dependent cardiac remodeling.
Revisiting calcineurin and human heart failure.
Serine-threonine protein phosphatase regulation of Cx43 dephosphorylation in arrhythmogenic disorders.
Skeletal muscle fibres synthesis in heart failure: role of PGC-1alpha, calcineurin and GH.
The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice.
Therapeutic Chemical Screen Identifies Phosphatase Inhibitors to Reconstitute PKB Phosphorylation and Cardiac Contractility in ILK-Deficient Zebrafish.
Thyroid hormone plus dual-specificity phosphatase-5 siRNA increases the number of cardiac muscle cells and improves left ventricular contractile function in chronic doxorubicin-injured hearts.
Vascular reactivity in heart failure: role of myosin light chain phosphatase.
Z-disc protein CHAPb induces cardiomyopathy and contractile dysfunction in the postnatal heart.
[Cardiac hypertrophy and calcium signaling]
[Effects of valsartan on sarcoplasmic reticulum calcium adenodine triphosphatase, protein kinase A and protein phosphatase 1 alpha in a rabbit model of heart failure]
[Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans].
[Role of calcineurin in down-regulation of left ventricular transmural voltage- dependent K(+) currents in mice with heart failure].
[The mutants of calcineurin transgenic mice]
Heart Septal Defects, Atrial
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Septal Defects, Ventricular
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Valve Diseases
[Calpain-2 and calcineurin protein expression in right atrial appendages from patients underwent valve replacement with or without atrial fibrillation].
Hematologic Neoplasms
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.
Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab.
Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin.
Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match.
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.
The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities.
Hematuria
Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients.
Hemic and Lymphatic Diseases
Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients.
Hemolytic-Uremic Syndrome
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.
Chronic renal failure and end-stage renal disease are associated with a high rate of mortality after heart transplantation.
Conversion to sirolimus in pediatric renal transplantation recipients.
Conversion to sirolimus in solid organ transplantation: a single-center experience.
Cyclosporine Induces Endothelial Cell Release of Complement-Activating Microparticles.
Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome.
Electron paramagnetic resonance study of erythrocyte membrane fluidity in renal transplant recipients.
Growth failure associated with sirolimus: case report.
Postrenal transplant hemolytic uremic syndrome/thrombotic microangiopathy: Ahmedabad experience.
Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience.
Rescue treatment for cyclosporine-associated hemolytic-uremic syndrome with intravenous immunoglobulin.
Hemophilia A
Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study.
Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus coinfection with special reference to hemophiliac recipients in Japan.
Hepatic Encephalopathy
Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation.
Neurologic complications after liver transplantation.
Hepatic Veno-Occlusive Disease
The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model.
Hepatitis
Accompanying renal injuries did not impact graft survival in patients with transplant glomerulopathy.
Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation.
Development of lymphoproliferative disease after liver transplantation.
Hepatitis C infection in liver transplantation.
Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy.
Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients.
PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury.
[A case of idiopathic postinfantile giant cell hepatitis treated with a calcineurin inhibitor].
Hepatitis B
A Genetic Variant of PPP1CB Influences Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma in Han Chinese: A Pathway Based Analysis.
Does Induction Type Influence Outcomes in Kidney Transplant Recipients at Different Phases of Hepatitis B Infection?
ER stress regulating protein phosphatase 2A-B56?, targeted by hepatitis B virus X protein, induces cell cycle arrest and apoptosis of hepatocytes.
Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients.
Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Outcome of second kidney transplant: a single center experience.
The interaction of hepatitis B virus X protein and protein phosphatase type 2 Calpha and its effect on IL-6.
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Hepatitis C
A single-center experience of the use of interleukin-2 receptor antagonists for various situations in liver transplant recipients.
Acute confusional state following liver transplantation for alcoholic liver disease.
Acute transplant glomerulopathy is associated with antibody-mediated rejection and poor graft outcome.
Approach to recurrent hepatitis C following liver transplantation.
Calcineurin A versus NS5A-TP2/HD domain containing 2: a case study of site-directed low-frequency random mutagenesis for dissecting target specificity of peptide aptamers.
Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient.
Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha.
Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: Effects on virus replication and recurrent hepatitis.
Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells.
Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients.
Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients.
Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors.
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors.
Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation.
Hepatitis C infection in liver transplantation.
Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6.
Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair.
Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis.
Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation.
Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation.
Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C.
Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients.
Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C.
Management of liver transplant recipients with recurrent hepatitis C.
MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course.
Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
Natural history of hepatitis C and outcomes following liver transplantation.
New-Onset Diabetes after Kidney Transplantation.
New-onset diabetes after renal transplantation.
New-onset diabetes after transplantation: risk factors and clinical impact.
New-onset diabetes mellitus after kidney transplantation: Current status and future directions.
New-onset diabetes mellitus after solid organ transplantation.
Of mice and men, calcineurin inhibitors and hepatitis C.
Outcome of second kidney transplant: a single center experience.
Protection of CD4+ T cells from hepatitis C virus infection-associated senescence via ?Np63-miR-181a-Sirt1 pathway.
PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism.
Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor.
Review article: hepatitis C virus and calcineurin inhibition after renal transplantation.
Risk assessment and management of post-transplant diabetes mellitus.
Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation.
Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice.
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
The role of antibody induction in liver transplantation.
The year in review--ATC 2002.
Therapeutic management of recurrent hepatitis C after liver transplantation.
Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry.
Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1.
[Treatment of recurrent HCV infection after liver transplantation]
[Treatment of recurrent hepatitis C infection after liver transplantation]
Hepatitis C, Chronic
Do anti-CD25 monoclonal antibodies potentiate posttransplant diabetes mellitus?
Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation.
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report.
Hepatitis E
Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus.
Hepatitis, Autoimmune
Autoimmune liver disease and rheumatic manifestations.
De novo autoimmune hepatitis after liver transplantation.
Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis.
Immunological aspects and therapeutic significance of an autoantibody against histone H1 in a rat model of concanavalin A-induced hepatitis.
Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience.
Hepatoblastoma
Glomerular filtration rate in liver transplant for unresectable hepatoblastoma.
Hepatomegaly
Complementary Indicators for Diagnosis of Hepatic Vein Stenosis After Pediatric Living-donor Liver Transplantation.
Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice.
Hepatorenal Syndrome
Role of endothelin and endothelin receptor antagonists in renal disease.
Simultaneous Liver-Kidney Transplant: Too Many or Just Enough?
Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation.
[Simultaneous Hepatorenal Transplantation from a Brain-Dead Donor for Graft Dysfunction and Renal Insufficiency in a Liver Transplant Recipient : A Case Report].
Herpes Simplex
A conserved domain of herpes simplex virus ICP34.5 regulates protein phosphatase complex in mammalian cells.
A host cell protein binds to a highly conserved sequence element (pac-2) within the cytomegalovirus a sequence.
Alkaline phosphodiesterase I and alkaline phosphatase I in plasma membranes of herpes simplex virus type 1 transformed hamster cells.
Calcineurin phosphatase activity regulates Varicella-Zoster Virus induced cell-cell fusion.
Effects of herpes simplex virus vectors encoding poreless TRPV1 or protein phosphatase 1? in a rat cystitis model induced by hydrogen peroxide.
Functions of the sequences at the ends of the inverted repeats of pseudorabies virus.
PPP6C Negatively Regulates STING-Dependent Innate Immune Responses.
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
The effect of herpes simplex virus vector-mediated gene therapy of protein phosphatase 1? on bladder overactivity and nociception.
The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.
The gamma134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells.
The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2.
Herpes Zoster
The protein phosphatase with EF-hand domain 1 is a calmodulin-binding protein that interacts with proteins involved in sperm capacitation, binding to the zona pellucida, and motility.
Hirschsprung Disease
Differential expression of FOXA1, DUSP6, and HA117 in colon segments of Hirschsprung's disease.
Histiocytoma, Malignant Fibrous
Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 in malignant fibrous histiocytoma.
Hodgkin Disease
Potential role of hypoxia in early stages of Hodgkin lymphoma pathogenesis.
Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma.
Huntington Disease
An immunohistochemical investigation of the human neostriatum in Huntington's disease.
Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation.
Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.
Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders.
Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.
Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: Role in excitotoxicity.
Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.
Synaptophysin expression in the striatum in Huntington's disease.
Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease.
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Hydatidiform Mole
[Expression and significance of LMP2 and PPM1A in gestational trophoblastic disease].
Hydrocephalus
Tacrolimus and cyclosporine A are of no benefit to young rats with kaolin-induced hydrocephalus.
Hyperaldosteronism
Recent insights into sodium and potassium handling by the aldosterone-sensitive distal nephron: implications on pathophysiology and drug discovery.
Hyperalgesia
Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis.
Increases in the phosphorylation of cyclic AMP response element binding protein (CREB) and decreases in the content of calcineurin accompany thermal hyperalgesia following chronic constriction injury in rats.
Melatonin relieves neuropathic allodynia through spinal MT2-enhanced PP2Ac and downstream HDAC4 shuttling-dependent epigenetic modification of hmgb1 transcription.
Potentiation of spinal NMDA-mediated nociception by cocaine- and amphetamine-regulated transcript peptide via PKA and PKC signaling pathways in rats.
Ropivacaine relieves pain and prevents chondrocyte degradation probably through Calcineurin/NFAT1 signaling pathway in osteoarthritis rats.
Upregulation of nuclear factor of activated T-cells by nerve injury contributes to development of neuropathic pain.
Hypercalcemia
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
Hypercholesterolemia
Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.
Impact of Cardiovascular Risk Factors on Long-Term Mortality After Liver Transplantation.
Loss of Down Syndrome Critical Region-1 Mediated-Hypercholesterolemia Accelerates Corneal Opacity Via Pathological Neovessel Formation.
Hyperferritinemia
Hemophagocytic Syndrome Complicated with Dermatomyositis Controlled Successfully with Infliximab and Conventional Therapies.
Hyperglycemia
A new cell-permeable peptide allows successful allogeneic islet transplantation in mice.
Activation of the PP2A catalytic subunit by ivabradine attenuates the development of diabetic cardiomyopathy.
Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans.
Cardiovascular risk estimates and risk factors in renal transplant recipients.
Conversion to sirolimus in kidney-pancreas and pancreas transplantation.
Early non-immunological post transplant complications: a single center experience.
Fasting and rapamycin: diabetes versus benevolent glucose intolerance.
Hyperglycemia induced activation of type-1 protein phosphatase activator (kinase FA) in perfused human placenta.
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.
mTOR and Cardiovascular Diseases: Diabetes Mellitus.
New-onset post-transplant diabetes mellitus after allogeneic hematopoietic cell transplant is initiated by insulin resistance, not immunosuppressive medications.
Role of ROCK upregulation in endothelial and smooth muscle vascular functions in diabetic rat aorta.
THE RATIONALE FOR USE OF INCRETINS IN THE MANAGEMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT).
Transgenic overexpression of active calcineurin in beta-cells results in decreased beta-cell mass and hyperglycemia.
[Outcome of renal transplantation after tacrolimus switch to cyclosporine].
Hyperkalemia
Aldosterone Resistance Due to Tacrolimus: A Case Report.
Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling.
Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen.
Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation.
Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia.
Fludrocortisone-a treatment for tubulopathy post-paediatric renal transplantation: A national paediatric nephrology unit experience.
Hyperchloremic metabolic acidosis in the kidney transplant patient.
Hyperkalemia and Hypertension Post Organ Transplantation - A Management Challenge.
Incidence of Co-Trimoxazole-Induced Hyperkalemia in a Tertiary Care Hospital.
Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients.
Severe Hyperkalemia Complicating Voriconazole Treatment in a Kidney Transplant Recipient With Histoplasmosis: A Case Report.
Specific disruption of calcineurin-signaling in the distal convoluted tubule impacts the transcriptome and proteome, and causes hypomagnesemia and metabolic acidosis.
Tacrolimus ameliorates the phenotypes of type 4 Bartter syndrome model mice through activation of sodium-potassium-2 chloride cotransporter and sodium-chloride cotransporter.
[Electrolyte and acid-base balance disorders in advanced chronic kidney disease]
Hyperlipidemias
Ablation of calcineurin A? reveals hyperlipidemia and signaling cross-talks with phosphodiesterases.
Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Cardiovascular risk estimates and risk factors in renal transplant recipients.
Chronic allograft nephropathy--immunologic and nonimmunologic factors.
Chronic allograft nephropathy: pathogenesis and management of an important posttransplant complication.
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway.
Cyclosporin A inhibits apolipoprotein AI gene expression.
De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient.
Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity.
Future directions in immunosuppression.
Hepatitis C: liver transplantation.
Obesity, lipid profiles and oxidative stress in children after liver transplantation.
Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study.
Renal dysfunction in liver transplantation: The problem and preventive strategies.
Sirolimus experience at a Swedish transplantation center.
Strategies to reduce toxicities and improve outcomes in renal transplant recipients.
The effect of cyclosporine A on the phosphorylation of the AMPK pathway in the rat hippocampus.
The pathogenesis and treatment of chronic allograft nephropathy.
The problem of late allograft loss in kidney transplantation.
Hyperoxaluria
Early renal failure after domino hepatic transplantation using the liver from a compound heterozygous patient with primary hyperoxaluria.
Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation.
Hyperparathyroidism
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet.
Hyperchloremic metabolic acidosis in the kidney transplant patient.
[Effects of kidney transplantation on bone: osteoporosis or other?]
Hypersensitivity
Atf1 is a target of the mitogen-activated protein kinase Pmk1 and regulates cell integrity in fission yeast.
Calcineurin and calcium channel CchA coordinate the salt stress response by regulating the cytoplasmic Ca2+ homeostasis in Aspergillus nidulans.
Calcineurin Inhibition Causes ?2?-1-Mediated Tonic Activation of Synaptic NMDA Receptors and Pain Hypersensitivity.
Calcineurin Inhibitor Induces Pain Hypersensitivity by Potentiating Pre- and Postsynaptic NMDA Receptor Activity in Spinal Cords.
Calcineurin is essential for virulence in Candida albicans.
Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains.
Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae.
Calcium- and calcineurin-independent roles for calmodulin in Cryptococcus neoformans morphogenesis and high-temperature growth.
Casein Kinase II Inhibition Reverses Pain Hypersensitivity and Potentiated Spinal N-Methyl-D-aspartate Receptor Activity Caused by Calcineurin Inhibitor.
Comparison of expression profiles induced by dust mite in airway epithelia reveals a common pathway.
Decreased abundance of TRESK two-pore domain potassium channels in sensory neurons underlies the pain associated with bone metastasis.
Ectopic Expression of SjCBL1, Calcineurin B-Like 1 Gene From Sedirea japonica, Rescues the Salt and Osmotic Stress Hypersensitivity in Arabidopsis cbl1 Mutant.
Editorial comments on this issue of the Journal.
Effects of variations in access to care for children with atopic dermatitis.
Genome-wide screening for genes associated with FK506 sensitivity in fission yeast.
Human protein phosphatase PP6 regulatory subunits provide Sit4-dependent and rapamycin-sensitive sap function in Saccharomyces cerevisiae.
Human skin safety test of green tea cell extracts in condition of allergic contact dermatitis.
Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
Rho2 is a target of the farnesyltransferase Cpp1 and acts upstream of Pmk1 mitogen-activated protein kinase signaling in fission yeast.
Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin.
Spatial regulation of the KH domain RNA-binding protein Rnc1 mediated by a Crm1-independent nuclear export system in Schizosaccharomyces pombe.
Spinal nNOS activation mediates sigma-1 receptor-induced mechanical and thermal hypersensitivity in mice: involvement of PKC-dependent NR1 phosphorylation.
Successful switch to oral tacrolimus in a patient with hypersensitivity reaction to parenteral vitamin K, cyclosporine, and tacrolimus: A case report.
Tacrolimus, a calcineurin inhibitor, promotes capsaicin-induced colonic pain in mice.
The effect of herpes simplex virus vector-mediated gene therapy of protein phosphatase 1? on bladder overactivity and nociception.
The protein phosphatase 7 regulates phytochrome signaling in Arabidopsis.
The Pzh1 protein phosphatase and the Spm1 protein kinase are involved in the regulation of the plasma membrane H+-ATPase in fission yeast.
The Vacuolar Ca2+ Exchanger Vcx1 Is Involved in Calcineurin-Dependent Ca2+ Tolerance and Virulence in Cryptococcus neoformans.
Zinc finger protein Prz1 regulates Ca2+ but not Cl- homeostasis in fission yeast. Identification of distinct branches of calcineurin signaling pathway in fission yeast.
[Evidence-based treatment options for allergic diseases in otolaryngology: an update].
[The practice guideline 'Atopic dermatitis' (first revision) from the Dutch College of General Practitioners; a response from the perspective of dermatology]
Hypertension
3A.03: HYPERTENSION IN PATIENTS AFTER LIVER TRANSPLANTATION.
Activation of NFATc3 down-regulates the beta1 subunit of large conductance, calcium-activated K+ channels in arterial smooth muscle and contributes to hypertension.
Age and gender may affect posterior reversible encephalopathy syndrome in renal disease.
An emerging role for calcineurin A{alpha} in the development and function of the kidney.
Anemia in solid organ transplantation.
Angiotensin-(1-7) prevents angiotensin II-induced fibrosis in cremaster microvessels.
Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient.
Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Approach and Management of Hypertension After Kidney Transplantation.
Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Association Between CYP3A5 Polymorphisms and Blood Pressure in Kidney Transplant Recipients Receiving Calcineurin Inhibitors.
AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats.
Axillary Artery Dissection After Ultrasound-Guided Infraclavicular Brachial Plexus Block: A Case Report.
Benefit-risk assessment of sirolimus in renal transplantation.
Blood pressure control according to the prevalence of diabetes in renal transplant recipients.
Blood Pressure in De novo Heart Transplant Recipients Treated with Everolimus Compared with a Cyclosporine-Based Regimen: Results from the Randomized SCHEDULE Trial.
Cadmium-induced hypertension is associated with renal myosin light chain phosphatase inhibition via increased T697 phosphorylation and p44 mitogen-activated protein kinase levels.
Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling.
Calcineurin expression and activity is regulated by the intracellular redox status and under hypertension in human neutrophils.
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Calcineurin inhibition normalizes beta-adrenergic responsiveness in the spontaneously hypertensive rat.
Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension.
Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms.
Calcineurin Inhibitor Toxicity in Solid Organ Transplantation.
Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment.
Calcineurin inhibitors and hypertension: a role for pharmacogenetics?
Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension.
Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder.
Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Cardiovascular risk estimates and risk factors in renal transplant recipients.
Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
Characteristics and Outcomes of Kidney Transplant Recipients with a Functioning Graft for More than 25 Years.
Chronic allograft nephropathy--immunologic and nonimmunologic factors.
Chronic allograft nephropathy: current concepts and future directions.
Chronic allograft nephropathy: pathogenesis and management of an important posttransplant complication.
Chronic renal allograft injury: early detection, accurate diagnosis and management.
Clinical Utility of Computed Tomography and Magnetic Resonance Imaging for Diagnosis of Posterior Reversible Encephalopathy Syndrome after Stem Cell Transplantation in Children and Adolescents.
Comparative in vitro effects of calcineurin inhibitors on functional vascular relaxations of both rat thoracic and abdominal aorta.
Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial.
Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report.
Correlation between Serum Calcineurin Activity and Left Ventricular Hypertrophy in Hypertensive Patients and Its Clinical Significance.
Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings.
De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient.
Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism.
Diltiazem use in tacrolimus-treated renal transplant recipients.
Early non-immunological post transplant complications: a single center experience.
Elucidating the mechanism of posterior reversible encephalopathy syndrome: a case of transient blindness after central venous catheterization.
Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension.
Future directions in immunosuppression.
Genomics of chronic allograft injury.
Hepatitis C: liver transplantation.
High Frequency of Arterial Hypertension in Patients After Liver Transplantation.
High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI).
How calcineurin inhibitors cause hypertension.
Hyperkalemia and Hypertension Post Organ Transplantation - A Management Challenge.
Hypertension after kidney transplant.
Hypertension after kidney transplantation: a pathophysiologic approach.
Hypertension after kidney transplantation: calcineurin inhibitors increase salt-sensitivity.
Hypertension after Kidney Transplantation: Clinical Significance and Therapeutical Aspects.
Hypertension after renal transplantation.
Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy.
Hypertension in renal allograft recipients.
Hypertension in renal transplantation: donor and recipient risk factors.
Hypertension, Living Kidney Donors, and Transplantation: Where Are We Today?
Immunology Update: Long-Term Care of Solid Organ Transplant Recipients.
Immunosuppression in liver transplantation.
Impact of Cardiovascular Risk Factors on Long-Term Mortality After Liver Transplantation.
Kidney Function after Treatment for Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study.
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Knockout of Dual-Specificity Protein Phosphatase 5 Protects Against Hypertension-Induced Renal Injury.
Late kidney allograft loss: what we know about it, and what we can do about it.
Left ventricular remodeling with exercise in hypertension.
Long-term results of liver transplantation.
Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
Maintenance of normal blood pressure is dependent on IP3R1-mediated regulation of eNOS.
Management of hypertension in solid-organ transplantation.
Management strategies for posttransplant hypertension.
MicroRNA-31 Regulates Immunosuppression in Ang II (Angiotensin II)-induced Hypertension by Targeting Ppp6C (Protein Phosphatase 6c).
Mitochondrial fission protein, dynamin-related protein 1, contributes to the promotion of hypertensive cardiac hypertrophy and fibrosis in Dahl-salt sensitive rats.
Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
Myeloid-Derived Suppressor Cells Ameliorate Cyclosporine A-Induced Hypertension in Mice.
Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.
Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation.
New onset diabetes after transplantation (NODAT): an overview.
Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Obesity, hyperlipidemia, and metabolic syndrome.
Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment.
Our approach to a renal transplant biopsy.
Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril.
Pathogenesis of calcineurin inhibitor-induced hypertension.
Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension.
Pathophysiology of Post Transplant Hypertension in Kidney Transplant: Focus on Calcineurin Inhibitors Induced Oxidative Stress and Renal Sodium Retention and Implications with RhoA/Rho Kinase Pathway.
Patterns of chronic injury in pediatric renal allografts.
Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study.
Posterior reversible encephalopathy syndrome after kidney transplantation in pediatric recipients: Two cases.
Posterior reversible encephalopathy syndrome in children with kidney disease.
Posterior reversible encephalopathy syndrome in children with kidney diseases.
Posttransplant diastolic hypertension: associations with intragraft transforming growth factor-beta, endothelin, and renin transcription.
Posttransplantation hypertension related to calcineurin inhibitors.
Predictors of decline in renal function after lung transplantation.
Pregnancy in renal transplant recipients: the Royal Free Hospital experience.
PREVALENCE AND TIME OF DEVELOPMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN PATIENTS AFTER LIVER TRANSPLANTATION.
Preventing renal transplant failure.
Proliferation signal inhibitors and cardiac allograft vasculopathy.
Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients.
Reduced endothelin-1- and nitric oxide-mediated arteriolar tone in hypertensive renal transplant recipients.
Regulation of gene expression by cyclic GMP.
Regulatory T-Cell Augmentation or Interleukin-17 Inhibition Prevents Calcineurin Inhibitor-Induced Hypertension in Mice.
Renal Deletion of 12 kDa FK506-Binding Protein Attenuates Tacrolimus-Induced Hypertension.
Renal dysfunction in liver transplantation: The problem and preventive strategies.
Renal function in pediatric liver transplantation: a long-term follow-up study.
Replacing calcineurin inhibitors with mTOR inhibitors in children.
Reversible leukoencephalopathy syndrome associated to leukopenia in a chronic hemodialysis patient.
Reversible posterior encephalopathy syndrome in children with nephrotic syndrome.
Review of symposium.
Rho GTPases in kidney physiology and diseases.
Risk factors for hypertension 3 years after renal transplantation in children.
Sarpogrelate attenuates pulmonary arterial hypertension via calcium/calcineurin axis.
SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients.
Sirolimus in pediatric renal transplantation.
Sirolimus in renal transplantation.
Sirolimus monotherapy in liver transplantation.
Specific disruption of calcineurin-signaling in the distal convoluted tubule impacts the transcriptome and proteome, and causes hypomagnesemia and metabolic acidosis.
Strategies to reduce toxicities and improve outcomes in renal transplant recipients.
Successful treatment of class V+IV lupus nephritis with multitarget therapy.
Sympathetic neural mechanisms of cyclosporine-induced hypertension.
Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?
The adolescent and liver transplantation.
The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.
The pathogenesis and treatment of chronic allograft nephropathy.
The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists.
The problem of late allograft loss in kidney transplantation.
The role and value of sirolimus administration in kidney and liver transplantation.
The role of immunosuppressive medications in the pathogenesis of hypertension and efficacy and safety of antihypertensive agents in kidney transplant recipients.
Three novel sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 3 isoforms. Expression, regulation, and function of the membranes of the SERCA3 family.
Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
[Arterial hypertension in renal transplant recipients]
[Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension]
[Chronic renal failure after heart, lung, liver, or intestine transplantation]
[Effect of immunosuppressive treatment on diurnal profile of blood pressure]
[Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children].
Hypertension, Malignant
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Hypertension, Portal
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
Hypertension, Pulmonary
Cyclosporin A Inhibits Hypoxia-induced Pulmonary Hypertension and Right Ventricle Hypertrophy.
DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy.
Myosin light chain phosphatase and kinase abnormalities in fetal sheep pulmonary hypertension.
Regulation of myosin light chain phosphatase and pulmonary arterial relaxation.
Hypertension, Renovascular
Angiotensin-converting enzyme inhibitor suppresses activation of calcineurin in renovascular hypertensive rats.
Blockade of calcineurin reverses cardiac hypertrophy and induces the down-regulation of JNK mRNA expression in renovascular hypertensive rats.
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension.
Hypertensive Encephalopathy
Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.
Hyperthyroidism
Cardiac microRNA-133 is down-regulated in thyroid hormone-mediated cardiac hypertrophy partially via Type 1 Angiotensin II receptor.
Cissampelos pareira Linn. ameliorates thyroxin-induced cardiac hypertrophy in rats.
Repression of T-cell function by thionamides is mediated by inhibition of the activator protein-1/nuclear factor of activated T-cells pathway and is associated with a common structure.
Hypertriglyceridemia
New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation.
[Mycosis fungoides in a heart transplant recipient].
Hypertrophy, Left Ventricular
Calcineurin and matrix protein expression in cardiac hypertrophy : Evidence for calcineurin B to control excessive hypertrophic signaling.
Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats.
Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training.
Cardiac calcineurin during transition from hypertrophy to heart failure in rats.
Caveolin-3 is Up-Regulated in the Physiological Left Ventricular Hypertrophy Induced by Voluntary Exercise Training in Rats.
Correlation between Serum Calcineurin Activity and Left Ventricular Hypertrophy in Hypertensive Patients and Its Clinical Significance.
Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation.
Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial.
Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats.
Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: involvement of calcineurin and mitogen-activated protein kinase signalings.
Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: Involvement of calcineurin and mitogen-activated protein kinase signalings.
Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy.
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Positive correlations between serum calcineurin activity and left ventricular hypertrophy.
Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin.
Proteomic analysis of left ventricular diastolic dysfunction hearts in renovascular hypertensive rats.
[The influence of calcineurin gene polymorphism on morphofunctional characteristics of cardiovascular system of athletes]
Hypertrophy, Right Ventricular
Inhibitory effect of ginsenoside Rb1 on cardiac hypertrophy induced by monocrotaline in rat.
L-type calcium channel blocker suppresses calcineurin signal pathway and development of right ventricular hypertrophy.
[Total ginsenosides fought against right ventricular hypertrophy through inhibiting calcineurin signal pathway].
Hypoalbuminemia
Predictors of Proctocolectomy in Children with Ulcerative Colitis.
Hypoglycemia
Estrogen regulates energy metabolic pathway and upstream adenosine 5'-monophosphate-activated protein kinase and phosphatase enzyme expression in dorsal vagal complex metabolosensory neurons during glucostasis and hypoglycemia.
Impact of severe hypoglycemia on the heat shock and related protein response.
Hypogonadism
Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism.
Prevalence and associated phenotypes of DUSP6, IL17RD and SPRY4 variants in a large Chinese cohort with isolated hypogonadotropic hypogonadism.
Hyponatremia
Aldosterone Resistance Due to Tacrolimus: A Case Report.
Fludrocortisone-a treatment for tubulopathy post-paediatric renal transplantation: A national paediatric nephrology unit experience.
Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation.
Hypopigmentation
Combination of non-ablative fractional photothermolysis and 0.1% tacrolimus ointment is efficacious for treating idiopathic guttate hypomelanosis.
Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: A single blind, randomised clinical trial.
PP2A and DUSP6 are involved in sphingosylphosphorylcholine-induced hypopigmentation.
Hypotension
Acute kidney injury epidemiology, risk factors, and outcomes in critically ill patients 16-25 years of age treated in an adult intensive care unit.
Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis.
Hypothyroidism
Developmental Iodine Deficiency and Hypothyroidism Impair Spatial Memory in Adolescent Rat Hippocampus: Involvement of CaMKII, Calmodulin and Calcineurin.
Developmental Iodine Deficiency and Hypothyroidism Reduce Phosphorylation of Calcium/Calmodulin-Dependent Kinase II in the Rat Entorhinal Cortex.
Expression of ZAKI-4 messenger ribonucleic acid in the brain during rat development and the effect of hypothyroidism.
Hypothyroidism following developmental iodine deficiency reduces hippocampal neurogranin, CaMK II and calmodulin and elevates calcineurin in lactational rats.
Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants.
Mitochondrial and energetic cardiac phenotype in hypothyroid rat. Relevance to heart failure.
Molecular studies on the protective effect of nicotine in adult-onset hypothyroidism-induced impairment of long-term potentiation.
Role of phosphorylated CaMKII and calcineurin in the differential effect of hypothyroidism on LTP of CA1 and dentate gyrus.
Thyroid hormone is required for the phenotype transitions induced by the pharmacological inhibition of calcineurin in adult soleus muscle of rats.
Hypoxia-Ischemia, Brain
Single-nucleotide polymorphism screening and RNA sequencing of key messenger RNAs associated with neonatal hypoxic-ischemia brain damage.
Ichthyosis
Dermatology Part 2: Ichthyoses and Psoriasis.
Ichthyosis, Lamellar
Harlequin ichthyosis. Variability in expression and hypothesis for disease mechanism.
Protein phosphatase activity in human keratinocytes cultured from normal epidermis and epidermis from patients with harlequin ichthyosis.
Immune System Diseases
Calcineurin inhibitors and nephrotoxicity in children.
Calcineurin/NFAT signaling and innate host defence: a role for NOD1-mediated phagocytic functions.
Hyperchloremic metabolic acidosis in the kidney transplant patient.
Massive Analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease MACE and miRNA profiling in CKD.
Selective inhibitors of nuclear factor of activated T cells: potential therapeutic drugs for the treatment of immunological and inflammatory diseases.
Tacrolimus inhibits oral carcinogenesis through cell cycle control.
Infarction, Middle Cerebral Artery
A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke.
Infections
A case of recurrent anemia due to chronic parvovirus B19 infection in a kidney transplant recipient. Can everolimus make a difference?
A Magnaporthe grisea cyclophilin acts as a virulence determinant during plant infection.
A multi-centre, parallel group superiority trial of silk therapeutic clothing compared to standard care for the management of eczema in children (CLOTHES Trial): study protocol for a randomised controlled trial.
A serine/threonine-protein phosphatase PP2A catalytic subunit is essential for asexual development and plant infection in Magnaporthe oryzae.
Activation of protein phosphatase-2A1 by HIV-1 Vpr cell death causing peptide in intact CD(4+) T cells and in vitro.
Addressing treatment challenges in atopic dermatitis with novel topical therapies.
Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.
Altering of host larval (Spodoptera exigua) calcineurin activity in response to ascovirus infection.
Anemia in solid organ transplantation.
Angiotensin II induces myocyte enhancer factor 2- and calcineurin/nuclear factor of activated T cell-dependent transcriptional activation in vascular myocytes.
Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.
Arabidopsis Protein Phosphatase DBP1 Nucleates a Protein Network with a Role in Regulating Plant Defense.
Atopic dermatitis.
Atopic Dermatitis: Early Treatment in Children.
Atopic dermatitis: skin care and topical therapies.
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with antineutrophil cytoplasmic antibody-associated vasculitis and nephrosis.
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with chronic renal failure on hemodialysis treatment.
Basiliximab: a review of its use as induction therapy in renal transplantation.
Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
Ca2+-Calcineurin Axis-Controlled NFAT Nuclear Translocation Is Crucial for Optimal T Cell Immunity in an Early Vertebrate.
Calcineurin A Is Essential in the Regulation of Asexual Development, Stress Responses and Pathogenesis in Talaromyces marneffei.
Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence.
Calcineurin as a Multifunctional Regulator: Unraveling Novel Functions in Fungal Stress Responses, Hyphal Growth, Drug Resistance, and Pathogenesis.
Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.
Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis.
Calcineurin inhibitor Tacrolimus impairs host immune response against urinary tract infection.
Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
Calcineurin Inhibitors and Variation in the Performance of Interferon-? Release Assays Used to Detect Tuberculosis Infection.
Calcineurin is essential for Candida albicans survival in serum and virulence.
Calcineurin is required for Candida albicans to survive calcium stress in serum.
Calcineurin Is Required for Pseudohyphal Growth, Virulence, and Drug Resistance in Candida lusitaniae.
Calcineurin Orchestrates Lateral Transfer of Aspergillus fumigatus During Macrophage Cell Death.
Calcineurin phosphatase activity regulates Varicella-Zoster Virus induced cell-cell fusion.
Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy.
Calcineurin Regulates Conidiation, Chlamydospore Formation and Virulence in Fusarium oxysporum f. sp. lycopersici.
Calcineurin signaling: lessons from Candida species.
Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production.
Calcineurin-mediated regulation of hyphal growth, septation, and virulence in Aspergillus fumigatus.
Calcineurin-NFAT signalling in myeloid leucocytes: new prospects and pitfalls in immunosuppressive therapy.
Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection.
Cellular serine/threonine phosphatase activity during human cytomegalovirus infection.
Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS.
Chronic allograft nephropathy in paediatric renal transplantation.
Chronic allograft nephropathy.
Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes.
Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
Cognitive Changes in Chronic Kidney Disease and After Transplantation.
Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Convergent Evolution of Calcineurin Pathway Roles in Thermotolerance and Virulence in Candida glabrata.
Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
COVID-19 pneumonia in lung transplant recipients: Report of 2 cases.
Coxsackievirus B3 targets TFEB to disrupt lysosomal function.
Critical involvement of IL-12 in IFN-gamma induction by calcineurin antagonists in activated human lymphocytes.
Cryptococcal meningitis following umbilical cord blood transplantation, association between the occurrence of cryptococcal infection and tacrolimus discontinuation among allogeneic hematopoietic stem cell recipients.
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme.
Cyclophilin A and calcineurin functions investigated by gene inactivation, cyclosporin A inhibition and cDNA arrays approaches in the phytopathogenic fungus Botrytis cinerea.
Cyclosporine a directly affects human and mouse b cell migration in vitro by disrupting a hIF-1 ?dependent, o2 sensing, molecular switch.
Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection.
Cytosolic CARP promotes angiotensin II- or pressure overload-induced cardiomyocyte hypertrophy through calcineurin accumulation.
De Novo Thrombotic Microangiopathy in Renal Transplant Patients.
Discovery of a protein phosphatase activity encoded in the genome of bacteriophage lambda. Probable identity with open reading frame 221.
Do anti-CD25 monoclonal antibodies potentiate posttransplant diabetes mellitus?
DUSP1 regulates apoptosis and cell migration, but not the JIP1-protected cytokine response, during Respiratory Syncytial Virus and Sendai Virus infection.
DUSP10 Negatively Regulates the Inflammatory Response to Rhinovirus through Interleukin-1? Signaling.
DUSP5 (dual-specificity protein phosphatase 5) suppresses BCG-induced autophagy via ERK 1/2 signaling pathway.
Early conversion to prednisolone/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial.
Early non-immunological post transplant complications: a single center experience.
Early Outcomes of Living-Donor Kidney Transplantation With Immunosuppression Therapy Induction With Tacrolimus Extended-Release: A Comparison With Cyclosporine.
Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.
Effects of light and the regulatory B-subunit composition of protein phosphatase 2A on the susceptibility of Arabidopsis thaliana to aphid (Myzus persicae) infestation.
Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation.
Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients.
Enhancement of lipopolysaccharide-stimulated JNK activity in rat aortic smooth muscle cells by pharmacological and adenovirus-mediated inhibition of inhibitory kappa B kinase signalling.
Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans calcineurin A mutant strain.
Everolimus in lung transplantation in Chile.
Expression analysis of a plum pathogenesis related 10 (PR10) protein during brown rot infection.
Five years' experience with thymoglobulin induction in a pediatric renal transplant population.
Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin.
Functional characterization of calcineurin homologs PsCNA1/PsCNB1 in Puccinia striiformis f. sp. tritici using a host-induced RNAi system.
Good fungi gone bad: the corruption of calcineurin.
Guidelines for the Management of Atopic Dermatitis in Singapore.
Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair.
High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI).
Human Herpesvirus-6 Infection and Calcineurin Inhibitor Pain Syndrome Interaction after Umbilical Cord Blood Transplant.
Hypothalamic digoxin deficiency in obsessive compulsive disorder and la Tourette's syndrome.
Identification of a PP2A gene in Bombyx mori with antiviral function against B. mori nucleopolyhedrovirus.
Identification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics.
Identification of the putative protein phosphatase gene PTC1 as a virulence-related gene using a silkworm model of Candida albicans infection.
ILKAP Binding to and Dephosphorylating HIF-1? is Essential for Apoptosis Induced by Severe Hypoxia.
Immunosuppressive agents for treating IgA nephropathy.
Immunosuppressive Therapy for Elderly Kidney Transplant Recipients.
Immunosuppressive treatment for proliferative lupus nephritis.
Impact of acute kidney injury on renal allograft survival.
Impaired calcineurin signaling in myeloid cells results in downregulation of pentraxin-3 and increased susceptibility to aspergillosis.
Incidence and risk factors of incisional hernia formation following abdominal organ transplantation.
Increased eIF2alpha phosphorylation attenuates replication of herpes simplex virus 2 vhs mutants in mouse embryonic fibroblasts and correlates with reduced accumulation of the PKR antagonist ICP34.5.
Increased inflammation and impaired resistance to Chlamydophila pneumoniae infection in Dusp1(-/-) mice: critical role of IL-6.
Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis.
Influence of glutathione S-transferase M1 and T1 polymorphisms with acute rejection in Iranian liver transplant recipients.
Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.
Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?
Is there such a thing as protocol immunosuppression in liver transplantation?
Kaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection.
Kidney Fibrosis: Origins and Interventions.
Kinome-Wide RNA Interference Screening Identifies Mitogen-Activated Protein Kinases and Phosphatidylinositol Metabolism as Key Factors for Rabies Virus Infection.
Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients.
Lipopolysaccharide activates calcineurin in ventricular myocytes.
Loss of chloroplast localized protein phosphatase 2Cs in Arabidopsis thaliana leads to enhancement of the plant immunity and resistance to Xanthomonas campestris pv. campestris infection.
Lysosomes Integrate Metabolic-Inflammatory Cross-talk in Primary Macrophage Inflammasome Activation.
Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients.
Massive Analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease MACE and miRNA profiling in CKD.
Measles Virus Infection Inactivates Cellular Protein Phosphatase 5 with Consequent Suppression of Sp1 and c-Myc Activities.
Metastatic lung adenocarcinoma- associated thrombotic microangiopathy in a renal transplant recipient.
Milk fermentation products of L. helveticus R389 activate calcineurin as a signal to promote gut mucosal immunity.
Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis.
Molecular cloning of the MARCH family in grass carp (Ctenopharyngodon idellus) and their response to grass carp reovirus challenge.
Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients.
Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation.
Neutrophil gelatinase-associated lipocalin in kidney transplantation: A review.
New-onset diabetes after renal transplantation.
New-onset diabetes after transplantation: risk factors and clinical impact.
New-onset diabetes mellitus after solid organ transplantation.
NFAT AND CREB REGULATE KAPOSI'S SARCOMA ASSOCIATED HERPES VIRUS (KSHV) INDUCED CYCLOOXYGENASE-2 (COX-2).
Nocardiosis in transplant recipients.
Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation.
Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors.
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
PGAM5-MAVS interaction regulates TBK1/ IRF3 dependent antiviral responses.
Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus.
Phosphorylation-mediated Regulatory Networks in Mycelia of Pyricularia oryzae Revealed by Phosphoproteomic Analyses.
Plasma phosphoproteome and differential plasma phosphoproteins with opisthorchis viverrini-related cholangiocarcinoma.
Porcine HMGCR Inhibits Porcine Circovirus Type 2 Infection by Directly Interacting with the Viral Proteins.
Posttransplantation chronic renal damage in nonrenal transplant recipients.
PP2Ac Modulates AMPK-Mediated Induction of Autophagy in Mycobacterium bovis-Infected Macrophages.
Preventing renal transplant failure.
Prevention of allogeneic cardiac graft rejection by transfer of ex vivo expanded antigen-specific regulatory T-cells.
Profiling Subcellular Protein Phosphatase Responses to Coxsackievirus B3 Infection of Cardiomyocytes.
Protection of CD4+ T cells from hepatitis C virus infection-associated senescence via ?Np63-miR-181a-Sirt1 pathway.
Protein Kinase B/Akt Is Present in Activated Form throughout the Entire Replicative Cycle of {Delta}US3 Mutant Virus but Only at Early Times after Infection with Wild-Type Herpes Simplex Virus 1.
Protein Phosphatase PP1 Negatively Regulates IRF3 in Response to GCRV Infection in Grass Carp (Ctenopharyngodon idella).
Protein Phosphatase, Mg2+/Mn2+-dependent 1A controls the innate antiviral and antibacterial response of macrophages during HIV-1 and Mycobacterium tuberculosis infection.
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Recurrent hepatitis C after liver transplantation.
Reduction of I(to) causes hypertrophy in neonatal rat ventricular myocytes.
Reductions in the Cardiac Transient Outward K+ Current Ito Caused by Chronic ?-Adrenergic Receptor Stimulation Are Partly Rescued by Inhibition of Nuclear Factor ?B.
Regulator of calcineurin 1 differentially regulates TLR-dependent MyD88 and TRIF signaling pathways.
Regulator of calcineurin 1 suppresses inflammation during respiratory tract infections.
Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?
Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
RIPK1 and PGAM5 Control Leishmania Replication through Distinct Mechanisms.
Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation.
Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation.
Risk factors of recipient receiving living donor liver transplantation in the comprehensive era of indication and perioperative managements.
Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain.
Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy.
Serine/threonine phosphatase (SP-STP), secreted from Streptococcus pyogenes, is a proapoptotic protein.
Serological and molecular detection of chicken anaemia virus in Iranian poultry flocks.
Single-center experience with tacrolimus-based immunosuppressive regimens in renal transplantation.
Skin-protective effects of a zinc oxide-functionalized textile and its relevance for atopic dermatitis.
Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Specific calcineurin isoforms are involved in Drosophila toll immune signaling.
Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors.
Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection.
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin.
Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
T11TS immunotherapy potentiates the repressed Calcineurin-NFAT signaling pathway of T cells in Cryptococcus neoformans infected rats: A cue towards T cell activation for antifungal immunity.
Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients.
Tacrolimus impairs Kupffer cell capacity to control bacteremia: why transplant recipients are susceptible to infection.
Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials.
Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus.
Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
Temporal and spatial assessment of defence responses in resistant and susceptible hop cultivars during infection with Verticillium nonalfalfae.
The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms.
The CRH family coding for cell wall glycosylphosphatidylinositol proteins with a predicted transglycosidase domain affects cell wall organization and virulence of Candida albicans.
The expression of IFN-? is suppressed by the viral 3D polymerase via its impact on PGAM5 expression during enterovirus D68 infection.
The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein.
The impact of calcineurin inhibitors with and without interferon on HCV titers in a chimeric mouse model of HCV infection.
The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'.
The role of three calcineurin subunits and a related transcription factor (Crz1) in conidiation, multistress tolerance and virulence in Beauveria bassiana.
The Wound Healing Peptide, AES16-2M, Ameliorates Atopic Dermatitis In Vivo.
Thrombotic microangiopathy in transplantation and malignancy.
Tinea incognito in Korea and its risk factors: nine-year multicenter survey.
Topical calcineurin inhibitors in cutaneous lupus erythematosus.
Topical tacrolimus for atopic dermatitis.
Topical Therapy in Atopic Dermatitis in Children.
Translation elongation factor EF-Tu is a target for Stp, a serine-threonine phosphatase involved in virulence of Listeria monocytogenes.
Transplantation for liver failure in patients with sickle cell disease: Challenging but feasible.
Treatment strategies for atopic dermatitis: optimizing the available therapeutic options.
Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry.
Upregulation of DUSP6 impairs infectious bronchitis virus replication by negatively regulating ERK pathway and promoting apoptosis.
Urinary Chemokines CXCL9 and CXCL10 Are Noninvasive Markers of Renal Allograft Rejection and BK Viral Infection.
Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report.
[Construction of rAAV2-GPIIb/IIIa vector and test of its expression and function in vitro]
[Effect of Epstein-Barr virus reactivation on gene expression profile of nasopharyngeal carcinoma]
[Management of transplant-associated thrombotic microangiopathy].
[Practice experience with topical calcineurin inhibitors]
[Treatment of diabetes mellitus in patients after renal transplantation]
Infertility
Alterations in sperm protein phosphorylation in male infertility.
Endometrial ILKAP expression among patients with endometriosis and its association with clinical characteristics.
Expression of Transgenic PPP1CC2 in the Testis of Ppp1cc-Null Mice Rescues Spermatid Viability and Spermiation but Does Not Restore Normal Sperm Tail Ultrastructure, Sperm Motility, or Fertility.
Integrative Proteomic and Phosphoproteomic Profiling of Testis from Wip1 Phosphatase-Knockout Mice: Insights into Mechanisms of Reduced Fertility.
Oligoasthenoteratospermia and sperm tail bending in PPP4C-deficient mice.
Selective Ablation of Ppp1cc Gene in Testicular Germ Cells Causes Oligo-Teratozoospermia and Infertility in Mice.
Infertility, Male
Alterations in sperm protein phosphorylation in male infertility.
Analysis of Ppp1cc-null mice suggests a role for PP1gamma2 in sperm morphogenesis.
DCW11, down-regulated gene 11 in CW-type cytoplasmic male sterile rice, encoding mitochondrial protein phosphatase 2c is related to cytoplasmic male sterility.
Loss of Protein Phosphatase 1c{gamma}(PPP1CC) Leads to Impaired Spermatogenesis Associated with Defects in Chromatin Condensation and Acrosome Development: An Ultrastructural Analysis.
New candidate targets of protein phosphatase-1c-gamma-2 in mouse testis revealed by a differential phosphoproteome analysis.
Protein phosphatase PP1 gamma 2 in sperm morphogenesis and epididymal initiation of sperm motility.
Selective Ablation of Ppp1cc Gene in Testicular Germ Cells Causes Oligo-Teratozoospermia and Infertility in Mice.
Significant expression levels of transgenic PPP1CC2 in testis and sperm are required to overcome the male infertility phenotype of Ppp1cc null mice.
Inflammatory Bowel Diseases
Amelioration of murine experimental colitis using biocompatible cyclosporine A lipid carriers.
Drug monitoring in inflammatory bowel disease: helpful or dispensable?
Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice.
Effective use of switching biologics for ulcerative colitis complicated with pyoderma gangrenosum and primary sclerosing cholangitis.
Immunomodulator and calcineurin inhibitors on inflammatory bowel disease.
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Role in Calcineurin Inhibitors for Inflammatory Bowel Disease in the Biologics Era: When and How to Use.
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease.
Influenza, Human
A role for protein phosphatase 2A in regulating p38 mitogen activated protein kinase activation and tumor necrosis factor-alpha expression during influenza virus infection.
Interactome analysis of the influenza A virus transcription/replication machinery identifies protein phosphatase 6 as a cellular factor required for efficient virus replication.
NH2-terminal modification of the phosphatase 2A catalytic subunit allows functional expression in mammalian cells.
The effect of sirolimus therapy on vaccine responses in transplant recipients.
Insulin Resistance
Ablation of calcineurin A? reveals hyperlipidemia and signaling cross-talks with phosphodiesterases.
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
BCAA Catabolic Defect Alters Glucose Metabolism in Lean Mice.
Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy.
Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.
Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus.
Ceramide-activated protein phosphatase involvement in insulin resistance via Akt, serine/arginine-rich protein 40, and ribonucleic acid splicing in L6 skeletal muscle cells.
Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.
Deciphering Tacrolimus-Induced Toxicity in Pancreatic ? Cells.
Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.
Dysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for management.
Effect of an Asp905Tyr mutation of the glycogen-associated regulatory subunit of protein phosphatase-1 on the regulation of glycogen synthesis by insulin and cyclic adenosine 3',5'-monophosphate agonists.
Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes.
Effects of calcineurin activation on insulin-, AICAR- and contraction-induced glucose transport in skeletal muscle.
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Genetic disruption of protein phosphatase 5 in mice prevents high-fat diet feeding-induced weight gain.
Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.
Hypomagnesemia after heart transplantation or left ventricular assist device implant for end-stage heart failure.
Immunology of pancreatic islet transplantation.
Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients.
In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides.
Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance.
Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance.
Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle.
Inositol-1,4,5-trisphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes.
Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors.
Insulin resistance induced by a high-fat diet is associated with the induction of genes related to leukocyte activation in rat peripheral leukocytes.
Lack of Improvement in Insulin Sensitivity After Pancreas Transplantation in Recipients With a High Level of Calcineurin Inhibitors.
Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Liver-specific deletion of Ppp2c? enhances glucose metabolism and insulin sensitivity.
Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes.
Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation.
MicroRNA-181b Improves Glucose Homeostasis and Insulin Sensitivity by Regulating Endothelial Function in White Adipose Tissue.
miR-140-5p Aggravates Insulin Resistance via Directly Targeting GYS1 and PPP1CC in Insulin-Resistant HepG2 Cells.
Molecular and linkage analysis of type-1 protein phosphatase catalytic beta-subunit gene: lack of evidence for its major role in insulin resistance in Pima Indians.
New-onset diabetes after renal transplantation.
New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management.
Phosphatase activity in rat adipocytes: effects of insulin and insulin resistance.
Post-transplant diabetic ketoacidosis--a possible consequence of immunosuppression with calcineurin inhibiting agents: a case series.
Protein phosphatase 1 regulatory subunit 12A and catalytic subunit ?, new members in the phosphatidylinositide 3 kinase insulin-signaling pathway.
Protein phosphatase 4 (PP4) functions as a critical regulator in tumor necrosis factor (TNF)-?-induced hepatic insulin resistance.
Protein Phosphatase 4 Promotes Hepatocyte Lipoapoptosis by Regulating RAC1/MLK3/JNK Pathway.
Protein phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes.
Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo.
SCR-1693 inhibits tau phosphorylation and improves insulin resistance associated cognitive deficits.
Selective hepatic insulin resistance in mice heterozygous for a mitochondrial trifunctional protein defect.
The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats.
The impact of calcineurin inhibitors on insulin sensitivity and insulin secretion: a randomized crossover trial in uraemic patients.
Insulinoma
Calcineurin activity as an indicator of oxidative stress in normal islet cells and insulinoma cells.
CRTC2 is required for ?-cell function and proliferation.
Cyclosporin A stimulation of glucose-induced insulin secretion in MIN6 cells.
Role of calcium in pancreatic islet cell death by IFN-gamma/TNF-alpha.
Intellectual Disability
B56?-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
Confirmed rare copy number variants implicate novel genes in schizophrenia.
De novo missense variants in PPP1CB are associated with intellectual disability and congenital heart disease.
De Novo Mutations Affecting the Catalytic C? Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.
De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome.
Novel truncating PPM1D mutation in a patient with intellectual disability.
PPP2R5D-Related Intellectual Disability and Neurodevelopmental Delay: A Review of the Current Understanding of the Genetics and Biochemical Basis of the Disorder.
Presence of potential G-quadruplex RNA forming motifs at the 5'-UTR of PP2Ac? mRNA repress translation.
Protein expression profiles that underpin the preventive and therapeutic potential of Moringa oleifera Lam against azoxymethane and dextran sodium sulfate-induced mouse colon carcinogenesis.
Protein Phosphatase 2A (PP2A) mutations in brain function, development, and neurologic disease.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Two unrelated girls with intellectual disability associated with a truncating mutation in the PPM1D penultimate exon.
Intervertebral Disc Degeneration
FK506 Induces the TGF-?1/Smad 3 Pathway Independently of Calcineurin Inhibition to Prevent Intervertebral Disk Degeneration.
Mitophagy in degenerative joint diseases.
Intestinal Pseudo-Obstruction
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Invasive Fungal Infections
Calcineurin regulates innate antifungal immunity in neutrophils.
Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus.
Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients.
Invasive Pulmonary Aspergillosis
Impaired calcineurin signaling in myeloid cells results in downregulation of pentraxin-3 and increased susceptibility to aspergillosis.
Iron Overload
Iron overload-induced calcium signals modulate mitochondrial fragmentation in HT-22 hippocampal neuron cells.
Ischemic Attack, Transient
Neuroprotective efficacy of FR901459, a novel derivative of cyclosporin A, in in vitro mitochondrial damage and in vivo transient cerebral ischemia models.
Ischemic Stroke
A novel PGAM5 inhibitor LFHP-1c protects blood-brain barrier integrity in ischemic stroke.
Cilostazol Reduces PAC-1 Expression on Platelets in Ischemic Stroke.
Gene polymorphism of platelet glycoprotein I balpha in Chinese patients with large- and small-artery subtypes of ischemic stroke.
Intra-arterial Stem Cell Therapy Diminishes Inflammasome Activation After Ischemic Stroke: a Possible Role of Acid Sensing Ion Channel 1a.
Intra-arterial stem cell therapy modulates neuronal calcineurin and confers neuroprotection after ischemic stroke.
Keloid
Innovative therapies in the treatment of keloids and hypertrophic scars.
Keratitis
Polyhexamethylene Biguanide and Calcineurin Inhibitors as Novel Antifungal Treatments for Aspergillus Keratitis.
Keratoconjunctivitis
Management of ocular allergy.
Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.
Topical Calcineurin Inhibitors in the Treatment of Steroid-Dependent Atopic Keratoconjunctivitis.
Keratoconjunctivitis Sicca
A topical aqueous calcineurin inhibitor for the treatment of naturally occurring keratoconjunctivitis sicca in dogs.
Ketosis
Post-transplant diabetic ketoacidosis--a possible consequence of immunosuppression with calcineurin inhibiting agents: a case series.
Kidney Diseases
"Smartphone Medication Adherence Saves Kidneys" for Kidney Transplantation Recipients: Protocol for a Randomized Controlled Trial.
Abdominal tuberculosis in renal transplant recipient. Presentation of a case and literature review
Clinical and genetic risk factors for new-onset diabetes mellitus after transplantation (NODAT) in major transplant centres in Malaysia.
Cyclosporine A protects podocytes by regulating WAVE1 phosphorylation.
Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome.
Glucocorticoids use in kidney transplant setting.
Impact of acute kidney injury on renal allograft survival.
Non-immunologic actions of calcineurin inhibitors in proteinuric kidney diseases.
Steroid-free immunosuppression after renal transplantation-long-term experience from a single centre.
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.
The long-term effect of simultaneous heart and kidney transplantation on native renal function.
Therapeutic Effects of FK506 on IgA Nephropathy Rat.
Kidney Diseases, Cystic
Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Kidney Failure, Chronic
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
A putative role for calcineurin in lymphopenia associated with chronic renal failure.
ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients.
Acute kidney injury in solid organ transplant recipients.
Aortic valve replacement performed twice through ministernotomy 15 years after lung transplantation.
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with chronic renal failure on hemodialysis treatment.
Calcineurin inhibitor withdrawal and conversion to mycophenolate mofetil and steroids in cardiac transplant recipients with chronic renal failure: a word of caution.
Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - assessment of renal and allograft function, cardiovascular risk factors and immune monitoring.
Combined heart and liver transplantation: a single-center experience.
Comparative study of the cellular pharmacodynamics of calcineurin inhibitors between patients with chronic renal failure awaiting renal transplantation and cirrhosis patients awaiting liver transplantation.
Comparative Study of the Cellular Pharmacodynamics of Calcineurin Inhibitors between Patients with Chronic Renal Failure Awaiting Renal Transplantation and Cirrhosis Patients Awaiting Liver Transplantation.
Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults.
Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death.
Decline in 51Cr-labelled EDTA measured glomerular filtration rate following lung transplantation.
Dual kidney transplantation after liver transplantation: a good option to rescue a patient from dialysis.
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Evolution of lung and kidney allograft function in patients receiving kidney after lung transplantation.
Glomerular Neovascularization in Nondiabetic Renal Allograft Is Associated with Calcineurin Inhibitor Toxicity.
Hot-topic debate on kidney function: renal-sparing approaches are ineffective.
Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.
Immunosuppressive treatment for proliferative lupus nephritis.
Immunosuppressive treatment of idiopathic membranous nephropathy: the dilemma continues.
Improvement in chronic renal failure after mycophenolate mofetil introduction and cyclosporine dose reduction: four-year results from a cohort of heart transplant recipients.
Incisional Hernia After Peritoneal Dialysis Catheter Placement in a Patient on Sirolimus.
Kidney after nonrenal transplantation-the impact of alemtuzumab induction.
Kidney transplantation after liver transplantation.
Kidney transplantation as a therapeutic option for end-stage renal disease developing after heart transplantation.
Management of steroid-resistant nephrotic syndrome in children and adolescents.
Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure.
Outcomes after liver transplantation: Chronic kidney disease.
Peritoneal dialysis after nonrenal solid organ transplantation: clinical outcomes and practical considerations.
Peritoneal Dialysis in Orthotopic Liver Transplantation Recipients.
Peritoneal-mediastinal communication complication in peritoneal dialysis.
pERK-dependent defective TCR-mediated activation of CD4(+) T cells in end-stage renal disease patients.
Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
Remission of proteinuria in multidrug resistant idiopathic nephrotic syndrome following immunoglobulin immunoadsorption.
Renal protective strategies in heart transplant patients.
Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity.
Simultaneous Liver-Kidney Transplant: Too Many or Just Enough?
Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure.
Supplementation with omega-3 polyunsaturated fatty acids and experimental tacrolimus-induced nephrotoxicity.
Thrombosis in end-stage renal disease.
Time to Conversion to an Everolimus-Based Regimen: Renal Outcomes in Liver Transplant Recipients From the EVEROLIVER Registry.
Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.
Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.
[Mycosis fungoides in a heart transplant recipient].
[Renal complications after hematopoietic stem cell transplantation].
[The effect of the different immunosuppression therapy on CD4(+)Foxp3(+) Treg cells in kidney recipients.]
Kidney Neoplasms
Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.
Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.
Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression.
Cordycepin promotes apoptosis by modulating the ERK-JNK signaling pathway via DUSP5 in renal cancer cells.
Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression.
Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.
Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.
Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells.
Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer.
Re: effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.
Lafora Disease
4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.
A bioassay for Lafora disease and laforin glucan phosphatase activity.
A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease.
A novel EPM2A mutation in a patient with Lafora disease presenting with early parkinsonism symptoms in childhood.
A novel EPM2A mutation yields a slow progression form of Lafora disease.
A PTG variant contributes to a milder phenotype in Lafora disease.
A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.
Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.
Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.
Advances in lafora progressive myoclonus epilepsy.
Advances in the genetics of progressive myoclonus epilepsy.
Are there errors in glycogen biosynthesis and is laforin a repair enzyme?
Assessing the Biological Activity of the Glucan Phosphatase Laforin.
Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease.
Biophysical characterization of laforin-carbohydrate interaction.
Bioptically demonstrated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters.
Brain glycogen in health and disease.
Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
Conservation of the glucan phosphatase laforin is linked to rates of molecular evolution and the glucan metabolism of the organism.
Correction to: Interdependence of laforin and malin proteins for their stability and functions could underlie the molecular basis of locus heterogeneity in Lafora disease.
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Degradation of altered mitochondria by autophagy is impaired in Lafora disease.
Dimeric quaternary structure of human laforin.
Dimerization of the glucan phosphatase laforin requires the participation of cysteine 329.
Early-onset Lafora body disease.
Endocytosis of the glutamate transporter 1 is regulated by laforin and malin: Implications in Lafora disease.
Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole.
EPM2A in-frame deletion slows neurological decline in Lafora Disease.
Escherichia coli expression, refolding and characterization of human laforin.
Expression, purification and characterization of soluble red rooster laforin as a fusion protein in Escherichia coli.
FDG-PET assessment and metabolic patterns in Lafora disease.
Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation.
Four novel and two recurrent NHLRC1 (EPM2B) and EPM2A gene mutations leading to Lafora disease in six Turkish families.
FoxO3a-mediated autophagy is down-regulated in the laforin deficient mice, an animal model for Lafora progressive myoclonus epilepsy.
Generation and characterization of a laforin nanobody inhibitor.
Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22.
Genetics of Lafora progressive myoclonic epilepsy: current perspectives.
Genotypes and phenotypes of patients with Lafora disease living in Germany.
Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase.
Glycogen hyperphosphorylation underlies lafora body formation.
Glycogen metabolism in tissues from a mouse model of Lafora disease.
Glycogen phosphorylation and Lafora disease.
Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex.
Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora.
Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease.
Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.
Identification of new and common mutations in the EPM2A gene in Lafora disease.
Incorporation of phosphate into glycogen by glycogen synthase.
Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
Increased Oxidative Stress and Impaired Antioxidant Response in Lafora Disease.
Increased oxidative stress and impaired antioxidant response in Lafora disease.
Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Interdependence of laforin and malin proteins for their stability and functions could underlie the molecular basis of locus heterogeneity in Lafora disease.
Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.
Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy.
Lafora disease - from pathogenesis to treatment strategies.
Lafora disease due to EPM2B mutations: a clinical and genetic study.
Lafora disease in a Malaysian with a rare mutation in the EPM2A gene.
Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin.
Lafora disease proteins laforin and malin negatively regulate the HIPK2-p53 cell death pathway.
Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment.
Lafora disease ubiquitin ligase malin promotes proteasomal degradation of neuronatin and regulates glycogen synthesis.
Lafora disease.
Lafora progressive Myoclonus Epilepsy mutation database-EPM2A and NHLRC1 (EMP2B) genes.
Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes.
Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration.
Laforin and malin deletions in mice produce similar neurologic impairments.
Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.
Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.
Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity.
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.
Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.
Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
Laforin, the most common protein mutated in Lafora disease, regulates autophagy.
Laforin-Malin Complex Degrades Polyglucosan Bodies in Concert with Glycogen Debranching Enzyme and Brain Isoform Glycogen Phosphorylase.
Late onset Lafora disease and novel EPM2A mutations: breaking paradigms.
Late-onset Lafora disease with prominent parkinsonism due to a rare mutation in EPM2A.
Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy.
Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.
Loss of laforin or malin results in increased Drp1 level and concomitant mitochondrial fragmentation in Lafora disease mouse models.
Malin and laforin are essential components of a protein complex that protects cells from thermal stress.
Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease.
Managing Lafora body disease with vagal nerve stimulation.
Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy.
Mechanistic Insights into Glucan Phosphatase Activity against Polyglucan Substrates.
Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.
Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease.
Molecular dynamics simulations and principal component analysis on human laforin mutation W32G and W32G/K87A.
MRI volumetry and proton MR spectroscopy of the brain in Lafora disease.
Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice.
Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Mutations in NHLRC1 cause progressive myoclonus epilepsy.
Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease.
Neuronatin-mediated Aberrant Calcium Signaling and Endoplasmic Reticulum Stress Underlie Neuropathology in Lafora Disease.
NHLRC1 homozygous dodecamer expansion in a Newfoundland dog with Lafora disease.
Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease.
Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy.
Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.
Phosphate incorporation during glycogen synthesis and Lafora disease.
Polyglucosan body structure in Lafora disease.
Progressive Myoclonus Epilepsy in Congenital Generalized Lipodystrophy type 2: Report of 3 cases and literature review.
Protein Degradation and Quality Control in Cells from Laforin and Malin Knockout Mice.
Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
Sensitive quantification of ?-glucans in mouse tissues, cell cultures, and human cerebrospinal fluid.
Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.
Structural and Functional Brain Abnormalities in Mouse Models of Lafora Disease.
Structural insights into glucan phosphatase dynamics using amide hydrogen-deuterium exchange mass spectrometry.
Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease.
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.
The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure.
The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain.
The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits.
The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2.
The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.
Three Patients With Lafora Disease: Different Clinical Presentations and a Novel Mutation.
Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex.
Whole exome sequencing identified a novel missense mutation in EPM2A underlying Lafora disease in a Pakistani family.
[Lafora disease: a review of the literature].
Learning Disabilities
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Leishmaniasis, Cutaneous
Phlebotomus papatasi saliva inhibits protein phosphatase activity and nitric oxide production by murine macrophages.
Leishmaniasis, Visceral
Lymph node cells from BALB/c mice with chronic visceral leishmaniasis exhibiting cellular anergy and apoptosis: involvement of Ser/Thr phosphatase.
Lentigo
Induced lentiginosis with use of topical calcineurin inhibitors.
Lentivirus Infections
[PPP3CA silence regulates MET process, cell apoptosis, proliferation and migration in metanephric mesenchyme cells].
Leprosy
Alterations in T cell signal transduction by M. leprae antigens is associated with downregulation of second messengers PKC, calcium, calcineurin, MAPK and various transcription factors in leprosy patients.
Leukemia
Activation of MAP kinase family members triggered by TPA or ionomycin occurs via the protein phosphatase 4 pathway in Jurkat leukemia T cells.
Age-related mutations associated with clonal hematopoietic expansion and malignancies.
Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.
Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of protein phosphatase 2A catalytic subunit in mammalian cells.
Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase.
Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.
Calyculin A modulates activation of the NADPH-oxidase in Me2SO-differentiated HL-60 cells.
Characterization of a variant of PAC-1 in large granular lymphocyte leukemia.
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Clinical significance of serum calcineurin in acute leukemia.
Cluster analysis and phylogenetic relationship in biomarker identification of type 2 diabetes and nephropathy.
Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Comparative effects of protein phosphatase inhibitors (okadaic acid and calyculin A) on human leukemia HL60, HL60/ADR and K562 cells.
Decreased calcineurin immunoreactivity in the postmortem brain of a patient with schizophrenia who had been prescribed the calcineurin inhibitor, tacrolimus, for leukemia.
Direct evidence that FK506 inhibition of FcepsilonRI-mediated exocytosis from RBL mast cells involves calcineurin.
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants.
Ex Vivo CD34(+)-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.
Haploidentical HSCT: a 15-year experience at San Raffaele.
IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.
Inhibition by calyculin A and okadaic acid of the Ca(2+) release-activated Ca(2+) entry pathway in rat basophilic leukemia cells: evidence for regulation by type 1/2A serine/threonine phosphatase activity.
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.
Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
Knockdown of protein phosphatase 5 (PPP5C) suppresses the growth of leukemic cell line U937.
Mitotic arrest and enhanced nuclear protein phosphorylation in human leukemia K562 cells by okadaic acid, a potent protein phosphatase inhibitor and tumor promoter.
Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line.
Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition.
Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl-2 mRNA and downregulation of bcl-2 protein.
Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia.
Protein phosphatase inhibitors induce the release of serotonin from rat basophilic leukemia cells (RBL-2H3).
RCAN1 is an important mediator of glucocorticoid-induced apoptosis in human leukemic cells.
Regulation of dual-specificity phosphatases M3/6 and hVH5 by phorbol esters. Analysis of a delta-like domain.
Role of protein phosphatases in the cancer microenvironment.
Sanguinarine as a potent and specific inhibitor of protein phosphatase 2C in vitro and induces apoptosis via phosphorylation of p38 in HL60 cells.
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
The effect of okadaic acid on histamine release, cell morphology and phosphorylation in rat basophilic leukemia (RBL-2H3) cells, human basophils and rat peritoneal mast cells.
Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling.
[Influence of calcineurin on apoptosis of pre-B lymphocytes and the leukemia cells derived from pre-B lymphocytes].
[Study on platelet activated state and platelet activated function in adults with acute leukemia]
Leukemia, B-Cell
Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.
Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment.
Leukemia, Erythroblastic, Acute
Ca2+/calmodulin-dependent and -independent down-regulation of c-myb mRNA levels in erythropoietin-responsive murine erythroleukemia cells. The role of calcineurin.
Leukemia, Large Granular Lymphocytic
Characterization of a variant of PAC-1 in large granular lymphocyte leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells.
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.
Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase.
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Leukemia, Myeloid
Down-regulation of c-Myc and Max genes is associated to inhibition of protein phosphatase 2A in K562 human leukemia cells.
Effects of tautomycin, a protein phosphatase inhibitor, on recycling of mammalian cell surface molecules.
Morphological changes and reorganization of actinfilaments in human myeloid leukemia cells induced by a novel protein phosphatase inhibitor, tautomycin.
Relationship between phosphatase activity and cytotoxic effect of two protein phosphatase inhibitors, okadaic acid and pervanadate, on human myeloid leukemia cell line.
The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells.
Leukemia, Myeloid, Acute
Clinical significance of serum calcineurin in acute leukemia.
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.
Deregulation of protein phosphatase expression in acute myeloid leukemia.
Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.
Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression.
Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells.
High expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) is associated with poor prognosis in acute myeloid leukemia.
Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia.
Potentiality of Protein phosphatase Mg2+ /Mn2+ dependent 1D as a biomarker for predicting prognosis in acute myeloid leukemia patients.
PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia.
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
Leukemia, Myelomonocytic, Juvenile
Role of protein phosphatases in the cancer microenvironment.
Leukemia, T-Cell
Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia.
Leukocytosis
Pleocytosis after hemopoietic stem cell transplantation.
Leukoencephalopathies
Cerebellar ataxia in a patient receiving calcineurin inhibitors after living donor liver transplantation: a case report.
Neurologic complications after solid organ transplantation.
Neurologic complications of transplantation.
Neurologic Complications of Transplantation.
Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors.
Reversible leukoencephalopathy syndrome associated to leukopenia in a chronic hemodialysis patient.
Reversible posterior leukoencephalopathy syndrome (RPLS) in a heart transplant recipient treated by substitution of cyclosporine A with tacrolimus.
Reversible posterior leukoencephalopathy syndrome: diagnosis and management in the setting of lung transplantation.
Successful retransplantation using rapamycin in a patient with previous calcineurin inhibitor-induced posterior leukoencephalopathy syndrome.
Transplantation for liver failure in patients with sickle cell disease: Challenging but feasible.
Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients.
Leukoencephalopathy, Progressive Multifocal
Neurologic Complications of Transplantation.
Lichen Planus
Anti-inflammatory treatment.
Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial.
Efficacy of topical calcineurin inhibitors in lichen planus.
Potential new indications of topical calcineurin inhibitors.
Lichen Planus, Oral
Calcineurin inhibitors in oral medicine.
Challenges in using topical calcineurin inhibitors as a treatment for recalcitrant oral lichen planus.
Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial.
Efficacy of Topical Calcineurin Inhibitors in Oral Lichen Planus.
Interventions for oral lichen planus: A systematic review and network meta-analysis of randomized clinical trials.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
The use of topical calcineurin inhibitors in the management of oral lichen planus.
Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis.
Lichen Sclerosus et Atrophicus
A retrospective analysis of pediatric patients with lichen sclerosus treated with a standard protocol of class I topical corticosteroid and topical calcineurin inhibitor.
Anti-inflammatory treatment.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Safety of calcineurin inhibitors in the management of lichen sclerosis.
The role of calcineurin inhibitors in the management of lichen sclerosus.
[Lichen sclerosus--a neglected disease].
[Lichen sclerosus. New aspects of pathogenesis and treatment]
Limbic Encephalitis
Risk Factor and Long-Term Outcome Analyses for Acute Limbic Encephalitis and Calcineurin Inhibitor-Induced Encephalopathy in Adults following Allogeneic Hematopoietic Cell Transplantation.
Lipid Metabolism Disorders
Comparison of Kidney Transplant Function, Lipid Metabolism Disorders, and Glucose and Hemoglobin Concentration in Transplant Patients Treated With Proliferation Signal Inhibitor (Everolimus) or Calcineurin Inhibitor (Tacrolimus).
Lipoma
Enhanced expression of catalytic subunits of protein phosphatase type 1 and high S-phase fraction in liposarcoma.
Liposarcoma
Enhanced expression of catalytic subunits of protein phosphatase type 1 and high S-phase fraction in liposarcoma.
Liver Cirrhosis
Activation of protein serine/threonine phosphatase PP2C? efficiently prevents liver fibrosis.
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: Effects on virus replication and recurrent hepatitis.
Endoplasmic Reticulum Stress Increases DUSP5 Expression via PERK-CHOP Pathway, Leading to Hepatocyte Death.
Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation.
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
Progression of liver fibrosis in HCV-positive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen.
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Liver Cirrhosis, Alcoholic
Deficiency in calcineurin activity in liver transplantation candidates with alcoholic cirrhosis or hepatocellular carcinoma.
Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.
Liver Cirrhosis, Biliary
Calcineurin Inhibitors and the IL12A Locus Influence Risk of Recurrent Primary Biliary Cirrhosis After Liver Transplantation.
Liver Diseases
A comprehensive review of immunosuppression used for liver transplantation.
Chemical and biological evidence links microcystins to salmon 'netpen liver disease'.
Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation.
De novo autoimmune hepatitis after liver transplantation.
Endoplasmic Reticulum Stress Increases DUSP5 Expression via PERK-CHOP Pathway, Leading to Hepatocyte Death.
Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants.
Impact of recipient age and preoperative fasting blood glucose level as the risk factors of living donor liver transplantation in cirrhotic patients in the recent comprehensive era with knowledge of indications: Recent status in a Japanese single center.
Pediatric post-transplant metabolic syndrome: New clouds on the horizon.
Renal function in pediatric liver transplantation: a long-term follow-up study.
Risk factors of recipient receiving living donor liver transplantation in the comprehensive era of indication and perioperative managements.
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients.
Liver Failure
Diagnosis and management of autoimmune hepatitis.
Metabolic Bone Disease in the Post-transplant Population: Preventative and Therapeutic Measures.
Rescue therapy with sirolimus in a renal transplant recipient with tacrolimus-induced hepatotoxicity.
Liver Neoplasms
Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3.
Protein phosphatase 2 regulatory subunit B''Alpha silencing inhibits tumor cell proliferation in liver cancer.
Transcriptional toxicity of the Yangtze River source water on mouse (Mus musculus) detected by cDNA microarray.
[Studies on protein phosphatase 1/2A in liver cancer tissues: preliminary report]
Liver Neoplasms, Experimental
Nucleolar phosphoprotein phosphatase from Novikoff hepatoma and rat liver: characterization and partial purification.
Phosphoprotein phosphatase activity of Novikoff hepatoma nucleoli.
Locked-In Syndrome
Recovery of locked-in syndrome following liver transplantation with calcineurin inhibitor cessation and supportive treatment.
Loeys-Dietz Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Lung Diseases
Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series.
Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.
Lung Diseases, Interstitial
Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.
Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis.
Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.
Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation.
Lung Injury
Dual specificity phosphatase DUSP6 promotes endothelial inflammation through inducible expression of ICAM-1.
Hypaphorine exerts anti-inflammatory effects in sepsis induced acute lung injury via modulating DUSP1/p38/JNK pathway.
Inhibition of calcineurin/NFATc4 signaling attenuates ventilator?induced lung injury.
Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.
Lung Neoplasms
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
An okadaic acid fragment analogue prevents nicotine-induced resistance to cisplatin by recovering PP2A activity in non-small cell lung cancer cells.
APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.
Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
Corrigendum to "APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP" [EBioMedicine (2019)].
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling.
Direct regulation of transforming growth factor ?-induced epithelial-mesenchymal transition by the protein phosphatase activity of unphosphorylated PTEN in lung cancer cells.
Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.
DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese.
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
Involvement of CHP2 in the Development of Non-Small Cell Lung Cancer and Patients' Poor Prognosis.
Key genes in lung cancer translational research: a meta-analysis.
MicroRNA-365b-3p represses the proliferation and promotes the apoptosis of non-small cell lung cancer cells by targeting PPP5C.
miR-1297 Promotes Cell Proliferation of Non-Small Cell Lung Cancer Cells: Involving in PTEN/Akt/Skp2 Signaling Pathway.
miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation.
Overexpression of Protein Phosphatase 4 Correlates with Poor Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma.
PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells.
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance.
Repressive role of stabilized hypoxia inducible factor 1? expression on transforming growth factor ?-induced extracellular matrix production in lung cancer cells.
Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer.
Sirolimus in heart transplantation: a single center initial experience.
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.
The effect of down regulation of calcineurin A? by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis.
The ISG15-specific protease USP18 regulates stability of PTEN.
Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway.
Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
[Expression and clinical significance of CIP2A in small cell lung cancer patients].
Lupus Erythematosus, Cutaneous
Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Therapeutic effectiveness of calcineurin inhibitors in canine vesicular cutaneous lupus erythematosus.
Topical calcineurin inhibitors in cutaneous lupus erythematosus.
Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus.
Lupus Erythematosus, Discoid
Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus.
Lupus Erythematosus, Systemic
Association between PPP2CA polymorphisms and clinical features in southwest Chinese systemic lupus erythematosus patients.
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.
Calcineurin inhibitors in systemic lupus erythematosus.
CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition.
Estradiol upregulates calcineurin expression via overexpression of estrogen receptor alpha gene in systemic lupus erythematosus.
Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus.
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Increased estrogen-dependent expression of calcineurin in female SLE T cells is regulated by multiple mechanisms.
Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor.
Molecular mechanisms involved in the estrogen-dependent regulation of calcineurin in systemic lupus erythematosus T cells.
Multiple variants in 5q31.1 are associated with systemic lupus erythematosus susceptibility and sub-phenotypes in the Han Chinese population.
Nifedipine suppresses Th1/Th2 cytokine production and increased apoptosis of anti-CD3 + anti-CD28-activated mononuclear cells from patients with systemic lupus erythematosus via calcineurin pathway.
Standard chronic immunosuppression after kidney transplantation for systemic lupus erythematosus eliminates recurrence of disease.
The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases.
Topical calcineurin inhibitors in systemic lupus erythematosus.
Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus.
Lupus Nephritis
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.
Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.
Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.
Calcineurin inhibitors in lupus nephritis.
Calcineurin Inhibitors in the Treatment of Lupus Nephritis: A Hare Versus Turtle Story?
Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis.
Cellular aspects of the pathogenesis of lupus nephritis.
Changing paradigms in the treatment of systemic lupus erythematosus.
Con: The use of calcineurin inhibitors in the treatment of lupus nephritis.
CYP3A and P-glycoprotein Drug-Drug Interactions with Voclosporin.
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
How cyclosporin reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.
Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial.
Kidney transplantation after liver transplantation.
Moderator's view: the use of calcineurin inhibitors in the treatment of lupus nephritis.
Pharmacokinetics of voclosporin in renal impairment and hepatic impairment.
Posterior Reversible Encephalopathy Syndrome in Henoch-Schonlein Purpura and Hemolytic Uremic Syndrome.
Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Recurrence of disease following organ transplantation in autoimmune liver disease and systemic lupus erythematosus.
Renal Biopsy in Children-Effect on Treatment Decisions: A Single-Center Experience.
The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.
The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis.
The pathology of T cells in systemic lupus erythematosus.
Therapeutic options for resistant lupus nephritis.
Towards new avenues in the management of lupus glomerulonephritis.
Treatment of severe lupus nephritis: the new horizon.
Treatment of young patients with lupus nephritis using calcineurin inhibitors.
Treatment with cyclosporine A improves SLE disease activity of Japanese patients with diffuse proliferative lupus nephritis.
Understanding lupus nephritis: diagnosis, management, and treatment options.
Update on clinical trials in systemic lupus erythematosus.
Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects.
Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis.
[Meta-analysis of calcineurin inhibitor in the treatment of lupus nephritis].
[Significance of calcineurin activation and CD40L expression in patients with active lupus nephritis].
Lymphatic Metastasis
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Lymphedema
Spontaneous Chylous Ascites After Liver Transplantation Secondary to Everolimus: A Case Report.
Lymphocele
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.
Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation.
Lymphocytic Choriomeningitis
Calcineurin Aalpha plays an exclusive role in TCR signaling in mature but not in immature T cells.
Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation.
Lymphocytosis
Omenn syndrome: therapeutic effects of cyclosporin.
Lymphoma
A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.
Association Between Malignancy and Topical Use of Pimecrolimus.
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Characterization of a mutant calcineurin A alpha gene expressed by EL4 lymphoma cells.
Conversion to sirolimus in posttransplant renal neoplasms.
Current approaches to the use of sirolimus in renal transplantation.
Cutaneous T cell lymphoma complicating severe atopic dermatitis. Is making a diagnosis the main challenge?
Dephosphorylation of catalytic subunit of cAMP-dependent protein kinase at Thr-197 by a cellular protein phosphatase and by purified protein phosphatase-2A.
Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.
Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity.
Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.
Evaluation of Cancer Risk Related to Atopic Dermatitis and Use of Topical Calcineurin Inhibitors.
FK506 (tacrolimus) inhibits extravasation of lymphoid cells by abrogating VLA-4/VCAM-1 mediated transendothelial migration.
Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1.
Laforin confers cancer resistance to energy deprivation-induced apoptosis.
Long-term use of everolimus in lung transplant patients.
Loss of calcineurin homologous protein-1 in chicken B lymphoma DT40 cells destabilizes Na+/H+ exchanger isoform-1 protein.
Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom.
Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Modulation of CD40L antigen expression in Jurkat cells: involvement of protein kinase C activity.
Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation.
Overexpression of the mTOR alpha4 phosphoprotein activates protein phosphatase 2A and increases Stat1alpha binding to PIAS1.
Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1).
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.
Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.
Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56? stabilizes its antiapoptotic activity.
Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics.
Study of "de novo" malignancies among greek renal transplant recipients.
Subthalamic nucleus deep brain stimulation protects neurons by activating autophagy via PP2A inactivation in a rat model of Parkinson's disease.
Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits.
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.
The natural tumorcide Manumycin-A targets protein phosphatase 1? and reduces hydrogen peroxide to induce lymphoma apoptosis.
The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth.
Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.
Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis.
Topical Treatments with Pimecrolimus, Tacrolimus and Medium- to High-Potency Corticosteroids, and Risk of Lymphoma.
Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma.
[Influence of dipyridamole on expression of PAC-1 and CD62p in patients with malignant lymphoma].
[Topical pimecrolimus and tacrolimus and the risk of cancer]
Lymphoma, B-Cell
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
Subthalamic nucleus deep brain stimulation protects neurons by activating autophagy via PP2A inactivation in a rat model of Parkinson's disease.
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
Lymphoma, Follicular
Differential expression of Ca(2+)-binding proteins on follicular dendritic cells in non-neoplastic and neoplastic lymphoid follicles.
Lymphoma, Large B-Cell, Diffuse
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants.
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
Lymphoma, Mantle-Cell
The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
Lymphoma, T-Cell
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Lymphoma, T-Cell, Cutaneous
Cutaneous T cell lymphoma complicating severe atopic dermatitis. Is making a diagnosis the main challenge?
Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk.
Lymphopenia
A putative role for calcineurin in lymphopenia associated with chronic renal failure.
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.
Lymphoproliferative Disorders
Advances in pediatric heart transplantation.
Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Biomarkers of immune tolerance in kidney transplantation: an overview.
Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: A retrospective analysis based on the prospective, international, multicenter PTLD-1 trials.
Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival.
Magnesium Deficiency
Hypomagnesemia is associated with new-onset diabetes mellitus following heart transplantation.
Interaction of cyclosporine and FK506 with diuretics in transplant patients.
Malaria
A unique protein phosphatase with kelch-like domains (PPKL) in Plasmodium modulates ookinete differentiation, motility and invasion.
Characterization of a novel serine/threonine protein phosphatase (PfPPJ) from the malaria parasite, Plasmodium falciparum.
Characterization of protein Ser/Thr phosphatases of the malaria parasite, Plasmodium falciparum: inhibition of the parasitic calcineurin by cyclophilin-cyclosporin complex.
Identification and characterization of an unusual double serine/threonine protein phosphatase 2C in the malaria parasite Plasmodium falciparum.
Parasite Calcineurin Regulates Host Cell Recognition and Attachment by Apicomplexans.
Plasmodium berghei serine/threonine protein phosphatase PP5 plays a critical role in male gamete fertility.
Plasmodium protein phosphatase 2C dephosphorylates translation elongation factor 1beta and inhibits its PKC-mediated nucleotide exchange activity in vitro.
Protein phosphatase beta, a putative type-2A protein phosphatase from the human malaria parasite Plasmodium falciparum.
Regulation of protein phosphatase type 1 and cell cycle progression by PfLRR1, a novel leucine-rich repeat protein of the human malaria parasite Plasmodium falciparum.
Malnutrition
Calcineurin B1 Deficiency in Glial Cells Induces Mucosal Degeneration and Inflammation in Mouse Small Intestine.
Malocclusion
A Missense Mutation in DUSP6 is Associated with Class III Malocclusion.
Corrigendum.
Mania
Deletion of GSK3? in D2R-expressing neurons reveals distinct roles for ?-arrestin signaling in antipsychotic and lithium action.
Maple Syrup Urine Disease
A novel regulatory defect in the branched-chain ?-keto acid dehydrogenase complex due to a mutation in the PPM1K gene causes a mild variant phenotype of maple syrup urine disease.
Catabolism of branched-chain amino acids in heart failure: insights from genetic models.
Marfan Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Mastocytosis
Mast cells as targets of pimecrolimus.
Mastocytosis, Cutaneous
Mast cells as targets of pimecrolimus.
Measles
Measles Virus Infection Inactivates Cellular Protein Phosphatase 5 with Consequent Suppression of Sp1 and c-Myc Activities.
Medulloblastoma
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
HDM2 promotes WIP1-mediated medulloblastoma growth.
p53 Function is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
PPM1D/WIP1 in medulloblastoma.
WIP1 modulates responsiveness to Sonic Hedgehog signaling in neuronal precursor cells and medulloblastoma.
Megacolon, Toxic
Medical Therapy of Active Ulcerative Colitis.
Melanoma
A landscape of driver mutations in melanoma.
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.
A mutation in protein phosphatase type 2A as a cause of melanoma progression.
Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.
Active ?-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A.
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.
Characterization of human melanoma cell lines and melanocytes by proteome analysis.
Circ_0002770, acting as a competitive endogenous RNA, promotes proliferation and invasion by targeting miR-331-3p in melanoma.
Combination of ?-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study.
Detection of driver mutations in FFPE samples from patients with verified malignant melanoma.
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells.
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Glucose-6-phosphate dehydrogenase and NADPH oxidase 4 control STAT3 activity in melanoma cells through a pathway involving reactive oxygen species, c-SRC and SHP2.
Identification by differential display of a protein phosphatase-2A regulatory subunit preferentially expressed in malignant melanoma cells.
Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype.
Inhibition of calcineurin by cyclosporine A exerts multiple effects on human melanoma cell lines HT168 and WM35.
Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
Involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma.
Ligand-Mimetic Anti-alphaIIbbeta3 Antibody PAC-1 Inhibits Tyrosine Signaling, Proliferation and Lung Colonization of Melanoma Cells.
Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A.
MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAFV600E-driven melanoma growth in vivo and BRAF/MEK inhibitor resistance.
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.
Oncogenic suppression of PHLPP1 in human melanoma.
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo.
PP6C Hotspot Mutations in Melanoma Display Sensitivity to Aurora Kinase Inhibition.
Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK.
Redox modulation of protein kinase/phosphatase balance in melanoma cells: the role of endogenous and gamma-glutamyltransferase-dependent H2O2 production.
Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Statistical Detection of Intrinsically Multivariate Predictive Genes.
Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.
Tacrolimus and ascomycin inhibit melanoma cell growth, migration and invasion via targeting nuclear factor of activated T-cell 3.
The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells.
The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization.
The protein phosphatase 6 catalytic subunit (Ppp6c) is indispensable for proper post-implantation embryogenesis.
Tumor suppressor and growth regulatory genes are overexpressed in severe early-onset preeclampsia--an array study on case-specific human preeclamptic placental tissue.
Weighted correlation network and differential expression analyses identify candidate genes associated with BRAF gene in melanoma.
[Ultraviolet A-induced DNA damage: role in skin cancer].
Melanoma, Experimental
Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
Memory Disorders
Bidirectional Regulation of Amyloid Precursor Protein-Induced Memory Defects by Nebula/DSCR1: A Protein Upregulated in Alzheimer's Disease and Down Syndrome.
Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia.
Crocin-protected malathion-induced spatial memory deficits by inhibiting TAU protein hyperphosphorylation and antiapoptotic effects.
Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole.
Immature dentate gyrus: an endophenotype of neuropsychiatric disorders.
Inhibition of protein phosphatases induces transport deficits and axonopathy.
Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition.
Laforin and malin deletions in mice produce similar neurologic impairments.
Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment.
Methionine-Mediated Protein Phosphatase 2A Catalytic Subunit (PP2Ac) Methylation Ameliorates the Tauopathy Induced by Manganese in Cell and Animal Models.
Selective induction of calcineurin activity and signaling by oligomeric amyloid beta.
Transthyretin: a key gene involved in the maintenance of memory capacities during aging.
Meniere Disease
Association of a functional polymorphism of PTPN22 encoding a lymphoid protein phosphatase in bilateral Meniere's disease.
Meningioma
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
p38MAPK activation and DUSP10 expression in meningiomas.
The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies.
Meningitis, Cryptococcal
Calcineurin is required for virulence of Cryptococcus neoformans.
Favorable Evolution of Cryptococcal Meningitis in the Context of Flucytosine Resistance.
The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein.
Meningitis, Fungal
A Mechanosensitive Channel Governs Lipid Flippase-Mediated Echinocandin Resistance in Cryptococcus neoformans.
Calcium Binding Protein Ncs1 Is Calcineurin Regulated in Cryptococcus neoformans and Essential for Cell Division and Virulence.
MERRF Syndrome
Advances in the genetics of progressive myoclonus epilepsy.
Metabolic Diseases
Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.
miR-140-5p Aggravates Insulin Resistance via Directly Targeting GYS1 and PPP1CC in Insulin-Resistant HepG2 Cells.
Variations in DNA elucidate molecular networks that cause disease.
Metabolic Syndrome
DUSP1 Gene Polymorphisms Are Associated with Obesity-Related Metabolic Complications among Severely Obese Patients and Impact on Gene Methylation and Expression.
Is a flavonoid-rich diet with steamer cooking safe during calcineurin inhibitors therapy?
Management of posttransplant hepatitis C infection.
Metabolic syndrome in transplant patients: an academic or a health burden?
New-onset diabetes mellitus after kidney transplantation: Current status and future directions.
Nutritional and metabolic issues in solid organ transplantation: targets for future research.
Pathophysiologic and Treatment Strategies for Cardiovascular Disease in End Stage Renal Disease and Kidney Transplantation.
methylenetetrahydrofolate dehydrogenase (nad+) deficiency
Altered protein phosphatase 2A methylation and Tau phosphorylation in the young and aged brain of methylenetetrahydrofolate reductase (MTHFR) deficient mice.
Migraine Disorders
Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms.
Mitochondrial Diseases
mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases.
Preparation and characterization of a polyclonal antibody against PTEN-Long.
Mouth Neoplasms
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Saliva as a tool for oral cancer diagnosis and prognosis.
Movement Disorders
Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.
Mucocutaneous Lymph Node Syndrome
Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant kawasaki disease.
Calcineurin inhibitors exacerbate coronary arteritis via the MyD88 signalling pathway in a murine model of Kawasaki disease.
The elevated serum levels of calcineurin and nuclear factor of activated T-cells 1 in children with Kawasaki disease.
Mucormycosis
A Novel Resistance Pathway for Calcineurin Inhibitors in the Human-Pathogenic Mucorales Mucor circinelloides.
Heterotrimeric G-alpha subunits Gpa11 and Gpa12 define a transduction pathway that control spore size and virulence in Mucor circinelloides.
Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors.
Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.
Tornadic Shear Stress Induces a Transient, Calcineurin-Dependent Hypervirulent Phenotype in Mucorales Molds.
Multiple Myeloma
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin.
Multiple Sclerosis
Dual-specific Phosphatase-6 (Dusp6) and ERK Mediate AMPA Receptor-induced Oligodendrocyte Death.
Inhibition of Calcineurin Abrogates While Inhibition of mTOR Promotes Regulatory T Cell Expansion and Graft-Versus-Host Disease Protection by IL-2 in Allogeneic Bone Marrow Transplantation.
Multiple System Atrophy
Cell type-specific neuronal loss in the putamen of patients with multiple system atrophy.
Muscle Cramp
Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients.
Muscle Spasticity
Recent insights into the mechanisms, predisposing factors, and racial differences of coronary vasospasm.
Muscular Atrophy
Anabolic steroids activate calcineurin-NFAT signaling and thereby increase myotube size and reduce denervation atrophy.
Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins.
Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.
Calcineurin signaling and PGC-1alpha expression are suppressed during muscle atrophy due to diabetes.
Maintenance of muscle mass is not dependent on the calcineurin-NFAT pathway.
miR-23a is decreased during muscle atrophy by a mechanism that includes calcineurin signaling and exosome-mediated export.
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.
Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study.
Tiny transporters: how exosomes and calcineurin signaling regulate miR-23a levels during muscle atrophy. Focus on "miR-23a is decreased during muscle atrophy by a mechanism that includes calcineurin signaling and exosome-mediated export".
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Muscular Atrophy, Spinal
CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
Muscular Diseases
Prevention of Recurrent Episodes of Rhabdomyolysis With Tacrolimus in a Transplant Recipient With Myopathy.
Muscular Disorders, Atrophic
Signaling mechanisms involved in disuse muscle atrophy.
Muscular Dystrophies
Dusp6 is a genetic modifier of growth through enhanced ERK activity.
Muscular Dystrophies, Limb-Girdle
Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy.
Muscular Dystrophy, Duchenne
Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles.
Decreased calcineurin activity in circulation of Duchenne muscular dystrophy.
Mutism
Liver Transplant Can Resolve Severe Neuropsychiatric Manifestations of Wilson Disease: A Case Report.
Mutism and Persistent Dysarthria Due to Tacrolimus-Based Immunosuppression Following Allogeneic Liver Transplantation.
Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.
Myasthenia Gravis
Clinical implications of the type 1/ type 2 balance of helper T cells and P-glycoprotein function in peripheral T lymphocytes of myasthenia gravis patients.
Factors associated with response to calcineurin inhibitors in myasthenia gravis.
Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis.
Suppressive potencies of calcineurin inhibitors against the mitogen-induced blastogenesis of peripheral-blood mononuclear cells of myasthenia gravis patients.
Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients.
[Calcineurin inhibitors and IVIg in the treatment of myasthenia gravis].
[Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis: therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids].
Mycoses
15N, 13C and 1H resonance assignments of FKBP12 proteins from the pathogenic fungi Mucor circinelloides and Aspergillus fumigatus.
Calcineurin inhibitors reduce NFAT-dependent expression of antifungal pentraxin-3 by human monocytes.
Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus.
Epithelial cells treated with genistein inhibit adhesion and endocytosis of Paracoccidioides brasiliensis.
Fungal infections in renal transplant patients.
Psoriasis-like tinea incognita: a case report and literature review.
Mycosis Fungoides
Follicular Eruption With Folliculotropic Lymphocytic Infiltrates Associated With Iatrogenic Immunosuppression: Report and Study of 3 Cases, and Review of the Literature.
Myelitis
Human Herpes Virus-6-Associated Encephalitis/Myelitis Mimicking Calcineurin Inhibitor-Induced Pain Syndrome in Allogeneic Stem Cell Transplantation Recipients.
Myelodysplastic Syndromes
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants.
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.
Myocardial Infarction
Association of platelet-derived microparticles with C-C chemokines on vascular complication in patients with acute myocardial infarction.
Calcineurin splicing variant calcineurin A?1 improves cardiac function after myocardial infarction without inducing hypertrophy.
Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction.
Hydrogen sulfide protects cardiomyocytes from myocardial ischemia-reperfusion injury by enhancing phosphorylation of apoptosis repressor with caspase recruitment domain.
Induction of the calcineurin variant CnA?1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization.
Mitochondrial phosphatase PGAM5 regulates Keap1-mediated Bcl-xL degradation and controls cardiomyocyte apoptosis driven by myocardial ischemia/reperfusion injury.
Mitochondrial Protein PGAM5 Regulates Mitophagic Protection against Cell Necroptosis.
PP2Cm overexpression alleviates MI/R injury mediated by a BCAA catabolism defect and oxidative stress in diabetic mice.
Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice.
Total Saponins of Aralia Elata (Miq) Seem Alleviate Calcium Homeostasis Imbalance and Endoplasmic Reticulum Stress-Related Apoptosis Induced by Myocardial Ischemia/Reperfusion Injury.
Myocardial Ischemia
AMP-activated protein kinase protects against necroptosis via regulation of Keap1-PGAM5 complex.
Immunology Update: Long-Term Care of Solid Organ Transplant Recipients.
Negative Cardiovascular Consequences of Small Molecule Immunosuppressants.
Serine-threonine protein phosphatase regulation of Cx43 dephosphorylation in arrhythmogenic disorders.
[The Role of Laboratory Medicine in Hematopoietic Stem Cell Transplantation "Echocardiogram"].
Myocarditis
Three types of striational antibodies in myasthenia gravis.
Myoclonic Epilepsies, Progressive
4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.
A novel compound heterozygous EPM2A mutation in a Chinese boy with Lafora disease.
A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.
Alternative splicing modulates subcellular localization of laforin.
Dimeric quaternary structure of human laforin.
Early-onset Lafora body disease.
Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole.
Escherichia coli expression, refolding and characterization of human laforin.
FDG-PET assessment and metabolic patterns in Lafora disease.
Four novel and two recurrent NHLRC1 (EPM2B) and EPM2A gene mutations leading to Lafora disease in six Turkish families.
Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase.
Glycogen metabolism in tissues from a mouse model of Lafora disease.
Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex.
Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora.
Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product.
Identification of new and common mutations in the EPM2A gene in Lafora disease.
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.
Lafora disease ubiquitin ligase malin promotes proteasomal degradation of neuronatin and regulates glycogen synthesis.
Lafora disease.
Laforin and malin deletions in mice produce similar neurologic impairments.
Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.
Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
Late-onset Lafora disease with prominent parkinsonism due to a rare mutation in EPM2A.
Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.
Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.
Mutation screening for Japanese Lafora's disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of EPM2A gene.
Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy.
Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Neuronatin-mediated Aberrant Calcium Signaling and Endoplasmic Reticulum Stress Underlie Neuropathology in Lafora Disease.
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease.
Phosphate incorporation during glycogen synthesis and Lafora disease.
Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B.
Protein Degradation and Quality Control in Cells from Laforin and Malin Knockout Mice.
Regional and developmental expression of Epm2a gene and its evolutionary conservation.
Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
Structural and Functional Brain Abnormalities in Mouse Models of Lafora Disease.
The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain.
Transcriptional profiling of a mouse model for Lafora disease reveals dysregulation of genes involved in the expression and modification of proteins.
Two novel mutations in the EPM2A gene in a Korean patient with Lafora's progressive myoclonus epilepsy.
[Lafora disease: a review of the literature].
Myoclonus
Corrigendum to "FoxO3a-mediated autophagy is down-regulated in the laforin deficient mice, an animal model for Lafora progressive myoclonus epilepsy" [Biochem. Biophys. Res. Commun. 474 (2) (2016) 321-327].
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Laforin and malin deletions in mice produce similar neurologic impairments.
Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy.
Myositis
Advances in the therapy of idiopathic inflammatory myopathies.
Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy.
Myxoma
Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability.
Nasopharyngeal Carcinoma
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma.
Necrobiosis Lipoidica
Treatment of ulcerative necrobiosis lipoidica with topical calcineurin inhibitor: case report and literature review.
Neoplasm Metastasis
Analysis of methylation profiling data of hyperplasia and primary and metastatic endometrial cancers.
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Antibody Array Revealed PRL-3 Affects Protein Phosphorylation and Cytokine Secretion.
Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling.
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
CircSEC24A promotes tumor progression through sequestering miR-455-3p in hepatocellular carcinoma.
CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression.
Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.
Detection of driver mutations in FFPE samples from patients with verified malignant melanoma.
Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer.
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer.
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.
Endothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2.
Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays.
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
FK506 binding proteins as targets in anticancer therapy.
Gene expression profile analysis of ENO1 knockdown in gastric cancer cell line MGC-803.
Gene heterogeneity in metastasis of colorectal cancer to the lung.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
In vivo Dynamics and Distinct Functions of Hypoxia in Primary Tumor Growth and Organotropic Metastasis of Breast Cancer.
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma.
KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity.
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Localizing PRL-2 expression and determining the effects of dietary Mg(2+) on expression levels.
Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer.
MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase.
Migration of renal tumor cells depends on dephosphorylation of Shc by PTEN.
Minimizing the risk of posttransplant malignancy.
miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F.
MiR-96 induced non-small-cell lung cancer progression through competing endogenous RNA network and affecting EGFR signaling pathway.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration.
Phosphatase of Regenerating Liver 3 (PRL3) provokes a tyrosine phosphoproteome to drive pro-metastatic signal transduction.
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Phosphatase POPX2 Exhibits Dual Regulatory Functions in Cancer Metastasis.
Phosphorylation of nucleophosmin at threonine 234/237 is associated with HCC metastasis.
Poor prognosis of phosphatase of regenerating liver 3 expression in gastric cancer: a meta-analysis.
Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.
PPM1D accelerates proliferation and metastasis of osteosarcoma by activating PKP2.
PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
PPM1D is a prognostic marker and therapeutic target in colorectal cancer.
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3.
PRL-3 activates NF-?B signaling pathway by interacting with RAP1.
PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.
Prognostic value of PPM1D in 800 gastric cancer patients.
Prognostic value of PRL-3 overexpression in early stages of colonic cancer.
Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.
Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Regulator of calcineurin 1 modulates cancer cell migration in vitro.
Regulatory mechanisms of phosphatase of regenerating liver (PRL)-3.
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.
Siglec-15 Promotes Tumor Progression in Osteosarcoma via DUSP1/MAPK Pathway.
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
Synaptopodin-2 promotes hepatocellular carcinoma metastasis via calcineurin-induced nuclear-cytoplasmic translocation.
Targeting PTPs with small molecule inhibitors in cancer treatment.
The Calcineurin-NFAT-Angiopoietin-2 Signaling Axis in Lung Endothelium Is Critical for the Establishment of Lung Metastases.
The Clinical Significance of PPEF1 as a Promising Biomarker and Its Potential Mechanism in Breast Cancer.
The effect of down regulation of calcineurin A? by lentiviral vector-mediated RNAi on the biological behavior of small-cell lung cancer and its bone metastasis.
Tissue-specific gene therapy directed to tumor angiogenesis.
TP53INP1 Downregulation Activates a p73-Dependent DUSP10/ERK Signaling Pathway to Promote Metastasis of Hepatocellular Carcinoma.
Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase.
Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.
Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner.
Tumor-associated macrophages promote the metastasis and growth of non-small-cell lung cancer cells through NF-?B/PP2Ac-positive feedback loop.
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway.
[Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs]
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
[Minimizing the risk of cancer in transplant patients.]
Neoplasms
1alpha,25-dihydroxyvitamin D3 activates T cells of tumor bearers through protein phosphatase 2A.
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.
A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients.
A comprehensive review and update on ulcerative colitis
A FRET-based screening method to detect potential inhibitors of the binding of CNNM3 to PRL2.
A Genetic Variant of PPP1CB Influences Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma in Han Chinese: A Pathway Based Analysis.
A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-)-epigallocatechin gallate and green tea--a review.
A Nonsynonymous/Synonymous Substitution Analysis of the B56 Gene Family Aids in Understanding B56 Isoform Diversity.
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts.
A potential role of the unfolded protein response in post-transplant cancer.
A proteomics analysis of cell signaling alterations in colorectal cancer.
A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.
A Review of DUSP26: Structure, Regulation and Relevance in Human Disease.
A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis.
A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
A stable association with PME-1 may be dispensable for PP2A demethylation - implications for the detection of PP2A methylation and immunoprecipitation.
A suppressive role of ionizing radiation-responsive miR-29c in the development of liver carcinoma via targeting WIP1.
A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins.
Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Activation of protein phosphatase causes alternative splicing of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): potential effect on immune surveillance.
Activation of tumor suppressor protein PTEN and induction of apoptosis are involved in cAMP-mediated inhibition of cell number in B92 glial cells.
Addressing treatment challenges in atopic dermatitis with novel topical therapies.
Adenomatous polyposis coli heterozygous knockout mice display hypoactivity and age-dependent working memory deficits.
Adjunctive therapies for Kawasaki disease.
ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells.
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.
Advances in the therapy of idiopathic inflammatory myopathies.
Age-related remodelling of oesophageal epithelia by mutated cancer drivers.
AGEs exacerbates coronary microvascular dysfunction in NoCAD by activating endoplasmic reticulum stress-mediated PERK signaling pathway.
AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway.
Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Allelic loss of the PTEN gene and mutation of the TP53 gene in choriocarcinoma arising from gastric adenocarcinoma: analysis of loss of heterozygosity in two male patients with extragonadal choriocarcinoma.
Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.
Alterations of the PPP1R3 gene in human cancer.
Alterations of the PPP2R1B gene in human lung and colon cancer.
Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development.
Alternative splicing of the human PTEN/MMAC1/TEP1 gene.
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells.
An immunocytochemical demonstration of calcineurin in human nerve cell tumors. A comparison with neuron-specific enolase and glial fibrillary acidic protein.
An okadaic acid fragment analogue prevents nicotine-induced resistance to cisplatin by recovering PP2A activity in non-small cell lung cancer cells.
An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome).
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Analysis on heat stress-induced hyperphosphorylation of stathmin at serine 37 in Jurkat cells by means of two-dimensional gel electrophoresis and tandem mass spectrometry.
Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.
Anti-tumor effects of perphenazine on canine lymphoma.
Antibody Array Revealed PRL-3 Affects Protein Phosphorylation and Cytokine Secretion.
Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Anticancer potential of curcumin: preclinical and clinical studies.
Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
Apigenin Inhibits the Growth of Hepatocellular Carcinoma Cells by Affecting the Expression of microRNA Transcriptome.
APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.
Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling.
Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Association Between Malignancy and Topical Use of Pimecrolimus.
Association between PPP2CA expression and colorectal cancer prognosis Tumour Marker Prognostic Study.
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Association of the tensin N-terminal protein-tyrosine phosphatase domain with the alpha isoform of protein phosphatase-1 in focal adhesions.
Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Atopic dermatitis: a review of topical nonsteroid therapy.
Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Aurovertin B exerts potent antitumor activity against triple-negative breast cancer in vivo and in vitro via regulating ATP synthase activity and DUSP1 expression.
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy.
Autophagy regulates levels of tumor suppressor enzyme protein phosphatase 6.
Autophagy-mediated Mir6981 degradation exhibits CDKN1B promotion of PHLPP1 protein translation.
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.
Basiliximab: a review of its use as induction therapy in renal transplantation.
Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death.
Biochemical characterization of the phosphatase domain of the tumor suppressor PH domain leucine-rich repeat protein phosphatase.
Biological evaluation of newly synthesized quinoline-5,8-quinones as Cdc25B inhibitors.
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.
Calcineurin a-binding protein, a novel modulator of the calcineurin-nuclear factor of activated T-cell signaling pathway, is overexpressed in wilms' tumors and promotes cell migration.
Calcineurin as a neuronal marker of human brain tumors.
Calcineurin deficiency decreases inflammatory lesions in transforming growth factor beta1-deficient mice.
Calcineurin homologous protein isoform 2 supports tumor survival via the sodium hydrogen exchanger isoform 1 in non-small cell lung cancer.
Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals.
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
Calcineurin mediates human tumor necrosis factor alpha gene induction in stimulated T and B cells.
Calcineurin potentiates the activation of procaspase-3 by accelerating its proteolytic maturation.
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
Calcineurin Regulates Homologous Desensitization of Natriuretic Peptide Receptor-A and Inhibits ANP-Induced Testosterone Production in MA-10 Cells.
Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.
Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription.
Calcineurin signaling as a negative determinant of keratinocyte cancer stem cell potential and carcinogenesis.
Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant.
Calcineurin, a calcium/calmodulin-regulated protein phosphatase, in mammalian neuroendocrine cells and neoplasms.
Calprotectin and the Initiation and Progression of Head and Neck Cancer.
Calyculin A causes sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by ROS-mediated down-regulation of cellular FLICE-inhibiting protein (c-FLIP) and by enhancing death receptor 4 mRNA stabilization.
Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
Can static electric fields increase the activity of nitric oxide synthase and induce oxidative stress and damage of spleen?
Cancer cell-derived immunoglobulin G activates platelets by binding to platelet Fc?RIIa.
Cancer predisposition: where's the phosphate?
Cancer therapy shapes the fitness landscape of clonal hematopoiesis.
Cancers after renal transplantation.
Cantharidic acid induces apoptosis in human nasopharyngeal carcinoma cells through p38-mediated upregulation of caspase activation.
Cardamonin Suppresses TGF-?1-Induced Epithelial Mesenchymal Transition via Restoring Protein Phosphatase 2A Expression.
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.
CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual specificity phosphatase 1.
Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity.
Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle.
Cellular transformation by Simian Virus 40 and Murine Polyoma Virus T antigens.
Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor.
Characterization of a membrane tyrosine phosphatase in AR42J cells: regulation by somatostatin.
Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D.
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Chronic microcystin exposure induces hepatocyte proliferation with increased expression of mitotic and cyclin-associated genes in P53-deficient mice.
CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression.
CircSEC24A promotes tumor progression through sequestering miR-455-3p in hepatocellular carcinoma.
CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression.
Circulating TGF-?1 and VEGF and risk of cancer among liver transplant recipients.
Circumventing Cellular Control of PP2A by Methylation Promotes Transformation in an Akt-Dependent Manner.
Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway.
Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes.
Clinical insights for cancer outcomes in renal transplant patients.
Clinical-pathological correlations in post-transplant thrombotic microangiopathy.
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Clonal hematopoiesis: Pre-cancer PLUS.
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease.
Cloning, tissue distribution, subcellular localization and overexpression of murine histidine-rich Ca2+ binding protein.
Co-Delivery of Oxaliplatin and Demethylcantharidin via a Polymer-Drug Conjugate.
Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Comparison of Kidney Transplant Function, Lipid Metabolism Disorders, and Glucose and Hemoglobin Concentration in Transplant Patients Treated With Proliferation Signal Inhibitor (Everolimus) or Calcineurin Inhibitor (Tacrolimus).
Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-? Transgenic Mice.
Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia.
Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.
Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice.
Constitutively active protein phosphatase 1alpha causes Rb-dependent G1 arrest in human cancer cells.
Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers.
Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Conversion to sirolimus in pediatric renal transplantation recipients.
Conversion to sirolimus in posttransplant renal neoplasms.
Conversion to sirolimus in renal transplant patients with tumors.
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
Correction: Liu, Y.-S.; et al. Inhibition of Protein Phosphatase 1 Stimulates Noncanonical ER Stress eIF2? Activation to Enhance Fisetin-Induced Chemosensitivity in HDAC Inhibitor-Resistant Hepatocellular Carcinoma Cells. Cancers 2019, 11, 918.
Correction: RIF1 promotes tumor growth and cancer stem cell-like traits in NSCLC by protein phosphatase 1-mediated activation of Wnt/?-catenin signaling.
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
Costimulatory Blockade and Use of Mammalian Target of Rapamycin Inhibitors: Avoiding Injury Part 1.
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.
Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme.
CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.
Curcumin inhibits TNFalpha-induced lectin-like oxidised LDL receptor-1 (LOX-1) expression and suppresses the inflammatory response in human umbilical vein endothelial cells (HUVECs) by an antioxidant mechanism.
Current approaches to the use of sirolimus in renal transplantation.
Current treatment of ulcerative colitis.
Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth.
Cyclosporin A promotes translational silencing of autocrine interleukin-3 via ribosome-associated deadenylation.
Cyclosporin A Promotes Tumor Angiogenesis in a Calcineurin-Independent Manner by Increasing Mitochondrial Reactive Oxygen Species.
Cyclosporine A Inhibits the T-bet-Dependent Antitumor Response of CD8(+) T Cells.
Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: Role of TGF? signaling pathway.
Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation.
Daunting but worthy goal : reducing the de novo cancer incidence after transplantation.
Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation.
De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation-8-year results.
Deactivation of sphingosine kinase 1 by protein phosphatase 2A.
Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer.
Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death.
Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells.
Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.
Dephosphorylation of Rb (Thr-821) in response to cell stress.
Dephosphorylation of the small heat shock protein hsp25 by calcium/calmodulin-dependent (type 2B) protein phosphatase.
Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.
Descriptive Analysis of Everolimus Conversion in Liver Transplant Recipients With Malignant Neoplastic Disease.
Design, synthesis and anticancer activity of constrained sphingolipid-phenoxazine/phenothiazine hybrid constructs targeting protein phosphatase 2A.
Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold.
Detection of driver mutations in FFPE samples from patients with verified malignant melanoma.
Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.
Developmental and light regulation of tumor suppressor protein PP2A in the retina.
Dexamethasone induced expression of phosphatase inhibits generation of reactive oxygen species in Ehrlich ascites tumor cells.
Differences in association of the serine/threonine protein phosphatase PP-2A with microtubules of metastatic and nonmetastatic tumor cells.
Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.
Differential contribution of protein phosphatase 1? to cell transformation of different cell types.
Differential Effects of Nitrostyrene Derivatives on Myelopoiesis Involve Regulation of C/EBP? and p38MAPK Activity.
Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.
Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma.
Differential micro ribonucleic acid expression profiling in ovarian endometrioma with leuprolide acetate treatment.
Differential protein expressions induced by adenovirus-mediated p16 gene transfer into Balb/c nude mouse.
Differential Requirement for Pten Lipid and Protein Phosphatase Activity during Zebrafish Embryonic Development.
Digital RNA Sequencing of Human Epidermal Keratinocytes Carrying Human Papillomavirus Type 16 E7.
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound.
Discovery of protein phosphatase 2C inhibitors by virtual screening.
Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110?/PIK3CA but not by HER2 or mutant AKT1.
Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells.
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process.
Does structural commonality of metal complex formation by PAC-1 (anticancer), DHBNH (anti-HIV), AHL (autoinducer), and UCS1025A (anticancer) denote mechanistic similarity? Signal transduction and medical aspects.
Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.
Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer.
Down-regulation of dual-specificity phosphatase 6, a negative regulator of oncogenic ERK signaling, by ACA-28 induces apoptosis in NIH/3T3 cells overexpressing HER2/ErbB2.
Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells.
Downregulation of calcineurin activity in cervical carcinoma.
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Downregulation of PPP2R5E expression by miR-23a suppresses apoptosis to facilitate the growth of gastric cancer cells.
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Drosophila PRL-1 is a growth inhibitor that counteracts the function of the Src oncogene.
Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway.
Dual Allosteric Inhibition of SHP2 Phosphatase.
Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN.
Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity.
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Dual-Modal Split-Type Immunosensor for Sensitive Detection of Microcystin-LR: Enzyme-Induced Photoelectrochemistry and Colorimetry.
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma.
Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.
Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53.
Dual-specificity phosphatase 5 acts as an anti-inflammatory regulator by inhibiting the ERK and NF-?B signaling pathways.
Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis.
Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.
Dual-specificity phosphatases regulate mitogen-activated protein kinase signaling in adipocytes in response to inflammatory stress.
DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer.
DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer.
DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
DUSP1 is involved in the progression of small cell carcinoma of the prostate.
DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma.
DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk.
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.
DUSP10 Is a Regulator of YAP1 Activity Promoting Cell Proliferation and Colorectal Cancer Progression.
DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis.
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
DUSP5 expression associates with poor prognosis in human neuroblastoma.
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.
DUSP6 protects murine podocytes from high glucose?induced inflammation and apoptosis.
DUSP6 regulates drug sensitivity by modulating DNA damage response.
DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma.
DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5.
Early conversion to prednisolone/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial.
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.
Effects of arsenite and UVA-1 radiation on calcineurin signaling.
Effects of protein phosphatase inhibition by okadaic acid on the differentiation of F9 embryonal carcinoma cells.
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination with Vedolizumab in Patients With Refractory Ulcerative Colitis.
Elevated expression of the cdc25A protein phosphatase in colon cancer.
Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth.
Endometrial ILKAP expression among patients with endometriosis and its association with clinical characteristics.
Endothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2.
Endotoxin conditioning induces VCP/p97-mediated and inducible nitric-oxide synthase-dependent Tyr284 nitration in protein phosphatase 2A.
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK and mTOR kinase inhibitors.
Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 associated with malignancy of osteogenic tumor.
Enhanced expression of catalytic subunits of protein phosphatase type 1 and high S-phase fraction in liposarcoma.
Enhanced expression of PP1gamma1, a catalytic subunit isoform of protein phosphatase type1 and expression of telomerase activity in Ewing's sarcoma cells.
Enhancement of fibroblast collagenase-1 (MMP-1) gene expression by tumor promoter okadaic acid is mediated by stress-activated protein kinases Jun N-terminal kinase and p38.
Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation.
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
Epithelial calcineurin controls microbiota-dependent intestinal tumor development.
Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
ERO1?-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1).
Erratum to: Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Estradiol suppresses phosphorylation of ER? serine 167 through upregulation of PP2A in breast cancer cells.
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Evaluation of Cancer Risk Related to Atopic Dermatitis and Use of Topical Calcineurin Inhibitors.
Everolimus and sirolimus in transplantation-related but different.
Everolimus in Heart Transplantation: An Update.
Everolimus in lung transplantation in Chile.
Everolimus monotherapy or combined therapy in liver transplantation: indications and results.
Evidence that Fas-induced apoptosis leads to S phase arrest.
Evolution of glomerular filtration rate, renal injury markers, anemia, and Angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Evolutionary Analysis of the B56 Gene Family of PP2A Regulatory Subunits.
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6-pentakisphosphate 3-phosphatase activity.
Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery.
Exploring the role of active site Mn2+ ions in the binding of protein phosphatase 5 with its substrate using molecular dynamics simulations.
Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours.
Expression and function of the high affinity alphaIIbbeta3 integrin in murine melanoma cells.
Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line.
Expression of calcineurin activity after lung transplantation: a 2-year follow-up.
Expression of Dual-Specificity Phosphatase 2 (DUSP2) in Patients with Serous Ovarian Carcinoma and in SKOV3 and OVCAR3 Cells In Vitro.
Expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) in tumor cells.
Expression of FXYD-3 Is an Independent Prognostic Factor in Rectal Cancer Patients with Preoperative Radiotherapy.
Expression of PHLPP2 correlates with clinicopathologic characteristics and prognosis in colorectal cancer.
Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Expression Pattern and Prognostic Utility of PME-1 in Patients with Hepatocellular Carcinoma.
Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.
Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche.
Extracellular signal-regulated kinase 1/2-mediated phosphorylation of JunD and FosB is required for okadaic acid-induced activator protein 1 activation.
Fibroblast-derived CXCL12 regulates PTEN expression and is associated with the proliferation and invasion of colon cancer cells via PI3k/Akt signaling.
Fine deletion mapping of chromosome 2q21-37 shows three preferentially deleted regions in oral cancer.
Fine-Tuning of Pten Localization and Phosphatase Activity Is Essential for Zebrafish Angiogenesis.
FK506 binding proteins as targets in anticancer therapy.
FK506 reduces calpain-regulated calcineurin activity in both the cytoplasm and the nucleus.
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma.
From Favorable Histology to Relapse: The Clonal Evolution of a Wilms Tumor.
FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.
Functional Analysis of the Protein Phosphatase Activity of PTEN.
Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese.
Functions and Regulation of the PTEN Gene in Colorectal Cancer.
Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Gene expression profile analysis of ENO1 knockdown in gastric cancer cell line MGC-803.
Gene networks involved in apoptosis induced by hyperthermia in human lymphoma U937 cells.
Genes are differentially expressed in the epididymal fat of rats rendered obese by a high-fat diet.
Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-?, tumour necrosis factor-? and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients.
Genetic network and gene set enrichment analysis to identify biomarkers related to cigarette smoking and lung cancer.
Genetic variants and mutations of PPM1D control the response to DNA damage.
Genetic variants in PPP2CA are associated with gastric cancer risk in a Chinese population.
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
Geraniol ameliorates diabetic nephropathy via interference with miRNA-21/PTEN/Akt/mTORC1 pathway in rats.
Global gene expression analysis of knockdown Triosephosphate isomerase (TPI) gene in human gastric cancer cell line MGC-803.
Glomerular diseases and cancer: evaluation of underlying malignancy.
Glucocorticoids use in kidney transplant setting.
GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling.
Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway.
Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation.
Hepatitis C: liver transplantation.
Herpes viruses and tumours in kidney transplant recipients. The role of immunosuppression.
HIF-1? suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1.
High Bcl-2/Bax ratio in Walker tumor cells protects mitochondria but does not prevent H2O2-induced apoptosis via calcineurin pathways.
High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation.
High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.
High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients.
High-resolution crystal structure of the catalytic domain of human dual-specificity phosphatase 26.
Higher intratumor than peritumor expression of DUSP6/MKP-3 is associated with recurrence after curative resection of hepatocellular carcinoma.
Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1? in cervical malignancy.
Human T cells depend on functional calcineurin, tumour necrosis factor-? and CD80/CD86 for expansion and activation in mice.
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.
Hypoxia promotes pancreatic cancer cell migration, invasion, and epithelial-mesenchymal transition via modulating the FOXO3a/DUSP6/ERK axis.
iASPP is important for bladder cancer cell proliferation.
Ibuprofen-induced Walker 256 tumor cell death: cytochrome c release from functional mitochondria and enhancement by calcineurin inhibition.
Identification and characterization of a radiation-inducible glycosylated human early-response gene.
Identification by differential display of a protein phosphatase-2A regulatory subunit preferentially expressed in malignant melanoma cells.
Identification of an AP1-ZFP36 Regulatory Network Associated with Breast Cancer Prognosis.
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Identification of differentially expressed genes after PPM1D silencing in breast cancer.
Identification of key processes underlying cancer phenotypes using biologic pathway analysis.
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.
Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma.
Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Immunostaining for calcineurin, a Ca2+/calmodulin-regulated protein phosphatase, in the diagnostic tumor pathology.
Immunosuppressive agents for treating IgA nephropathy.
Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
Inactivation of a redox-sensitive protein phosphatase during the early events of tumor necrosis factor/interleukin-1 signal transduction.
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation.
Incidence of non-skin de novo post-transplant malignancy in kidney transplant recipients maintained on calcineurin inhibitor (cin)/sirolimus (srl) is lower compared to cin/mycophenolate mofetil (mmf) therapy.
Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors.
Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis.
Increased Calcineurin A Expression Is Associated with a Lower Relapse-Free Survival Rate after Colorectal Cancer Surgery.
Increased expression of calcineurin in human colorectal adenocarcinomas.
Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo.
Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant to cis-diamminedichloroplatinum (II).
Indications and effectiveness of the mammalian target of rapamycin in liver transplantation.
Indications and management of everolimus after liver transplantation.
Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage.
Induction of differentiation and c-jun expression in human leukemic cells by okadaic acid, an inhibitor of protein phosphatases.
Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites.
Induction of Suicidal Erythrocyte Death by Cantharidin.
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Influence of dual-specificity protein phosphatase 5 on mechanical properties of rat cerebral and renal arterioles.
Infrequent methylation of the DUSP6 phosphatase in endometrial cancer.
Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Inhibition of calcineurin by cyclosporine A exerts multiple effects on human melanoma cell lines HT168 and WM35.
Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor.
Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Inhibition of protein phosphatase PPM1D enhances retinoic acid-induced differentiation in human embryonic carcinoma cell line.
Inhibition of protein phosphatases by microcystins and nodularin associated with hepatotoxicity.
Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.
Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
Inhibition of Wild-type p53-induced phosphatase 1 promotes liver regeneration in mice by direct activation of mTOR.
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Inhibitory role for calcineurin in stimulus-secretion coupling revealed by FK506 and cyclosporin A in pituitary corticotrope tumor cells.
INPP4B: the new kid on the PI3K block.
Inside out: targeting NHE1 as an intracellular and extracellular regulator of cancer progression.
Insulin resistance induced by a high-fat diet is associated with the induction of genes related to leukocyte activation in rat peripheral leukocytes.
Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors.
Investigation of POPX2 phosphatase functions by comparative phosphoproteomic analysis.
Investigation of two Wnt signalling pathway single nucleotide polymorphisms in a breast cancer-affected Australian population.
Involvement of Akt1/protein kinase Balpha in tumor conditioned medium-induced endothelial cell migration and survival in vitro.
Involvement of SET in the Wnt signaling pathway and the development of human colorectal cancer.
Is protein phosphatase inhibition responsible for the toxic effects of okadaic Acid in animals?
Is there such a thing as protocol immunosuppression in liver transplantation?
Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
Keratinocyte growth factor induces gene expression signature associated with suppression of malignant phenotype of cutaneous squamous carcinoma cells.
KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity.
Knockdown of PPP5C inhibits growth of hepatocellular carcinoma cells in vitro.
Knockdown of Protein Phosphatase Magnesium-dependent 1 (PPM1D) through Lentivirus-mediated RNA Silencing Inhibits Colorectal Carcinoma Cell Proliferation.
Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro.
KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer.
Laforin confers cancer resistance to energy deprivation-induced apoptosis.
Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms.
Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia.
Liquid chromatography-linked protein phosphatase bioassay; a highly sensitive marine bioscreen for okadaic acid and related diarrhetic shellfish toxins.
Liver transplantation and liver cell transplantation.
Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis.
Liver tumor promotion by the cyanobacterial cyclic peptide toxin microcystin-LR.
Localized Rho GTPase activation regulates RNA dynamics and compartmentalization in tumor cell protrusions.
Localizing PRL-2 expression and determining the effects of dietary Mg(2+) on expression levels.
Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1.
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy.
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Long-term safety of tacrolimus ointment in atopic dermatitis.
Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells invasiveness.
Loss of phosphatase activity in PTEN (phosphatase and tensin homolog deleted on chromosome ten) results in endometrial carcinoma in humans: An in-silico study.
Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer.
Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D -driven tumor promotion.
Loss of protein phosphatase 6 in mouse keratinocytes increases susceptibility to ultraviolet-B-induced carcinogenesis.
Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.
Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors.
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms.
Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial.
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Malignancies in 2,753 kidney recipients transplanted during a 39-year experience.
Malignancy after transplantation.
Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Malignancy in kidney transplant recipients.
Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers.
Mechanisms of action of okadaic acid class tumor promoters on mouse skin.
Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A.
Membrane protein CNNM4-dependent Mg2+ efflux suppresses tumor progression.
Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion.
Metastatic Phosphatase PRL-3 Induces Ovarian Cancer Stem Cell Sub-population through Phosphatase-Independent Deacetylation Modulations.
Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen.
MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6.
MicroRNA-16 sensitizes drug-resistant breast cancer cells to Adriamycin by targeting Wip1 and Bcl-2.
MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.
MicroRNA-205-5p is upregulated in myelodysplastic syndromes and induces cell proliferation via PTEN suppression.
MicroRNA-21 Orchestrates High Glucose-induced Signals to TOR Complex 1, Resulting in Renal Cell Pathology in Diabetes.
MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
microRNA-95 knockdown inhibits epithelial-mesenchymal transition and cancer stem cell phenotype in gastric cancer cells through MAPK pathway by upregulating DUSP5.
Minimizing the risk of posttransplant malignancy.
mir-182-5p Regulates Cell Growth of Liver Cancer via Targeting RCAN1.
MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1.
miR-938 promotes colorectal cancer cell proliferation via targeting tumor suppressor PHLPP2.
miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation.
miR?338?3p mediates gluconeogenesis via targeting of PP4R1 in hepatocytes.
Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.
Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells.
Mitogen-activated protein kinase signal transduction in solid tumors.
Mitophagy in degenerative joint diseases.
Mitotic arrest and enhanced nuclear protein phosphorylation in human leukemia K562 cells by okadaic acid, a potent protein phosphatase inhibitor and tumor promoter.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Modulation of protein phosphatase 2A (PP2A) activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
Modulation of ROS/MAPK signaling pathways by okadaic acid leads to cell death via, mitochondrial mediated caspase-dependent mechanism.
Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment.
Modulation of VEGF receptor 2 signaling by protein phosphatases.
Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells.
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.
Molecular cloning of cDNA for the catalytic subunit of rat liver type 2A protein phosphatase, and detection of high levels of expression of the gene in normal and cancer cells.
Molecular cloning of rat phosphoprotein phosphatase 2A beta cDNA and increased expressions of phosphatase 2A alpha and 2A beta in rat liver tumors.
Molecular mechanisms of pancreatic carcinogenesis.
Mouse 4T1 Breast Cancer Cell-Derived Exosomes Induce Proinflammatory Cytokine Production in Macrophages via miR-183.
mTOR Inhibition and Kidney Diseases.
mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
mTOR inhibitors for hepatocellular cancer: a forward-moving target.
mTOR inhibitors in pediatric liver transplant recipients.
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model.
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.
Mutational Analysis of a Conserved Glutamate Reveals Unique Mechanistic and Structural Features of the Phosphatase PRL-3.
Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary.
Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients.
N'-[(E)-Arylidene]-2-(2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)-acetohydrazides: Synthesis and Evaluation of Caspase Activation Activity and Cytotoxicity.
NDR family of AGC kinases--essential regulators of the cell cycle and morphogenesis.
Neuroimaging and neurologic complications after organ transplantation.
Neurologic Toxicities Associated with Tumor Necrosis Factor Inhibitors and Calcineurin Inhibitors.
Neurotensin Signaling Activates MicroRNAs -21 and -155 and Akt, Promotes Tumor Growth in Mice, and is Increased in Human Colon Tumors.
New Acetohydrazides Incorporating 2-Oxoindoline and 4-Oxoquinazoline: Synthesis and Evaluation of Cytotoxicity and Caspase Activation Activity.
New concepts and best practices for management of pre- and post-transplantation cancer.
NF-kappa B activation in tumor necrosis factor alpha-stimulated neutrophils is mediated by protein kinase Cdelta. Correlation to nuclear Ikappa Balpha.
Niacin deficiency modulates genes involved in cancer: Are smokers at higher risk?
Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation.
Non-canonical function of nuclear PTEN and its implication on tumorigenesis.
Novel Anticancer Agents Based on Targeting the Trimer Interface of the PRL Phosphatase.
Novel approaches for chemosensitization of breast cancer cells: the E1A story.
Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases.
Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer.
Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation.
Nuclear accumulation of Calcineurin B Homologous Protein 2 (CHP2) results in enhanced proliferation of tumor cells.
Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase.
Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death.
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Obg-like ATPase 1 regulates global protein serine/threonine phosphorylation in cancer cells by suppressing the GSK3?-inhibitor 2-PP1 positive feedback loop.
Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs).
Okadaic acid biologically mimics the role of calcium/phospholipid dependent kinase inhibitors in the process of HL-60 cell differentiation.
Okadaic acid identifies a phosphorylation/dephosphorylation cycle controlling the inhibitory guanine-nucleotide-binding regulatory protein Gi2.
Okadaic acid inhibits PDGF-induced proliferation and decreases PDGF receptor number in C3H/10T1/2 mouse fibroblasts.
Okadaic acid mediates p53 hyperphosphorylation and growth arrest in cells with wild-type p53 but increases aberrant mitoses in cells with non-functional p53.
Okadaic acid stimulated TRE binding activity in a papilloma producing mouse keratinocyte cell line involves increased AP-1 expression.
Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.
Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).
Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation.
Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.
Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway.
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.
Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer.
Overexpression of wip1 is associated with biologic behavior in human clear cell renal cell carcinoma.
p21 expression is induced by activation of nuclear nerve growth factor-induced Balpha (Nur77) in pancreatic cancer cells.
p53 protein-mediated up-regulation of MAP kinase phosphatase 3 (MKP-3) contributes to the establishment of the cellular senescent phenotype through dephosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2).
p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.
PAC-1 and its derivative WF-210 Inhibit Angiogenesis by inhibiting VEGF/VEGFR pathway.
Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1).
Partners in crime: POPX2 phosphatase and its interacting proteins in cancer.
PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase.
Pentosan polysulfate, a potent anti HIV and anti tumor agent, inhibits protein serine/threonine and tyrosine kinases.
PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
PHLPP regulates hexokinase 2-dependent glucose metabolism in colon cancer cells.
PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2.
PHLPP2 as a novel metastatic and prognostic biomarker in non-small cell lung cancer patients.
PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein.
PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.
PHLPPing the balance: restoration of protein kinase C in cancer.
Phosphatase and Tensin Homolog in Non-neoplastic Digestive Disease: More Than Just Tumor Suppressor.
Phosphatase assay for multi-phosphorylated substrates using phosphatase specific-motif antibody.
Phosphatase of regenerating liver maintains cellular magnesium homeostasis.
Phosphatase of regenerating liver sensitizes MET to functional activation by hepatocyte growth factor.
Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells.
Phosphatase of regenerating liver: a novel target for cancer therapy.
Phosphatase POPX2 Exhibits Dual Regulatory Functions in Cancer Metastasis.
Phosphatase POPX2 interferes with cell cycle by interacting with Chk1.
Phosphatase Wip1 Masters IL-17-producing Neutrophil-mediated Colitis in Mice.
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.
Phosphoproteome and drug response effects mediated by the three Protein Phosphatase 2A inhibitor proteins CIP2A, SET and PME-1.
Photoaffinity labeling of protein phosphatase 2A, the receptor for a tumor promoter okadaic acid, by [27-3H]methyl 7-O-(4-azidobenzoyl)okadaate.
Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.
Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
POPX2 phosphatase regulates apoptosis through the TAK1-IKK-NF-?B pathway.
Possible involvement of protein phosphatase type 2A in tumor necrosis factor alpha-induced tissue factor expression in endothelial cells.
Post-transcriptional modulation of protein phosphatase PPP2CA and tumor suppressor PTEN by endogenous siRNA cleaved from hairpin within PTEN mRNA 3'UTR in human liver cells.
Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia.
Post-transplant de novo malignancies in renal transplant recipients: the past and present.
Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.
Post-Traumatic Brain Injury: Genetic Susceptibility to Outcome.
Posttransplant Kaposi's sarcoma: report from a single center.
Potential biomarkers of HCC based on gene expression and DNA methylation profiles.
Potential small-molecule activators of caspase-7 identified using yeast-based caspase-3 and -7 screening assays.
Potential targets identified in adenoid cystic carcinoma point out new directions for further research.
Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer.
PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKK? and sustained activation of the NF-?B pathway.
PP2A-B55? Antagonizes Cyclin E1 Proteolysis and Promotes Its Dysregulation in Cancer.
PP2A-dependent disruption of centrosome replication and cytoskeleton organization in Drosophila by SV40 small tumor antigen.
PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer.
PP2A: unveiling a reluctant tumor suppressor.
PP2AC? of Alveolar Macrophages Is a Novel Protective Factor for LPS-Induced Acute Respiratory Distress Syndrome.
PP2C? inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.
PP4C facilitates lung cancer proliferation and inhibits apoptosis via activating MAPK/ERK pathway.
PP4R1 interacts with HMGA2 to promote non-small-cell lung cancer migration and metastasis via activating MAPK/ERK-induced epithelial-mesenchymal transition.
PP4R4/KIAA1622 Forms a Novel Stable Cytosolic Complex with Phosphoprotein Phosphatase 4.
PP6 Disruption Synergizes with Oncogenic Ras to Promote JNK-Dependent Tumor Growth and Invasion.
PPM1A is a RelA phosphatase with tumor suppressor-like activity.
PPM1D accelerates proliferation and metastasis of osteosarcoma by activating PKP2.
PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
PPM1D controls nucleolar formation by up-regulating phosphorylation of nucleophosmin.
PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.
PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
PPM1D is a potential target for 17q gain in neuroblastoma.
PPM1D is a prognostic marker and therapeutic target in colorectal cancer.
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells.
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.
PPM1H is a p27 phosphatase implicated in trastuzumab resistance.
PPM1H is an independent prognostic biomarker of non-small cell lung cancer.
PPP1CA contributes to the senescence program induced by oncogenic Ras.
PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
PPP2R2C loss promotes castration-resistant prostate cancer growth and is associated with increased prostate cancer-specific mortality.
PPP2R5A: A multirole protein phosphatase subunit in regulating cancer development.
PPP3CB contributes to poor prognosis through activating nuclear factor of activated T-cells signaling in neuroblastoma.
Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
Premature chromosome condensation revisited: a novel chemical approach permits efficient cytogenetic analysis of cancers.
PRL phosphatases as potential molecular targets in cancer.
PRL-3 activates NF-?B signaling pathway by interacting with RAP1.
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
PRL-3 induces a positive signaling circuit between glycolysis and activation of STAT1/2.
PRL-3 Mediates the Protein Maturation of ULBP2 by Regulating the Tyrosine Phosphorylation of HSP60.
PRL-3 phosphatase and cancer metastasis.
PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.
Pro-necrotic molecules impact local immunosurveillance in human breast cancer.
Pro?apoptotic effects of pycnogenol on HT1080 human fibrosarcoma cells.
Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.
Procaspase-activating compound 1 induces a caspase-3-dependent cell death in cerebellar granule neurons.
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
Production of DUSP1 protein using the baculovirus insect cell expression system and its in vitro effects on cancer cells.
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Prognostic value of PPM1D in 800 gastric cancer patients.
Prognostic value of PRL-3 overexpression in early stages of colonic cancer.
Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.
Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.
Proliferation signal inhibitors in cardiac transplantation.
Proliferation signal inhibitors in heart transplantation: a 5-year experience.
Protein expression profiles in hematopoietic stem/progenitor cells after exposure of mice to silicon (28Si) ions.
Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis.
Protein phosphatase 1alpha activity prevents oncogenic transformation.
Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.
Protein phosphatase 2 regulatory subunit B''Alpha silencing inhibits tumor cell proliferation in liver cancer.
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Protein Phosphatase 2A as a Potential Target for Anticancer Therapy.
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53.
Protein phosphatase 2A promotes the transition to G0 during terminal differentiation in Drosophila.
Protein phosphatase 4 (PP4) functions as a critical regulator in tumor necrosis factor (TNF)-?-induced hepatic insulin resistance.
Protein phosphatase 4 catalytic subunit is overexpressed in glioma and promotes glioma cell proliferation and invasion.
Protein phosphatase 4 catalytic subunit regulates Cdk1 activity and microtubule organization via NDEL1 dephosphorylation.
Protein phosphatase 4 interacts with and down-regulates insulin receptor substrate 4 following tumor necrosis factor-alpha stimulation.
Protein phosphatase 4 is involved in tumor necrosis factor-alpha-induced activation of c-Jun N-terminal kinase.
Protein phosphatase 5 and the tumor suppressor P53 down-regulate each other's activities in mice.
Protein phosphatase 6 subunit with conserved Sit4-associated protein domain targets IkappaBepsilon.
Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.
Protein Phosphatase Magnesium-Dependent 1? (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors.
Protein phosphatase magnesium-dependent 1? (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma.
Protein phosphatase magnesium-dependent 1? is a novel tumor marker and target in hepatocellular carcinoma.
Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer.
Protein phosphatase Mg2+/Mn2+ dependent 1F promotes smoking-induced breast cancer by inactivating phosphorylated-p53-induced signals.
Protein phosphatase PP4 is overexpressed in human breast and lung tumors.
Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks.
Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells.
Protein phosphatase type 1-dependent dephosphorylation of the retinoblastoma tumor suppressor protein in ultraviolet-irradiated human skin and keratinocytes.
Protein phosphatase, Mg2+/Mn2+-dependent 1D (PPM1D) mutations in haematological cancer.
Protein phosphatase-2A association with microtubules and its role in restricting the invasiveness of human head and neck squamous cell carcinoma cells.
Protein phosphatase-2A modulates the serine and tyrosine phosphorylation of paxillin in Lewis lung carcinoma tumor variants.
Protein phosphatase-2A regulates endothelial cell motility and both the phosphorylation and the stability of focal adhesion complexes.
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Protein phosphatase-2A restricts migration of Lewis lung carcinoma cells by modulating the phosphorylation of focal adhesion proteins.
Protein phosphatases and DNA tumor viruses: transformation through the back door?
Protein serine/threonine phosphatases: life, death, and sleeping.
Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells.
Proteomics analysis of in vitro protein methylation during Src-induced transformation.
Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma.
PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.
PTEN Inhibition in Human Disease Therapy.
PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis.
PTEN Mouse Models of Cancer Initiation and Progression.
PTEN Protein Phosphatase Activity Correlates with Control of Gene Expression and Invasion, a Tumor-Suppressing Phenotype, But Not with AKT Activity.
PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility.
PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma.
PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation.
Purification and characterization of butyrate-induced protein phosphatase involved in apoptosis of Ehrlich ascites tumor cells.
Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters.
Quantitative and dynamic analysis of PTEN phosphorylation by NMR.
Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma.
Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer.
RCAN1 in the inverse association between Alzheimer's disease and cancer.
RCAN1-4 is a thyroid cancer growth and metastasis suppressor.
RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
Recent Patents and Advances in Genomic Biomarker Discovery for Colorectal Cancers.
Reciprocal REG?-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.
Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
Redox modulation of protein kinase/phosphatase balance in melanoma cells: the role of endogenous and gamma-glutamyltransferase-dependent H2O2 production.
Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.
Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling.
Reduction-Sensitive Fluorinated-Pt(IV) Universal Transfection Nanoplatform Facilitating CT45-Targeted CRISPR/dCas9 Activation for Synergistic and Individualized Treatment of Ovarian Cancer.
Regulation of mammalian ribonucleotide reductase by the tumor promoters and protein phosphatase inhibitors okadaic acid and calyculin A.
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.
Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition.
Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology.
Regulation of tumor necrosis factor cytotoxicity by calcineurin.
Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells.
Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Regulator of Calcineurin 1 Gene Transcription is Regulated by Nuclear Factor-kappaB.
Regulator of calcineurin 1 modulates cancer cell migration in vitro.
Regulatory mechanisms of phosphatase of regenerating liver (PRL)-3.
Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.
Renal cancer in kidney transplanted patients.
Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?
Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway.
Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.
Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation.
RIF1 promotes tumor growth and cancer stem cell-like traits in NSCLC by protein phosphatase 1-mediated activation of Wnt/?-catenin signaling.
RNA expression profiling of normal and tumor cells following photodynamic therapy with 5-aminolevulinic acid-induced protoporphyrin IX in vitro.
Role of AKT and ERK pathways in controlling sensitivity to ionizing radiation and adaptive response induced by low-dose radiation in human immune cells.
Role of cantharidin in the activation of IKK?/I?B?/NF??B pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines.
Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy.
Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer.
Role of Gadd45a in Wip1-dependent regulation of intestinal tumorigenesis.
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients.
Role of PHLPP1 in inflammation response: Its loss contributes to gliomas development and progression.
Role of PP2C-alpha in cell growth, in radio- and chemosensitivity, and in tumorigenicity.
Role of protein phosphatase in malignant osteogenic and soft tissue tumors.
Role of protein phosphatases in genitourinary cancers.
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants.
Role of serine/threonine protein phosphatase 2A in cancer.
Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling.
Role of wild-type p53-induced phosphatase 1 in cancer.
Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Saliva as a tool for oral cancer diagnosis and prognosis.
Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis.
Scribble-mediated membrane targeting of PHLPP1 is required for its negative regulation of Akt.
Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis.
Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
Serendipitous discovery of light-induced (In Situ) formation of an Azo-bridged dimeric sulfonated naphthol as a potent PTP1B inhibitor.
Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A.
Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Serine/Threonine Protein Phosphatase-5 Accelerates Cell Growth and Migration in Human Glioma.
SET levels contribute to cohesion fatigue.
Severe everolimus-associated pneumonitis in a renal transplant recipient.
SEVERE HYPERTRIGLYCERIDEMIA ASSOCIATED WITH EVEROLIMUS TREATMENT AFTER HEART TRANSPLANTATION.
Sevoflurane inhibits the proliferation and invasion of hepatocellular carcinoma cells through regulating the PTEN/Akt/GSK?3?/??catenin signaling pathway by downregulating miR?25?3p.
Signal transducer and activator of transcription 3 (STAT3) degradation by proteasome controls a developmental switch in neurotrophin dependence.
SIGNIFICANTLY LOWER MALIGNANCY RATES IN RENAL TRANSPLANT RECIPIENTS CONVERTED FROM CALCINEURIN INHIBITORS (CNIs) TO SIROLIMUS (SRL) COMPARED WITH THOSE WHO CONTINUED CNI THERAPY.
Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Simian virus 40 small t antigen cooperates with mitogen-activated kinases to stimulate AP-1 activity.
Simian virus 40 small tumor antigen induces deregulation of the actin cytoskeleton and tight junctions in kidney epithelial cells.
Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma.
Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation.
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
Sirolimus therapy in liver transplant patients: an initial experience at a single center.
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.
Skeletal muscle cell hypertrophy induced by inhibitors of metalloproteases; myostatin as a potential mediator.
Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair.
Skin conditions: new drugs for managing skin disorders.
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice.
SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.
Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.
Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics.
Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.
STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation.
Steroids versus other immune modulators in the management of allergic dermatoses.
Stimulation of Suicidal Erythrocyte Death by Phosphatase Inhibitor Calyculin A.
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.
STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells.
Structure and function of the co-chaperone protein phosphatase 5 in cancer.
Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins.
Structure-activity relationship within a series of okadaic acid derivatives.
Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis(3'-indoly)-1-(p-substituted phenyl)methanes.
Structure-function relationships of microcystins, liver tumor promoters, in interaction with protein phosphatase.
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.
Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299.
Synthesis and Biological Evaluation of Novel 4-(2-Fluorophenoxy)-2-(1H-tetrazol-1-yl)pyridines Bearing Semicarbazone Moieties as Potent Antitumor Agents.
Synthesis of Dual Target CPT-Ala-Nor Conjugates and Their Biological Activity Evaluation.
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.
Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors.
Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.
Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship.
Tacrolimus ointment: a new therapy for atopic dermatitis--review of the literature.
Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials.
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.
Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.
Targeting Angiogenesis in Prostate Cancer.
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis.
Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents.
Targeting PTPs with small molecule inhibitors in cancer treatment.
Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines.
Tescalcin/c-Src/IGF1R?-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1.
The "black box" warning and allergy drugs.
The 17q23 amplicon and breast cancer.
The 1p36 Tumor Suppressor KIF 1B? Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis.
The 3D structure of protein phosphatase 2A: new insights into a ubiquitous regulator of cell signaling.
The ARE-binding protein Tristetraprolin (TTP) is a novel target and mediator of calcineurin tumor suppressing function in the skin.
The calcineurin B subunit induces TNF-related apoptosis-inducing ligand (TRAIL) expression via CD11b-NF-?B pathway in RAW264.7 macrophages.
The Calcineurin-NFAT-Angiopoietin-2 Signaling Axis in Lung Endothelium Is Critical for the Establishment of Lung Metastases.
The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice.
The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report.
The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
The Clinical Significance of PPEF1 as a Promising Biomarker and Its Potential Mechanism in Breast Cancer.
The critical role of calcineurin/NFAT (C/N) pathways and effective antitumor prospect for colorectal cancers.
The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer.
The Dual-Specificity Phosphatase 10 (DUSP10): Its Role in Cancer, Inflammation, and Immunity.
The DUSP26 phosphatase activator adenylate kinase 2 regulates FADD phosphorylation and cell growth.
The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma.
The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients.
The effect of decitabine on the expression and methylation of the PPP1CA, BTG2, and PTEN in association with changes in miR-125b, miR-17, and miR-181b in NALM6 cell line.
The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection.
The effect of RCAN1 on the biological behaviors of small cell lung cancer.
The expression and clinical prognostic value of protein phosphatase 1 catalytic subunit beta in pancreatic cancer.
The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
The functions of tumor suppressor PTEN in innate and adaptive immunity.
The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells.
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.
The immunosuppressed traveler.
The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.
The Interplay between PP2A and microRNAs in Leukemia.
The intrinsically disordered tails of PTEN and PTEN-L have distinct roles in regulating substrate specificity and membrane activity.
The ISG15-specific protease USP18 regulates stability of PTEN.
The mechanism of action of the tumour suppressor gene PTEN.
The membrane immunoglobulin receptor utilizes a Shc/Grb2/hSOS complex for activation of the mitogen-activated protein kinase cascade in a B-cell line.
The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies.
The Metastasis-Promoting Phosphatase PRL-3 Shows Activity toward Phosphoinositides.
The multiple functions of protein phosphatase 6.
The natural anticancer agent cantharidin alters GPI-anchored protein sorting by targeting Cdc1-mediated remodeling in endoplasmic reticulum.
The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways.
The Oncogenic PRL Protein Causes Acid Addiction of Cells by Stimulating Lysosomal Exocytosis.
The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.
The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.
The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression.
The pleiotropic effects of mTor inhibitors.
The POPX2 phosphatase regulates cancer cell motility and invasiveness.
The PP4R1 sub-unit of protein phosphatase PP4 is essential for inhibition of NF-?B by merkel polyomavirus small tumour antigen.
The ratio of thioredoxin/Keap1 protein level is a predictor of distant metastasis in colorectal cancer.
The Regulation of Trophoblastic p53 Homeostasis by the p38-Wip1 Feedback Loop is Disturbed in Placentas from Pregnancies Complicated by Preeclampsia.
The retinoid anticancer signal: mechanisms of target gene regulation.
The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells.
The role of basiliximab in the evolving renal transplantation immunosuppression protocol.
The role of PPM1D in cancer and advances in studies of its inhibitors.
The role of proliferation signal inhibitors in post-transplant malignancies.
The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer.
The role of SET/I2PP2A in canine mammary tumors.
The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer.
The synergistic interaction between the calcineurin B subunit and IFN-? enhances macrophage antitumor activity.
The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
The unintended effects of a boxed warning.
Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
Tissue-specific gene therapy directed to tumor angiogenesis.
Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis.
Topical calcineurin inhibitors in eczema and cancer association: A cohort study.
Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.
Topical Calcineurin Inhibitors, Topical Glucocorticoids and Cancer in Children: A Nationwide Study.
Toxicity and uptake mechanism of cylindrospermopsin and lophyrotomin in primary rat hepatocytes.
Transcription factor C/EBP-? induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells.
Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells.
Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase.
Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options.
Treatment of young patients with lupus nephritis using calcineurin inhibitors.
Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry.
TRPV6 calcium channel regulation, downstream pathways, and therapeutic targeting in cancer.
Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma.
Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers.
Tumor necrosis factor-alpha activation of nuclear transcription factor-kappaB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of Ikappa Balpha.
Tumor necrosis factor-alpha, a new tumor promoter, engendered by biochemical studies of okadaic acid.
Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis.
Tumor Tolerance-Promoting Function of Regulatory T Cells Is Optimized by CD28, but Strictly Dependent on Calcineurin.
Tumor-specific mutation and down-regulation of ING5 detected in oral squamous cell carcinoma.
Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma.
Turning off AKT: PHLPP as a drug target.
Two cases of colon LST in transplanted liver patients.
Type-2A protein phosphatase activity is required to maintain death receptor responsiveness.
Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression.
Understanding PTEN regulation: PIP2, polarity and protein stability.
Unique features of the okadaic acid activity class of tumor promoters.
Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.
Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases.
Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.
Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway.
Validation of Reference Genes for Oral Cancer Detection Panels in a Prospective Blinded Cohort.
VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C.
Violacein cytotoxicity on human blood lymphocytes and effect on phosphatases.
Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A.
Weighted correlation network and differential expression analyses identify candidate genes associated with BRAF gene in melanoma.
Wild-type p53-induced phosphatase 1 (WIP1) regulates the proliferation of swine Sertoli cells through P53.
Wild-type p53-induced Phosphatase 1 Deficiency Exacerbates Myocardial Infarction-induced Ischemic Injury.
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma.
Wip1 cooperates with KPNA2 to modulate the cell proliferation and migration of colorectal cancer via a p53-dependent manner.
Wip1 deficiency impairs haematopoietic stem cell function via p53 and mTORC1 pathways.
Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response.
WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma.
WIP1 phosphatase at the crossroads of cancer and aging.
Wip1 phosphatase in breast cancer.
Wip1 phosphatase modulates ATM-dependent signaling pathways.
WIP1 regulates the proliferation and invasion of nasopharyngeal carcinoma in vitro.
Wip1: A candidate phosphatase for cancer diagnosis and treatment.
X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis.
[Calcineurin contributed to tumor necrosis factor alpha-induced cardiomyocyte hypertrophy in rats].
[Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs]
[Central neurocytomas of the lateral ventricle. A series of 35 cases with review of the literature].
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
[Function of Proto-oncogene Product PPM1D and Development of PPM1D Inhibitors for Cancer Chemotherapy].
[Influence of calcineurin on apoptosis of pre-B lymphocytes and the leukemia cells derived from pre-B lymphocytes].
[Minimizing the risk of cancer in transplant patients.]
[Research progress of suppressor gene PTEN].
[The mechanism and current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation].
Neoplasms, Germ Cell and Embryonal
A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours.
MKP-8, a novel MAPK phosphatase that inhibits p38 kinase.
Neoplastic Cells, Circulating
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Nephritis
Con: The use of calcineurin inhibitors in the treatment of lupus nephritis.
mRNAs in urinary nano-extracellular vesicles as potential biomarkers for non-invasive kidney biopsy.
Polyomavirus in kidney and kidney-pancreas transplant recipients.
Nephritis, Interstitial
Investigating the threshold for early renal allograft biopsy: A South African single-centre perspective.
Nephrocalcinosis
A rare case of nephrocalcinosis in the distal tubules caused by hereditary renal hypouricemia three months after kidney transplantation.
Direct evidence for calcineurin binding to the exon-7 loop of the sodium-bicarbonate cotransporter NBCn1.
Nephrolithiasis
Direct evidence for calcineurin binding to the exon-7 loop of the sodium-bicarbonate cotransporter NBCn1.
Synthesis, Maturation, and Trafficking of Human Na+-Dicarboxylate Cotransporter NaDC1 Requires the Chaperone Activity of Cyclophilin B.
Nephrosclerosis
Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient.
[Deceased Donor Kidney Transplantation from a Liver Transplantation Recipient].
Nephrosis
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with antineutrophil cytoplasmic antibody-associated vasculitis and nephrosis.
Collecting duct (Na+/K+)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes.
Nephrosis, Lipoid
Different targets for treating focal segmental glomerular sclerosis.
miR-499 Ameliorates Podocyte Injury by Targeting Calcineurin in Minimal Change Disease.
Persistent CD-19 Depletion by Rituximab is Cost-effective in Maintaining Remission in Calcineurin-inhibitor Dependent Podocytopathy.
Renal Complications of Hematopoietic Stem Cell Transplantation: Report of a Case and Review of the Literature.
Nephrotic Syndrome
A case report of immunoglobulin M nephropathy manifesting as crescentic glomerulonephritis and nephrotic syndrome in an adult.
A comparative study on renal biopsy before and after long-term calcineurin inhibitors therapy: an insight for pathogenesis of its toxicity.
A new 'tac' for childhood nephrotic syndrome.
Annexin V in children with idiopathic nephrotic syndrome treated with cyclosporine A.
Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
Antifibrotic actions of mycophenolic acid.
Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome.
Calcineurin inhibitors and nephrotoxicity in children.
Calcineurin inhibitors and renal biopsy in children with idiopathic nephrotic syndrome.
Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review.
CD44-Positive Glomerular Parietal Epithelial Cells in a Mouse Model of Calcineurin Inhibitors-Induced Nephrotoxicity.
Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.
Collecting duct (Na+/K+)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes.
Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome.
Cyclosporine in the treatment of childhood idiopathic steroid resistant nephrotic syndrome: a single centre experience in Nigeria.
Different targets for treating focal segmental glomerular sclerosis.
Early Use of Rituximab in Calcineurin Inhibitor-Refractory and Steroid-Resistant Nephrotic Syndrome.
Efficacy and Safety of Cyclosporine versus Tacrolimus in Steroid and Cyclophosphamide Resistant Nephrotic Syndrome: A Prospective Study.
Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome.
Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.
Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
Familial forms of nephrotic syndrome.
Glucose metabolism disorders in children with refractory nephrotic syndrome.
Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Infrequent tacrolimus-induced nephrotoxicity in French patients with steroid-dependent nephrotic syndrome.
Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
Long-Term Outcomes in Children with Steroid-Resistant Nephrotic Syndrome Treated with Calcineurin Inhibitors.
Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy.
Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
Nephrotic syndrome.
New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.
Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.
Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome.
Posterior Reversible Encephalopathy Syndrome in Henoch-Schonlein Purpura and Hemolytic Uremic Syndrome.
Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Remission of proteinuria in multidrug resistant idiopathic nephrotic syndrome following immunoglobulin immunoadsorption.
Renal Biopsy in Children-Effect on Treatment Decisions: A Single-Center Experience.
Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.
Rituximab efficiency in children with steroid-dependent nephrotic syndrome.
Rituximab in children with resistant idiopathic nephrotic syndrome.
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome.
Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?
Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome.
Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
Steroid-resistant nephrotic syndrome associated with steroid sulfatase deficiency-x-linked recessive ichthyosis: a case report and review of literature.
Successful treatment of recurrent focal segmental glomerulosclerosis combined with calcineurin inhibitor nephrotoxicity four yr after kidney transplantation.
The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective.
The prevalence and clinicopathological profile of IgM nephropathy in children with steroid-resistant nephrotic syndrome at a single centre in Pakistan.
Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors.
Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.
Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome.
Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing.
[Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Nervous System Diseases
A Friend or Foe: Calcineurin across the Gamut of Neurological Disorders.
Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy.
Fecal corticosterone levels in RCAN1 mutant mice.
Regulation of Synaptic Transmission and Plasticity by Protein Phosphatase 1.
[Expression of protein phosphatase 2AC in the brain of mice and Alzheimer's patients].
Neuralgia
Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation.
Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states.
Changes in calcineurin message, enzyme activity and protein content in the spinal dorsal horn are associated with chronic constriction injury of the rat sciatic nerve.
DUSP1 Promotes Microglial Polarization toward M2 Phenotype in the Medial Prefrontal Cortex of Neuropathic Pain Rats via Inhibition of MAPK Pathway.
Identification of Key Pathways and Genes in L4 Dorsal Root Ganglion (DRG) After Sciatic Nerve Injury via Microarray Analysis.
Loss of calcineurin in the spinal dorsal horn contributes to neuropathic pain, and intrathecal administration of the phosphatase provides prolonged analgesia.
miR-32-5p-mediated Dusp5 downregulation contributes to neuropathic pain.
Nerve Injury Increases GluA2-lacking AMPA Receptor Prevalence in Spinal Cords: Functional Significance and Signaling Mechanisms.
Protein kinase C gamma-mediated phosphorylation of GluA1 in the postsynaptic density of spinal dorsal horn neurons accompanies neuropathic pain, and dephosphorylation by calcineurin is associated with prolonged analgesia.
Ulinastatin attenuates neuropathic pain induced by L5-VRT via the calcineurin/IL-10 pathway.
Neurilemmoma
Modulation of cell rounding and apoptosis in trigeminal neurinoma cells by protein phosphatase inhibitors.
Neuroblastoma
?-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.
A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration.
A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes.
A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
Calcineurin dephosphorylates glycogen synthase kinase-3 beta at serine-9 in neuroblast-derived cells.
Calcineurin involvement in the regulation of high-threshold Ca2+ channels in NG108-15 (rodent neuroblastoma x glioma hybrid) cells.
Calpastatin overexpression reduces oxidative stress-induced mitochondrial impairment and cell death in human neuroblastoma SH-SY5Y cells by decreasing calpain and calcineurin activation, induction of mitochondrial fission and destruction of mitochondrial fusion.
Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells.
Cyclic AMP induces activity increase of kinase FA (a transmembrane signal of insulin) during NG108-15 hybrid cell differentiation.
Differential susceptibilities of serine/threonine phosphatases to oxidative and nitrosative stress.
Dimethyl Fumarate Exerts Neuroprotection by Modulating Calcineurin/NFAT1 and NF?B Dependent BACE1 Activity in a Neuronal Model of Alzheimer's Disease.
Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling.
Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
DUSP5 expression associates with poor prognosis in human neuroblastoma.
Effect of let-7c on the PI3K/Akt/FoxO signaling pathway in hepatocellular carcinoma.
Evidence of okadaic acid production in a cultured strain of the marine dinoflagellate Prorocentrum rhathymum from Malaysia.
Expression of calmodulin-dependent phosphodiesterase, calmodulin-dependent protein phosphatase, and other calmodulin-binding proteins in human SMS-KCNR neuroblastoma cells.
Heterocyclic thioureylenes protect from calcium-dependent neuronal cell death.
Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species.
Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells.
Increased production of paired helical filament epitopes in a cell culture system reduces the turnover of tau.
Inhibition of protein phosphatases induces transport deficits and axonopathy.
Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
Involvement of a ceramide activated protein phosphatase in the differentiation of neuroblastoma Neuro2a cells.
Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.
Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions.
Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity.
Melatonin reduces the impairment of axonal transport and axonopathy induced by calyculin A.
Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Methamphetamine toxicity-induced calcineurin activation, nuclear translocation of nuclear factor of activated T-cells and elevation of cyclooxygenase 2 levels are averted by calpastatin overexpression in neuroblastoma SH-SY5Y cells.
Modulation by calcineurin of 5-HT3 receptor function in NG108-15 neuroblastoma x glioma cells.
Neuroblastoma PTPome analysis unveils association of DUSP5 and PTPN1 expression with poor prognosis.
Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
Oxidative inactivation of calcineurin by Cu,Zn superoxide dismutase G93A, a mutant typical of familial amyotrophic lateral sclerosis.
Oxidative modulation of nuclear factor-kappaB in human cells expressing mutant fALS-typical superoxide dismutases.
PPM1D is a potential target for 17q gain in neuroblastoma.
Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation.
Protein phosphatase in neuroblastoma cells: [3H]cantharidin binding site in relation to cytotoxicity.
Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.
Structural Insight into the Critical Role of the N-Terminal Region in the Catalytic Activity of Dual-Specificity Phosphatase 26.
The 1p36 Tumor Suppressor KIF 1B? Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis.
The phosphatase inhibitor okadaic acid induces a phosphorylated paired helical filament tau epitope in human LA-N-5 neuroblastoma cells.
The retinoid anticancer signal: mechanisms of target gene regulation.
Transcriptional response to muscarinic acetylcholine receptor stimulation: regulation of Egr-1 biosynthesis by ERK, Elk-1, MKP-1, and calcineurin in carbachol-stimulated human neuroblastoma cells.
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma.
[Alzheimer-like protein phosphatase deficiency leads to abnormal phosphorylation and accumulation of neurofilaments]
Neurocytoma
Immunocytochemical detection of calcineurin and microtubule-associated protein 2 in central neurocytoma.
Neurodegenerative Diseases
A central role for calcineurin in protein misfolding neurodegenerative diseases.
A stable association with PME-1 may be dispensable for PP2A demethylation - implications for the detection of PP2A methylation and immunoprecipitation.
A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.
Alterations of STEP46 and STEP61 Expression in the Rat Retina with Age and AMD-Like Retinopathy Development.
Calcineurin proteolysis in astrocytes: Implications for impaired synaptic function.
Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
Degradation of altered mitochondria by autophagy is impaired in Lafora disease.
Detailed in vitro pharmacological analysis of FK506-induced neuroprotection.
FK506 attenuates intracerebroventricular streptozotocin-induced neurotoxicity in rats.
Genetics of Lafora progressive myoclonic epilepsy: current perspectives.
Genotypes and phenotypes of patients with Lafora disease living in Germany.
Glycogen metabolism in tissues from a mouse model of Lafora disease.
High level calcineurin activity predisposes neuronal cells to apoptosis.
Human prion protein-mediated calcineurin activation induces neuron cell death via AMPK and autophagy pathway.
Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.
Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
Increased Oxidative Stress and Impaired Antioxidant Response in Lafora Disease.
Increased oxidative stress and impaired antioxidant response in Lafora disease.
Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.
Inhibition of Calcineurin A by FK506 Suppresses Seizures and Reduces the Expression of GluN2B in Membrane Fraction.
Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy.
Lafora Disease: A Review of Molecular Mechanisms and Pathology.
Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.
Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.
Loss of malin, but not laforin, results in compromised autophagic flux and proteasomal dysfunction in cells exposed to heat shock.
Malin and laforin are essential components of a protein complex that protects cells from thermal stress.
Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease.
Mechanistic Insights into Glucan Phosphatase Activity against Polyglucan Substrates.
Methionine-Mediated Protein Phosphatase 2A Catalytic Subunit (PP2Ac) Methylation Ameliorates the Tauopathy Induced by Manganese in Cell and Animal Models.
Molecular dynamics simulations and principal component analysis on human laforin mutation W32G and W32G/K87A.
Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice.
Neuroprotective effect of dual specificity phosphatase 6 against glutamate-induced cytotoxicity in mouse hippocampal neurons.
Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy.
Partial Inhibition of Calcineurin Activity by Rcn2 as a Potential Remedy for Vps13 Deficiency.
Persistent accumulation of unrepaired DNA damage in rat cortical neurons: nuclear organization and ChIP-seq analysis of damaged DNA.
PP2AC? of Alveolar Macrophages Is a Novel Protective Factor for LPS-Induced Acute Respiratory Distress Syndrome.
Proteasome inhibition stabilizes tau inclusions in oligodendroglial cells that occur after treatment with okadaic acid.
Protein Phosphatase 2a (Pp2a) Regulates Innate Immune and Proteolytic Responses to Cigarette Smoke Exposure in the Lung.
Proteomic analysis of rat cerebral cortex following subchronic acrolein toxicity.
Relationship between glycogen accumulation and the laforin dual specificity phosphatase.
Role of calcineurin in neurodegeneration produced by misfolded proteins and endoplasmic reticulum stress.
Structural insights into glucan phosphatase dynamics using amide hydrogen-deuterium exchange mass spectrometry.
Substituent effect of N-benzylated gramine derivatives that prevent the PP2A inhibition and dissipate the neuronal Ca2+ overload, as a multitarget strategy for the treatment of Alzheimer's disease.
The Emerging Roles of the Calcineurin-Nuclear Factor of Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases.
The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits.
The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2.
The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity.
Translating protein phosphatase research into treatments for neurodegenerative diseases.
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Neurodermatitis
[Selective calcineurin inhibitor. Neurodermatitis patients need fewer corticoids]
Neuroendocrine Tumors
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy.
Neurofibrosarcoma
Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Neuroinflammatory Diseases
Calcineurin and glial signaling: neuroinflammation and beyond.
Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders.
Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models.
Calcineurin, Calcium-Dependent Serine-Threonine Phosphatase Activation by Prion Peptide 106-126 Enhances Nuclear Factor-?B-Linked Proinflammatory Response through Autophagy Pathway.
Calcineurin/nuclear factor-?B signaling mediates isoflurane-induced hippocampal neuroinflammation and subsequent cognitive impairment in aged rats.
Deletion of calcineurin from GFAP-expressing astrocytes impairs excitability of cerebellar and hippocampal neurons through astroglial Na+ /K+ ATPase.
Early Minocycline and Late FK506 Treatment Improves Survival and Alleviates Neuroinflammation, Neurodegeneration, and Behavioral Deficits in Prion-Infected Hamsters.
Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity.
miR-32-5p-mediated Dusp5 downregulation contributes to neuropathic pain.
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
Tacrolimus Protects against Age-Associated Microstructural Changes in the Beagle Brain.
Neurologic Manifestations
A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation.
Neurologic complications of transplantation.
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
Neuronal Ceroid-Lipofuscinoses
Advances in the genetics of progressive myoclonus epilepsy.
Neutropenia
Calcineurin Inhibitors and Neutropenia: Is Cyclosporine Superior to Tacrolimus?
Impaired interferon-gamma responses, increased interleukin-17 expression, and a tumor necrosis factor-alpha transcriptional program in invasive aspergillosis.
Nocardia Infections
Nocardia Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study.
Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study.
Non-alcoholic Fatty Liver Disease
Dual-specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice through TAK1 Suppression.
New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation.
Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice.
Pediatric post-transplant metabolic syndrome: New clouds on the horizon.
Noonan Syndrome
A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair.
Further evidence that variants in PPP1CB cause a rasopathy similar to Noonan syndrome with loose anagen hair.
Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations.
Noonan syndrome with loose anagen hair with variants in the PPP1CB gene: First familial case reported.
SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Obesity
Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo.
Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.
Dual specificity phosphatase 6 deficiency is associated with impaired systemic glucose tolerance and reversible weight retardation in mice.
Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice.
DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases.
DUSP5 functions as a feedback regulator of TNF?-induced ERK1/2 dephosphorylation and inflammatory gene expression in adipocytes.
Frequency and risks associated with Clostridium difficile-associated diarrhea after pediatric solid organ transplantation: a single-center retrospective review.
Genetic disruption of protein phosphatase 5 in mice prevents high-fat diet feeding-induced weight gain.
Incidence of development of obesity after heart transplantation according to the calcineurin inhibitor.
Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance.
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
MAP kinase phosphatase DUSP1 is overexpressed in obese humans and modulated by physical exercise.
New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation.
New-onset diabetes mellitus after kidney transplantation: Current status and future directions.
Patterns of chronic injury in pediatric renal allografts.
Phosphoprotein phosphatase 1CB (PPP1CB), a novel adipogenic activator, promotes 3T3-L1 adipogenesis.
PPM1l encodes an inositol requiring-protein 1 (IRE1) specific phosphatase that regulates the functional outcome of the ER stress response.
Risk assessment and management of post-transplant diabetes mellitus.
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management.
The expanding phenotypes of cohesinopathies: one ring to rule them all!
TRPV4 deficiency increases skeletal muscle metabolic capacity and resistance against diet-induced obesity.
Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases.
Variations in DNA elucidate molecular networks that cause disease.
Ocular Hypertension
Calcineurin activation causes retinal ganglion cell degeneration.
Oligospermia
Oligoasthenoteratospermia and sperm tail bending in PPP4C-deficient mice.
Oliguria
Adenosine receptor antagonism in acute tacrolimus toxicity.
Opportunistic Infections
Biomarkers of immune tolerance in kidney transplantation: an overview.
Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.
Electromagnetic fields may act via calcineurin inhibition to suppress immunity, thereby increasing risk for opportunistic infection: Conceivable mechanisms of action.
Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.
Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
Inpatient Neurologic Consultation in Solid Organ Transplant Patients.
Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary.
Neuroimaging and neurologic complications after organ transplantation.
Neurologic Complications of Transplantation.
NFATc1 releases BCL6-dependent repression of CCR2 agonist expression in peritoneal macrophages from Saccharomyces cerevisiae infected mice.
Nocardiosis in transplant recipients.
Pulmonary abnormalities in inflammatory bowel disease.
The role of basiliximab in the evolving renal transplantation immunosuppression protocol.
[Chronic renal failure after hematopoietic stem cell transplantation]
Optic Atrophy
[Down-regulation of Protein Phosphatase 2A Catalytic Subunit Involved in Mitochondria Fission/fusion Dynamics Imbalance and Functional Impairment Induced by Human tau].
Optic Atrophy, Autosomal Dominant
PGAM5 regulates PINK1/Parkin-mediated mitophagy via DRP1 in CCCP-induced mitochondrial dysfunction.
Optic Nerve Diseases
Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals.
Oral Manifestations
Gingival overgrowth in renal transplant recipients: a study concerning prevalence, severity, periodontal, and predisposing factors.
Orbital Cellulitis
Bilateral cavernous sinus thrombosis in a patient with tacrolimus-associated posttransplant thrombotic microangiopathy.
Osteoarthritis
Calcineurin is expressed and plays a critical role in inflammatory arthritis.
Calcineurin modulates the catabolic and anabolic activity of chondrocytes and participates in the progression of experimental osteoarthritis.
DUSP5 suppresses interleukin-1?-induced chondrocyte inflammation and ameliorates osteoarthritis in rats.
Mitophagy in degenerative joint diseases.
Protein phosphatase magnesium-dependent 1A induces inflammation in rheumatoid arthritis.
Osteochondroma
Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
Osteolysis
Inhibition of protein phosphatase 2A attenuates titanium-particle induced suppression of bone formation.
Protein phosphatase 2A as a new target for downregulating osteoclastogenesis and alleviating titanium particle-induced bone resorption.
Osteonecrosis
Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.
From marrow oedema to osteonecrosis: common paths in the development of post-transplant bone pain.
Pain syndrome with stress fractures in transplanted patients treated with calcineurin inhibitors.
Osteoporosis
Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.
Calcineurin regulates bone formation by the osteoblast.
Cellular and molecular consequences of calcineurin A alpha gene deletion.
Drug-induced bone loss: a major safety concern in Europe.
DUSP5 promotes osteogenic differentiation through SCP1/2-dependent phosphorylation of SMAD1.
DUSP6 expression is associated with osteoporosis through the regulation of osteoclast differentiation via ERK2/Smad2 signaling.
Integrative genomics analysis of eQTL and GWAS summary data identifies PPP1CB as a novel bone mineral density risk genes.
Liver and gastrointestinal transplantation at the University of Miami.
Pain syndrome with stress fractures in transplanted patients treated with calcineurin inhibitors.
Peptide 11R-VIVIT stimulates osteoblastogenesis through regulating the expression of nuclear factor of activated T cells cytoplasmic 1.
The Calcineurin-NFAT Pathway and Bone: Intriguing New Findings.
Osteosarcoma
Elevated expression of serine/threonine phosphatase type 5 correlates with malignant proliferation in human osteosarcoma.
Enhanced expression of PP1gamma1, a catalytic subunit isoform of protein phosphatase type1 and expression of telomerase activity in Ewing's sarcoma cells.
Inhibitors of protein synthesis and RNA synthesis protect against okadaic acid-induced apoptosis in human osteosarcoma cell line MG63 cells but not in Saos-2 cells.
MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
MicroRNA-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion by targeting DUSP1 in osteosarcoma.
MicroRNA-499a-5p inhibits osteosarcoma cell proliferation and differentiation by targeting protein phosphatase 1D through protein kinase B/glycogen synthase kinase 3? signaling.
Okadaic acid activates the PKR pathway and induces apoptosis through PKR stimulation in MG63 osteoblast-like cells.
Okadaic acid induces apoptosis through double-stranded RNA-dependent protein kinase/eukaryotic initiation factor-2alpha pathway in human osteoblastic MG63 cells.
Okadaic acid induces tyrosine phosphorylation of IkappaBalpha that mediated by PKR pathway in human osteoblastic MG63 cells.
P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
PPM1D accelerates proliferation and metastasis of osteosarcoma by activating PKP2.
RCAN1.4 suppresses the osteosarcoma growth and metastasis via interfering with the calcineurin/NFAT signaling pathway.
Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics.
Tripartite Motif Containing 11 Interacts with DUSP6 to Promote the Growth of Human Osteosarcoma Cells through Regulating ERK1/2 Pathway.
Ovarian Cysts
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Ovarian Neoplasms
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.
Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells.
Dual-specificity phosphatase 5 suppresses ovarian cancer progression by inhibiting IL-33 signaling.
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells.
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
Gi protein-mediated translocation of serine/threonine phosphatase to the plasma membrane and apoptosis of ovarian cancer cell in response to gonadotropin-releasing hormone antagonist cetrorelix.
Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview.
Gonadotropin-releasing hormone retards doxorubicin-induced apoptosis and serine/threonine phosphatase inhibition in ovarian cancer cells.
Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer.
Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes.
Knockdown of protein phosphatase 5 inhibits ovarian cancer growth in vitro.
KRAS K104 modification affects the KRASG12D-GEF interaction and mediates cell growth and motility.
Mosaic mutations in blood DNA sequence are associated with solid tumor cancers.
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer.
Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway.
PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
Protein phosphatase magnesium-dependent 1? (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma.
Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid.
RE: PPM1D Mutations in Circulating White Blood Cells and the Risk for Ovarian Cancer.
Regulation of LC3-Dependent Protective Autophagy in Ovarian Cancer Cells by Protein Phosphatase 2A.
Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy.
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
The integrin-linked kinase-associated phosphatase (ILKAP) is a regulatory hub of ovarian cancer cell susceptibility to platinum drugs.
Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma.
Overweight
Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis.
Pancreatic Neoplasms
Abrogation of DUSP6 by hypermethylation in human pancreatic cancer.
An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells.
AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer.
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Effect of PPM1H on malignant phenotype of human pancreatic cancer cells.
Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression.
Expression of Concern: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine.
Expression of TMEFF2 in Human Pancreatic Cancer Tissue and the Effects of TMEFF2 Knockdown on Cell, Proliferation, and Apoptosis in Human Pancreatic Cell Lines.
Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells.
Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer.
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Infrequent methylation of the DUSP6 phosphatase in endometrial cancer.
Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro.
Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924.
Molecular mechanisms of pancreatic carcinogenesis.
Molecular pathology of pancreatic cancer: implications for molecular targeting therapy.
p21 expression is induced by activation of nuclear nerve growth factor-induced Balpha (Nur77) in pancreatic cancer cells.
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
The growth inhibitory effect of gambogic acid on pancreatic cancer cells.
The role of phosphoprotein phosphatases catalytic subunit genes in pancreatic cancer.
Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras.
Pancreatitis
A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?
Bile acids induce pancreatic acinar cell injury and pancreatitis by activating calcineurin.
Disulfide stress: a novel type of oxidative stress in acute pancreatitis.
Effect of calcineurin inhibitor on post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with liver transplantation: a propensity-matched cohort study.
Effects of silencing the DUSP1 gene using lentiviral vector-mediated siRNA on the release of proinflammatory cytokines through regulation of the MAPK signaling pathway in mice with acute pancreatitis.
Exposure to Radiocontrast Agents Induces Pancreatic Inflammation by Activation of Nuclear Factor-?B, Calcium Signaling, and Calcineurin.
PENTOXIFYLLINE PREVENTS LOSS OF PP2A PHOSPHATASE ACTIVITY AND RECRUITMENT OF HISTONE ACETYLTRANSFERASES TO PRO-INFLAMMATORY GENES IN ACUTE PANCREATITIS.
Pharmacologic and genetic inhibition of calcineurin protects against carbachol-induced pathologic zymogen activation and acinar cell injury.
Protease activation during in vivo pancreatitis is dependent on calcineurin activation.
Protease Activation during in vivo Pancreatitis is Dependent upon Calcineurin Activation.
RCAN1 is a marker of oxidative stress, induced in acute pancreatitis.
SOCE induced calcium overload regulates autophagy in acute pancreatitis via calcineurin activation.
Targeted inhibition of pancreatic acinar cell calcineurin is a novel strategy to prevent post-ERCP pancreatitis.
The Protective Effects of Calcineurin on Pancreatitis in Mice Depend on the Cellular Source.
Transient High Pressure in Pancreatic Ducts Promotes Inflammation and Alters Tight Junctions via Calcineurin Signaling in Mice.
Pancreatitis, Chronic
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Pancytopenia
Acute Graft-vs-Host Disease After Liver Transplantation: Experience at a High-volume Liver Transplantation Center in Korea.
Sirolimus in heart transplantation: a single center initial experience.
Papilloma
Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.
Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Egyptian clinical practice guideline for kidney transplantation.
Loss of protein phosphatase 6 in mouse keratinocytes increases susceptibility to ultraviolet-B-induced carcinogenesis.
Okadaic acid stimulated TRE binding activity in a papilloma producing mouse keratinocyte cell line involves increased AP-1 expression.
Papillomavirus Infections
Downregulation of calcineurin activity in cervical carcinoma.
Paracoccidioidomycosis
Evidence for the role of calcineurin in morphogenesis and calcium homeostasis during mycelium-to-yeast dimorphism of Paracoccidioides brasiliensis.
Paraganglioma
Calcineurin, a calcium/calmodulin-regulated protein phosphatase, in mammalian neuroendocrine cells and neoplasms.
Genomic organization and precise physical location of protein phosphatase 2A regulatory subunit A beta isoform gene on chromosome band 11q23.
Paralysis
Isolated diplopia associated with calcineurin inhibitor therapy in a patient with idiopathic membranous nephropathy: a case report.
Mitochondrial health and muscle plasticity after spinal cord injury.
Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci.
Screening and identification of proteins interacting with nucleostemin.
Paraplegia
Neurologic complications in renal transplantation.
Paresthesia
Completeness of reporting of adverse events in trials of maintenance immunosuppression in kidney transplantation: a systematic review.
Neurologic complications after solid organ transplantation.
Parkinson Disease
Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
Calcineurin as a possible new target for treatment of Parkinson's disease.
Calcineurin immunoreactivity in striatonigral degeneration.
Calcineurin in human brain and its relation to extrapyramidal system. Immunohistochemical study on postmortem human brains.
Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.
Mitophagy in degenerative joint diseases.
Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
PARL Protease: A Glimpse at Intramembrane Proteolysis in the Inner Mitochondrial Membrane.
Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration.
The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity.
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Parkinsonian Disorders
A novel EPM2A mutation in a patient with Lafora disease presenting with early parkinsonism symptoms in childhood.
Cell type-specific neuronal loss in the putamen of patients with multiple system atrophy.
Late-onset Lafora disease with prominent parkinsonism due to a rare mutation in EPM2A.
Pemphigoid, Bullous
Anti-inflammatory treatment.
Pemphigus
Anti-inflammatory treatment.
Pemphigus, Benign Familial
A Case of Hailey-Hailey Disease Managed With Oral Magnesium Citrate and High-Dose Vitamin D3.
Safety of Topical Calcineurin Inhibitors for Hailey-Hailey Disease.
Periodontal Diseases
Regulator of Calcineurin 1 in Periodontal Disease.
Periodontitis
Elevated platelet and leukocyte response to oral bacteria in periodontitis.
Periodontitis is associated with platelet activation.
Protective effects of Tacrolimus, a calcineurin inhibitor, in experimental periodontitis in rats.
Peripheral Nerve Injuries
Deletion of Calcineurin in Schwann Cells Does Not Affect Developmental Myelination, But Reduces Autophagy and Delays Myelin Clearance after Peripheral Nerve Injury.
Peripheral Nervous System Diseases
Inpatient Neurologic Consultation in Solid Organ Transplant Patients.
Peripheral Vascular Diseases
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Peritonitis
Time Is Not Always the Matter: An Instance of Encapsulating Peritoneal Sclerosis Developing in a Patient on Peritoneal Dialysis for a Short Term.
Persistent Infection
Our approach to a renal transplant biopsy.
Protein phosphatase 2A impairs IFN?-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation.
Pheochromocytoma
Calmodulin-dependent phosphatases of PC12, GH3, and C6 cells: physical, kinetic, and immunochemical properties.
Effects of protein kinase inhibitors and protein phosphatase inhibitors on cyclic AMP-dependent down-regulation of vesicular monoamine transport in pheochromocytoma PC12 cells.
Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia.
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy.
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.
Photosensitivity Disorders
UVA1 radiation inhibits calcineurin through oxidative damage mediated by photosensitization.
Pinealoma
Calcineurin, a calcium/calmodulin-regulated protein phosphatase, in mammalian neuroendocrine cells and neoplasms.
Pituitary Neoplasms
Calcineurin feedback inhibition of agonist-evoked cAMP formation.
Calmodulin-dependent phosphatases of PC12, GH3, and C6 cells: physical, kinetic, and immunochemical properties.
Mechanism of Ca(2+)-dependent inactivation of L-type Ca2+ channels in GH3 cells: direct evidence against dephosphorylation by calcineurin.
The effects of calyculin A upon calcium-, guanine nucleotides- and phorbol 12-myristate 13-acetate-stimulated ACTH secretion from AtT-20 cells.
Thyroid hormone antagonizes tumor necrosis factor-alpha signaling in pituitary cells through the induction of dual specificity phosphatase 1.
Pityriasis
An exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba.
Pneumococcal Infections
Calcineurin subunit B is an immunostimulatory protein and acts as a vaccine adjuvant inducing protective cellular and humoral responses against pneumococcal infection.
Pneumonia
Ab initio calcineurin inhibitor-based monotherapy immunosuppression after liver transplantation reduces the risk for Pneumocystis jirovecii pneumonia.
Early-Onset Pneumonia After Liver Transplant: Microbial Causes, Risk Factors, and Outcomes, Mansoura University, Egypt, Experience.
In Vivo Platelet Activation in Critically-Ill Patients with Primary H1N1 Influenza.
The Protective Effects of Calcineurin on Pancreatitis in Mice Depend on the Cellular Source.
Pneumonia, Bacterial
Regulator of calcineurin 1 suppresses inflammation during respiratory tract infections.
Pneumonia, Pneumocystis
Ab initio calcineurin inhibitor-based monotherapy immunosuppression after liver transplantation reduces the risk for Pneumocystis jirovecii pneumonia.
High-dose calcineurin inhibitor-free everolimus as a maintenance regimen for heart transplantation may be a risk factor for Pneumocystis pneumonia.
Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients.
Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation.
Polycystic Kidney, Autosomal Dominant
Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Polycythemia
Hypertension after renal transplantation.
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Polycythemia Vera
Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
Polymyositis
Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis.
Polyomavirus Infections
Late kidney allograft loss: what we know about it, and what we can do about it.
Porphyria, Acute Intermittent
Pretransplant evaluation of a patient with acute intermittent porphyria.
The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria.
Porphyrias
Pretransplant evaluation of a patient with acute intermittent porphyria.
The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria.
Posterior Leukoencephalopathy Syndrome
Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation.
Basiliximab for posterior reversible encephalopathy syndrome after lung transplantation.
Brain MR imaging abnormalities in kidney transplant recipients.
Calcineurin inhibitor-free strategies for prophylaxis and treatment of GVHD in children with posterior reversible encephalopathy syndrome after stem cell transplantation.
Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review.
Neurologic complications in renal transplantation.
Neurologic Complications of Transplantation.
Neurotoxicity including posterior reversible encephalopathy syndrome after initiation of calcineurin inhibitors in transplanted methylmalonic acidemia patients: Two case reports and review of the literature.
Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Posterior reversible encephalopathy syndrome after liver transplantation in children: a rare complication related to calcineurin inhibitor effects.
Posterior Reversible Encephalopathy Syndrome After Orthotopic Heart Transplantation: A Case Report.
Posterior reversible encephalopathy syndrome due to immunosuppressant after living-donor lobar lung transplantation: report of a case.
Posterior reversible encephalopathy syndrome in children with kidney disease.
Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors.
Reversible posterior leukoencephalopathy syndrome (RPLS) in a heart transplant recipient treated by substitution of cyclosporine A with tacrolimus.
Reversible posterior leukoencephalopathy syndrome: diagnosis and management in the setting of lung transplantation.
Seizure treatment in transplant patients.
Successful retransplantation using rapamycin in a patient with previous calcineurin inhibitor-induced posterior leukoencephalopathy syndrome.
Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.
Tacrolimus-Induced Vision Loss in a Renal Transplant Patient: Posterior Reversible Encephalopathy Syndrome.
Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients.
[Retrospective analysis of posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation]
Pouchitis
Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery.
Poxviridae Infections
Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.
Pre-Eclampsia
miR-141-5p regulate ATF2 via effecting MAPK1/ERK2 signaling to promote preeclampsia.
Posterior Reversible Encephalopathy Syndrome Associated with Hemorrhage.
Silencing of AFAP1-AS1 lncRNA impairs cell proliferation and migration by epigenetically promoting DUSP5 expression in pre-eclampsia.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein degradation.
Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with Calcineurin inhibition to promote T-ALL cell death.
Clinical significance of serum calcineurin in acute leukemia.
CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.
Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells.
Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia.
Molecular cloning of a novel PPEF-1 gene variant from a T-cell lymphoblastic lymphoma cell line.
Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with Calcineurin inhibition to promote T-ALL cell death.
CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.
Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia.
NFAT transcription factors are essential and redundant actors for leukemia initiating potential in T-cell acute lymphoblastic leukemia.
Prediabetic State
Prediabetes in Pediatric Recipients of Liver Transplant: Mechanism and Risk Factors.
Prion Diseases
Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity.
Calcineurin Activation by Prion Protein Induces Neurotoxicity via Mitochondrial Reactive Oxygen Species.
Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival.
Calcineurin, Calcium-Dependent Serine-Threonine Phosphatase Activation by Prion Peptide 106-126 Enhances Nuclear Factor-?B-Linked Proinflammatory Response through Autophagy Pathway.
Early Minocycline and Late FK506 Treatment Improves Survival and Alleviates Neuroinflammation, Neurodegeneration, and Behavioral Deficits in Prion-Infected Hamsters.
Human prion protein-mediated calcineurin activation induces neuron cell death via AMPK and autophagy pathway.
Inhibition of the FKBP family of peptidyl prolyl isomerases induces abortive translocation and degradation of the cellular prion protein.
Prostatic Hyperplasia
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Prostatic Intraepithelial Neoplasia
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Prostatic Neoplasms
Active ?-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A.
Androgen attenuates the inactivating phospho-Ser-127 modification of yes-associated protein 1 (YAP1) and promotes YAP1 nuclear abundance and activity.
Caveolin-1 interacts with protein phosphatase 5 and modulates its activity in prostate cancer cells.
Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells.
Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer.
Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer.
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Effects of a fluorescent Myosin light chain phosphatase inhibitor on prostate cancer cells.
Exploitation of the Ability of ?-Tocopherol to Facilitate Membrane Co-localization of Akt and PHLPP1 to Develop PHLPP1-Targeted Akt Inhibitors.
Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases.
Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.
Identification of androgen-regulated genes in human prostate.
Induction of p27(kip1) by 2,4,3',5'- tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells.
KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells.
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Modulation of protein phosphatase 2A (PP2A) activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
New Acetohydrazides Incorporating 2-Oxoindoline and 4-Oxoquinazoline: Synthesis and Evaluation of Cytotoxicity and Caspase Activation Activity.
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Positive feedback loop mediated by protein phosphatase 1? mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer.
PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
PPP2R2C loss promotes castration-resistant prostate cancer growth and is associated with increased prostate cancer-specific mortality.
PPP5C promotes cell proliferation and survival in human prostate cancer by regulating of the JNK and ERK1/2 phosphorylation.
Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.
PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer.
Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin.
Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction.
Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.
Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1.
Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
protein-serine/threonine phosphatase deficiency
Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.
Calcineurin Antagonizes AMPK to Regulate Lipolysis in Caenorhabditis elegans.
Calcineurin deficiency decreases inflammatory lesions in transforming growth factor beta1-deficient mice.
Clinical and Genetic Study on a Chinese Patient with Infantile Onset Epileptic Encephalopathy carrying a PPP3CA Null Variant: a case report.
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
Dual specificity phosphatase 6 deficiency is associated with impaired systemic glucose tolerance and reversible weight retardation in mice.
Dual-specificity Phosphatase 1 Deficiency Induces Endometrioid Adenocarcinoma Progression via Activation of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Pathway.
Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice.
DUSP26 regulates podocyte oxidative stress and fibrosis in a mouse model with diabetic nephropathy through the mediation of ROS.
FoxO3a-mediated autophagy is down-regulated in the laforin deficient mice, an animal model for Lafora progressive myoclonus epilepsy.
Functional characterization of a mitochondrial Ser/Thr protein phosphatase in cell death regulation.
Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy.
Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D -driven tumor promotion.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
PGAM5 is a key driver of mitochondrial dysfunction in experimental lung fibrosis.
Phosphoglycerate mutase 5 exacerbates cardiac ischemia-reperfusion injury through disrupting mitochondrial quality control.
Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction.
pmp1+, a suppressor of calcineurin deficiency, encodes a novel MAP kinase phosphatase in fission yeast.
Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1.
PP2A regulates kinetochore-microtubule attachment during meiosis I in oocyte.
Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.
The Ablation of Mitochondrial Protein Phosphatase Pgam5 Confers Resistance Against Metabolic Stress.
The mitochondrial protein PGAM5 suppresses energy consumption in brown adipocytes by repressing expression of uncoupling protein 1.
The POPX2 phosphatase regulates cancer cell motility and invasiveness.
Two classes of plant cDNA clones differentially complement yeast calcineurin mutants and increase salt tolerance of wild-type yeast.
[Alzheimer-like protein phosphatase deficiency leads to abnormal phosphorylation and accumulation of neurofilaments]
[PPP3CA silence regulates MET process, cell apoptosis, proliferation and migration in metanephric mesenchyme cells].
Proteinuria
An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
Angiotensin II Contributes to Podocyte Injury by Increasing TRPC6 Expression via an NFAT-Mediated Positive Feedback Signaling Pathway.
Antifibrotic actions of mycophenolic acid.
Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.
Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Calcineurin inhibitors ameliorate PAN-induced podocyte injury through the NFAT-Angptl4 pathway.
Calcineurin inhibitors and proximal renal tubular injury in renal transplant patients with proteinuria and chronic allograft nephropathy.
Calpain-Mediated Cleavage of Calcineurin in Puromycin Aminonucleoside-Induced Podocyte Injury.
Cellular effects of everolimus and sirolimus on podocytes.
Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients.
CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Collecting duct (Na+/K+)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes.
Comparative Proteomic Analysis of Rapamycin Versus Cyclosporine Combination Treatment in Mouse Podocytes.
Consensus Guidelines on Management of Steroid-Resistant Nephrotic Syndrome.
Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria.
Conversion to everolimus in kidney transplant recipients with decreased renal function.
Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults.
Cyclosporine A protects podocytes via stabilization of cofilin-1 expression in the unphosphorylated state.
Cyclosporine versus everolimus: effects on the glomerulus.
Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients.
Determinants of proteinuria after conversion from calcineurin inhibitor- to sirolimus-based immunosuppression: results from the multicenter convert trial.
Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria.
Effect of Clinical Variables and Immunosuppression on Serum Cystatin C and Beta-Trace Protein in Kidney Transplant Recipients.
Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation.
Endoplasmic Reticulum Stress Predicts Clinical Response to Cyclosporine Treatment in Primary Membranous Nephropathy.
Evolution of glomerular filtration rate, renal injury markers, anemia, and Angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.
Experience with belatacept rescue therapy in kidney transplant recipients.
Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules.
FK506 alleviates proteinuria in rats with adriamycin-induced nephropathy by down-regulating TRPC6 and CaN expression.
FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats.
High sirolimus levels may induce focal segmental glomerulosclerosis de novo.
Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
Is sirolimus responsible for proteinuria?
Knockout of Dual-Specificity Protein Phosphatase 5 Protects Against Hypertension-Induced Renal Injury.
Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.
Long-term outcome of third kidney transplants.
Lupus Nephritis in Asia: Clinical Features and Management.
Lupus nephritis: An update on treatments and pathogenesis.
Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
Membranous Nephropathy: Approaches to Treatment.
mTOR inhibitor-associated proteinuria in kidney transplant recipients.
mTOR inhibitors and renal allograft: Yin and Yang.
mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies.
Proteinuria following a switch from calcineurin inhibitors to sirolimus.
Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.
Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor.
Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.
Renal Biopsy in Children-Effect on Treatment Decisions: A Single-Center Experience.
Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Reversible posterior encephalopathy syndrome in children with nephrotic syndrome.
Role of calcineurin (CN) in kidney glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm.
Sirolimus and Proteinuria in Renal Transplant Patients: Evidence for a Dose-Dependent Effect on Slit Diaphragm-Associated Proteins.
Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
Sirolimus-associated proteinuria and renal dysfunction.
Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients.
The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4.
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury.
The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis.
The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
Treatment of membranous nephropathy: time for a paradigm shift.
[Changes in renal function in renal transplantation. Predictive factors for functional deterioration]
[Clinical and pathological features and mutational types of WT1 mutation-associated nephropathy].
[Clinical results of immunosuppressive triple therapies in living-related renal transplantation--a single center experience]
[Renal Involvement in Connective Tissue Diseases].
Prurigo
Actinic prurigo in a dermatological reference center in Colombia: 108 cases
Prurigo Nodularis and Its Management.
Pruritus
An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature.
Atopic dermatitis.
Atopic Dermatitis: Managing the Itch.
Chronic pruritus: targets, mechanisms and future therapies.
Clinical Efficacy of Oligofructans from Ophiopogon japonicus in Reducing Atopic Dermatitis Flare-ups in Caucasian Patients.
Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review.
Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients.
MECHANISMS OF SENSORY EFFECTS OF TACROLIMUS ON THE SKIN.
Practical algorithm to inform clinical decision-making in the topical treatment of atopic dermatitis.
Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Short-term efficacy of tacrolimus ointment and impact on quality of life.
Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use.
Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin.
Topical therapy of atopic dermatitis with a focus on pimecrolimus.
Topical treatment of perianal eczema with tacrolimus 0.1%
Treatment strategies for atopic dermatitis: optimizing the available therapeutic options.
[Antipruritic effects of pimecrolimus and tacrolimus]
[Lichen nitidus and lichen striatus].
[Pruritus and dryness of the skin in chronic kidney insufficiency and dialysis patients - a review]
[The treatment of atopic dermatitis in adults with topical calcineurin inhibitors]
Pseudomonas Infections
Regulator of calcineurin 1 differentially regulates TLR-dependent MyD88 and TRIF signaling pathways.
Psoriasis
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.
Changes in the expression pattern of DUSP1-7 and miRNA regulating their expression in the keratinocytes treated with LPS and adalimumab.
Dermatology Part 2: Ichthyoses and Psoriasis.
Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunisation.
DUSP1/MKP-1 regulates proliferation and apoptosis in keratinocytes through the ERK/Elk-1/Egr-1 signaling pathway.
Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review.
Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study.
Efficacy of topical calcineurin inhibitors in psoriasis.
Excimer laser therapy for hairline psoriasis: a useful addition to the scalp psoriasis treatment algorithm.
Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management.
Inhibition of calcineurin by cyclosporine A exerts multiple effects on human melanoma cell lines HT168 and WM35.
Inverse Psoriasis: From Diagnosis to Current Treatment Options.
ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
LITAF, HHEX, and DUSP1 expression in mesenchymal stem cells from patients with psoriasis.
Mechanisms of action of topical therapies and the rationale for combination therapy.
Nanostructured lipid carrier co-delivering tacrolimus and TNF-? siRNA as an innovate approach to psoriasis.
NF-?B-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Pharmacogenetics of topical and systemic treatment of psoriasis.
Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies.
Pimecrolimus for psoriasis.
Potential new indications of topical calcineurin inhibitors.
Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis.
Psoriasis clinical implications and treatment: a review.
Psoriasis of the face and flexures.
Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas.
The expression of dual specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin.
Therapeutic options in the treatment of psoriasis and atopic dermatitis.
Tumor necrosis factor antagonist-induced psoriasis in a 3-year-old boy with Kawasaki disease.
Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.
Voclosporin as a treatment for noninfectious uveitis.
[Calcineurin inhibitors for topical therapy in psoriasis.]
[Systemic voclosporin for uveitis treatment]
[Update of the topical treatment of psoriasis]
Puberty, Precocious
Study of lipid metabolism-related genes as candidate genes of sexual precocity in Nellore cattle.
Pulmonary Arterial Hypertension
Sarpogrelate attenuates pulmonary arterial hypertension via calcium/calcineurin axis.
Pulmonary Aspergillosis
A new and clinically relevant murine model of solid-organ transplant aspergillosis.
Pulmonary Atelectasis
Early-Onset Pneumonia After Liver Transplant: Microbial Causes, Risk Factors, and Outcomes, Mansoura University, Egypt, Experience.
Pulmonary Disease, Chronic Obstructive
?1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses.
Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.
Enhancing tristetraprolin activity reduces the severity of cigarette smoke-induced experimental chronic obstructive pulmonary disease.
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD.
PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
The GPx1-PTP1B-PP2A Axis: A Key Determinant of Airway Inflammation and Alveolar Destruction.
[Qibaipingfei Capsule down-regulate the levels of calcineurin and nuclear factor of activated T-cells isoform c3 (NFATc3) in chronic obstructive pulmonary disease].
Pulmonary Embolism
Comparison of denovo sirolimus vs. Calcineurin inhibitor immunosuppression regarding incidence of deep venous thrombosis and pulmonary embolism following renal transplantation.
Pulmonary Eosinophilia
Regulator of calcineurin 1 (rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice.
Pulmonary Fibrosis
Long-term use of everolimus in lung transplant patients.
PGAM5 is a key driver of mitochondrial dysfunction in experimental lung fibrosis.
Purpura
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to Henoch-Schönlein purpura.
Purpura, Thrombocytopenic
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.
Purpura, Thrombocytopenic, Idiopathic
Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopenia.
Pyelonephritis
Clinical Significance of Renal Allograft Protocol Biopsies: A Single Tertiary Center Experience in Malaysia.
Comparison between doppler ultrasound resistive index, serum creatinine, and histopathologic changes in patients with kidney transplant dysfunction in early posttransplantation period: A single center study with review of literature.
Our approach to a renal transplant biopsy.
Pyoderma Gangrenosum
Effective use of switching biologics for ulcerative colitis complicated with pyoderma gangrenosum and primary sclerosing cholangitis.
Efficacy of topical calcineurin inhibitors in pyoderma gangrenosum.
pyruvate dehydrogenase system deficiency
Diagnosis of partial deficiency of the pyruvate dehydrogenase complex in biopsied muscle.
Rectal Neoplasms
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
MAP kinase genes and colon and rectal cancer.
Red-Cell Aplasia, Pure
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report.
Reflex Sympathetic Dystrophy
Calcineurin Inhibitor-Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report.
Sympathetic dystrophy associated with sirolimus therapy.
Reflex, Abnormal
Unusual cerebral white matter change in a Chinese family with Spinocerebellar ataxia type 12.
Refsum Disease
Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.
Renal Artery Obstruction
Egyptian clinical practice guideline for kidney transplantation.
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.1 Differential diagnosis of chronic graft dysfunction.
Risk factors for hypertension 3 years after renal transplantation in children.
[Arterial hypertension in renal transplant recipients]
Renal Insufficiency
A case of polyomavirus-associated nephropathy presenting late after transplantation.
A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation.
An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation.
Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency.
Calcineurin Inhibitor Sparing With Mycophenolate Mofetil in Liver Transplantion: A Systematic Review of Randomized Controlled Trials.
Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment.
Challenging immunosuppression treatment in lung transplant recipients with kidney failure.
Chronic renal insufficiency in heart transplant recipients: risk factors and management options.
Combined Heart-Kidney Transplant versus Sequential Kidney Transplant in Heart Transplant Recipients.
Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation.
Controversies about induction therapy.
Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction.
Discontinuation of calcineurin inhibitors in heart transplant patients with end stage renal insufficiency as an alternative model of immunosuppression.
Early renal failure after domino hepatic transplantation using the liver from a compound heterozygous patient with primary hyperoxaluria.
Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First Year Post-Liver Transplantation.
Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency.
Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
Incidence of cardiovascular and cerebrovascular events associated with sirolimus use after liver transplantation.
Kidney transplantation in previous heart or lung recipients.
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.
Liver transplantation and liver cell transplantation.
Long-term effects on renal function of dose-reduced calcineurin inhibitor and sirolimus in cardiac transplant patients.
Multi organ transplantation: a review of the Irish experience.
Nephrotoxicity of intravenous immmunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic.
Nonnephrotoxic immunosuppression in patients after liver transplantation.
Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment.
Phase iii prospective, randomised study to compare conversion from calcineurin inhibitors to sirolimus versus standard therapy for twelve months in established renal allograft recipients with mild to moderate renal insufficiency.
Randomized Controlled Trial of Sirolimus Conversion in Cardiac Transplant Recipients With Renal Insufficiency.
Recommendations of everolimus use in liver transplant.
Relationship between renal resistance index and renal function in liver transplant recipients after cessation of calcineurin inhibitor.
Renal dysfunction following bone marrow transplantation.
Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal.
Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity.
Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Repeated Daclizumab Administration to Delay the Introduction of Calcineurin Inhibitors in Heart Transplant Patients With Postoperative Renal Dysfunction.
Repeated daclizumab administration to delay the introduction of calcineurin inhibitors in heart transplant patients with postoperative renal dysfunction.
Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Risk Factors for Chronic Renal Insufficiency Following Cardiac Transplantation.
Risk factors for hypertension 3 years after renal transplantation in children.
Role of endothelin and endothelin receptor antagonists in renal disease.
Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report.
Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
Sirolimus conversion after heart transplant: risk factors for acute rejection and predictors of renal function response.
Sirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.
Sirolimus experience in heart transplantation.
Sirolimus in heart transplantation: a single center initial experience.
Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients.
Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency.
The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial.
The effects of rapamycin in murine peripheral nerve isografts and allografts.
The Functional Implications of Common Genetic Variation in CYP3A5 and ABCB1 in Human Proximal Tubule Cells.
The long-term effect of simultaneous heart and kidney transplantation on native renal function.
Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study.
Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis.
Usefulness of Rabbit Anti-thymocyte Globulin in Patients With Giant Cell Myocarditis.
Vitamin D and systemic lupus erythematosus: an update.
[A case of gout secondary to primary myelofibrosis].
[Kidney and statins]
[Living donor liver transplantation for a patient with renal failure]
[Renal failure following liver transplantation]
Renal Insufficiency, Chronic
Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Calcineurin inhibitor-associated new-onset diabetes mellitus in chronic kidney disease treatment: a 4-year single-center cross-sectional study in China.
Chronic kidney disease after heart transplantation.
Chronic kidney disease after nonrenal solid organ transplantation: a histological assessment and utility of chronic allograft damage index scoring.
Chronic kidney disease after orthotopic liver transplantation in recipients receiving tacrolimus.
Chronic renal insufficiency in heart transplant recipients: risk factors and management options.
Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.
Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.
Effectiveness and cost of replacing a calcineurin inhibitor with sirolimus to slow the course of chronic kidney disease in renal allografts.
Egyptian clinical practice guideline for kidney transplantation.
End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation.
Hyperkalemia and blood pressure regulation.
Immunosuppressive therapy in older cardiac transplant patients.
Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same?
Influence of Blood Pressure and Calcineurin Inhibitors on Kidney Function After Heart or Liver Transplantation.
Initial single-center experience with sirolimus after lung transplantation.
Kidney dysfunction in the recipients of liver transplants.
Kidney injury molecule-1 correlates with kidney function in heart allograft recipients.
Kidney Transplantation in Patients With Chronic Kidney Disease After a Previous Lung Transplantation.
Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices.
Loss of expression of protein phosphatase magnesium-dependent 1A during kidney injury promotes fibrotic maladaptive repair.
Outcomes after liver transplantation: Chronic kidney disease.
Peri-operative kidney injury and long-term chronic kidney disease following orthotopic heart transplantation in children.
Prediction of chronic kidney disease progression used by calcineurin inhibitor concentration and estimated glomerular filtration rate early after liver transplantation.
Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: a cross-sectional study in hospitalized patients.
Prophylaxis of chronic kidney disease after liver transplantation - experience from west China.
Renal Complications of Hematopoietic Stem Cell Transplantation: Report of a Case and Review of the Literature.
Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
Renal histological lesions and outcome in liver transplant recipients.
Risk factors associated with moderate-to-severe renal dysfunction among heart transplant patients: results from the CAPRI study.
Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.
Safety of mTOR inhibitors in adult solid organ transplantation.
Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients.
Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency.
TT genotype of transforming growth factor beta1 +869C/T is associated with the development of chronic kidney disease after liver transplantation.
Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.
[Infective endocarditis caused by Chlamydia pneumoniae after liver transplantation. Case report].
Reperfusion Injury
A Sarcoplasmic Reticulum Localized Protein Phosphatase Regulates Phospholamban Phosphorylation and Promotes Ischemia Reperfusion Injury in the Heart.
Antioxidant supplementation may improve renal transplant function: a preliminary report.
Apoptosis in Ca2 + reperfusion injury of cultured astrocytes: roles of reactive oxygen species and NF-kappaB activation.
Calcineurin Abeta gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction.
Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury.
Chronic allograft nephropathy in paediatric renal transplantation.
Chronic allograft nephropathy--immunologic and nonimmunologic factors.
Chronic allograft nephropathy: current concepts and future directions.
Chronic renal allograft dysfunction.
Construction of rat calcineurin A alpha cDNA recombinant adenovirus vector and its identification.
Decreased lung ischemia-reperfusion injury in rats after preoperative administration of cyclosporine and tacrolimus.
DUSP1 alleviates cerebral ischaemia reperfusion injury via inactivating JNK-Mff pathways and repressing mitochondrial fission.
Effect of perioperative administration of a drug regimen on the primary function of human renal allografts.
Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion.
FK506 reduces calpain-regulated calcineurin activity in both the cytoplasm and the nucleus.
Genomics of chronic allograft injury.
Hydrogen sulphide as a novel therapy to ameliorate cyclosporine nephrotoxicity.
Influence of glutathione S-transferase M1 and T1 polymorphisms with acute rejection in Iranian liver transplant recipients.
Methylxanthines and the kidney.
MicroRNA-760-mediated low expression of DUSP1 impedes the protective effect of NaHS on myocardial ischemia-reperfusion injury.
MiRNAs in kidney transplantation: potential role as new biomarkers.
Mitochondrial Protein PGAM5 Regulates Mitophagic Protection against Cell Necroptosis.
Okadaic acid, an inhibitor of protein phosphatase, exerts a protective effect on ischemia-reperfusion injury in rat kidneys.
Phosphoglycerate mutase 5 exacerbates cardiac ischemia-reperfusion injury through disrupting mitochondrial quality control.
Preconditioning: from experimental findings to novel therapies in acute kidney injury.
Sirolimus: a current perspective.
Sirolimus: a ten-year perspective.
Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.
Transient Receptor Potential Vanilloid 1 Regulates Mitochondrial Membrane Potential and Myocardial Reperfusion Injury.
Trends in donation after cardiac death.
Use of Anti-Thymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Review.
[Use of new non-nephrotoxic immunosuppressive drugs in kidney transplantation, especially after ischemia-reperfusion injury].
Respiratory Distress Syndrome
Fulminant Acute Respiratory Distress Syndrome after Calcineurin Inhibitor-belatacept Conversion in a Lung Transplant Recipient.
Respiratory Tract Infections
Regulator of calcineurin 1 suppresses inflammation during respiratory tract infections.
Retinal Degeneration
A novel human serine-threonine phosphatase related to the Drosophila retinal degeneration C (rdgC) gene is selectively expressed in sensory neurons of neural crest origin.
Accumulation of calcium in degenerating photoreceptors of several Drosophila mutants.
Functional characterization of the three Drosophila retinal degeneration C (RDGC) protein phosphatase isoforms.
Identification and characterization of a conserved family of protein serine/threonine phosphatases homologous to Drosophila retinal degeneration C.
PP7 is a positive regulator of blue light signaling in Arabidopsis.
Retinoblastoma
Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate.
Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells.
Dephosphorylation of Rb (Thr-821) in response to cell stress.
DUSP1 promotes senescence of retinoblastoma cell line SO-Rb5 cells by activating AKT signaling pathway.
Evidence that Fas-induced apoptosis leads to S phase arrest.
Functions of ceramide in coordinating cellular responses to stress.
G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia.
High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein.
Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell line.
Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.
Inhibitory phosphorylation of PP1alpha catalytic subunit during the G(1)/S transition.
Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors.
Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Protein Phosphatase 1 binds strongly to the retinoblastoma protein but not to p107 or p130 in vitro and in vivo.
Protein phosphatase 1alpha-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein.
Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control.
Protein phosphatase type 1-dependent dephosphorylation of the retinoblastoma tumor suppressor protein in ultraviolet-irradiated human skin and keratinocytes.
Regulation of E2Fs and senescence by PML nuclear bodies.
Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment.
Site-specific and temporally-regulated retinoblastoma protein dephosphorylation by protein phosphatase type 1.
The carboxyl-terminal region of the retinoblastoma protein binds non-competitively to protein phosphatase type 1alpha and inhibits catalytic activity.
The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis.
The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit.
The tumor suppressor Pml regulates cell fate in the developing neocortex.
Retinoschisis
Characterization of two unusual RS1 gene deletions segregating in Danish retinoschisis families.
Rett Syndrome
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Rhabdomyolysis
Mild rhabdomyolysis after renal transplantation.
Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia.
Rheumatic Diseases
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.
Rhinitis, Allergic, Seasonal
Identification of novel targets for seasonal allergic rhinitis during and outside the pollen season by microarray analysis.
Rift Valley Fever
Protein Phosphatase 1? Interacts with Venezuelan Equine Encephalitis Virus Capsid Protein and Regulates Viral Replication through Modulation of Capsid Phosphorylation.
Rosacea
Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial.
Pimecrolimus for treatment of acne rosacea.
Rosacea-like eruption due to topical pimecrolimus.
Topical calcineurin inhibitors as a double-edged sword in rosacea: A systematic review.
Topical therapies for rosacea.
Salmonella Infections
Posttransplant Kaposi's sarcoma: report from a single center.
Sarcoidosis
Hypothalamic digoxin, hemispheric chemical dominance and sarcoidosis.
Sarcoma
Current approaches to the use of sirolimus in renal transplantation.
Synergistic cytotoxic effect between serine-threonine phosphatase inhibitors and 5-fluorouracil: a novel concept for modulation of cytotoxic effect.
The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells.
[Experimental study of hematopoietic cell gene expression profile induced by panax notoginosides in vitro]
Sarcoma, Avian
Activation of protein serine/threonine kinases p42, p63, and p87 in Rous sarcoma virus-transformed cells: signal transduction/transformation-dependent MBP kinases.
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Sarcoma, Ewing
Enhanced expression of PP1gamma1, a catalytic subunit isoform of protein phosphatase type1 and expression of telomerase activity in Ewing's sarcoma cells.
Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.
Sarcoma, Kaposi
Early non-immunological post transplant complications: a single center experience.
First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation.
No recurrence of Kaposi's sarcoma in a case of renal retransplantation under a calcineurin inhibitor free immunosuppressive regimen: first report.
Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
Sirolimus conversion for patients with posttransplant Kaposi's sarcoma.
Sirolimus monotherapy in liver transplantation.
Sarcoma, Synovial
Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
Sarcopenia
Posttransplant Sarcopenia: An Underrecognized Early Consequence of Liver Transplantation.
Scleroderma, Diffuse
Fibrosis caused by loss of PTEN expression by fibroblasts is crucially dependent on CCN2.
Scleroderma, Localized
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Scleroderma, Systemic
Fibrosis caused by loss of PTEN expression by fibroblasts is crucially dependent on CCN2.
Scoliosis
Mutation analysis of MESP2, HES7 and DUSP6 gene exons in patients with congenital scoliosis.
Seizures
A Wide Spectrum of Genetic Disorders Causing Severe Childhood Epilepsy in Taiwan: A Case Series of Ultrarare Genetic Cause and Novel Mutation Analysis in a Pilot Study.
AMPA Receptor Antagonists Facilitate NEDD4-2-Mediated GRIA1 Ubiquitination by Regulating PP2B-ERK1/2-SGK1 Pathway in Chronic Epilepsy Rats.
AMPA/kainate receptor-mediated downregulation of GABAergic synaptic transmission by calcineurin after seizures in the developing rat brain.
Anticonvulsant effect of the calcineurin inhibitor ascomycin on seizures induced by picrotoxin microperfusion in the rat hippocampus.
Bioinformatics Analysis of Microarray Profiling Identifies That the miR-203-3p Target Ppp2ca Aggravates Seizure Activity in Mice.
De Novo Mutations in PPP3CA Cause Severe Neurodevelopmental Disease with Seizures.
Decreased expression of calmodulin kinase II and calcineurin messenger RNAs in the mouse hippocampus after kainic acid-induced seizures.
Drug-induced alterations in Mg2+ homoeostasis.
Early-onset infant epileptic encephalopathy associated with a de novo PPP3CA gene mutation.
Effects of MK-801, dantrolene, and FK506 on convulsive seizures and brain nitric oxide production in seizure-susceptible EL mice.
Epileptic spasms in PPP1CB-associated Noonan-like syndrome: a case report with clinical and therapeutic implications.
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Hypomagnesaemia in cystic fibrosis patients referred for lung transplant assessment.
Hypoxia enhances high-voltage-activated calcium currents in rat primary cortical neurons via calcineurin.
Inhibition of Calcineurin A by FK506 Suppresses Seizures and Reduces the Expression of GluN2B in Membrane Fraction.
Kainate seizures cause acute dendritic injury and actin depolymerization in vivo.
Laforin and malin deletions in mice produce similar neurologic impairments.
Malin and laforin are essential components of a protein complex that protects cells from thermal stress.
Managing Lafora body disease with vagal nerve stimulation.
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors.
Neurologic complications of transplantation.
Pathophysiology and Management of Hyperammonemia in Organ Transplant Patients.
Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies.
Posterior reversible encephalopathy syndrome in children with kidney disease.
Rapamycin: brain excitability studied in vitro.
Seeing the forest and the trees: dendritic injury after status epilepticus.
Seizure treatment in transplant patients.
Single audiogenic seizures induce increases in calcineurin and Ca²+-calmodulin-dependent protein kinase II in the rat brain.
Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease.
Tacrolimus-Associated Psychotic Disorder: A Report of 2 Cases.
The Ca2+/calmodulin signaling system in the neural response to excitability. Involvement of neuronal and glial cells.
The Impact of Electrographic Seizures on Developing Hippocampal Dendrites Is Calcineurin Dependent.
Transplantation for liver failure in patients with sickle cell disease: Challenging but feasible.
Traumatic Brain Injury Causes a Tacrolimus-Sensitive Increase in Non-Convulsive Seizures in a Rat Model of Post-Traumatic Epilepsy.
[Single audiogenic seizure promote the increased levels of calcineurin and Ca(2+)-calmodulin-dependent protein kinase II in the rat's brain]
Sepsis
Clinical-pathological correlations in post-transplant thrombotic microangiopathy.
Cyclosporine A attenuates cardiac dysfunction induced by sepsis via inhibiting calcineurin and activating AMPK signaling.
Determination of protein phosphatase type 2A in monocytes from multiple trauma patients: a potential biomarker for sepsis.
Dual specificity phosphatase DUSP6 promotes endothelial inflammation through inducible expression of ICAM-1.
Fever in a transplant recipient: think beyond infection.
Neutrophil Gelatinase-Associated Lipocalin: Ready for Routine Clinical Use? An International Perspective.
Postoperative Acute Kidney Injury in Young Adults with Congenital Heart Disease.
Renal dysfunction following bone marrow transplantation.
Role of platelet TLR4 expression in pathogensis of septic thrombocytopenia.
Sepsis, calcineurin, and cardiac dysfunction: the saga of life and death.
Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report.
Wip1 Deficiency Promotes Neutrophil Recruitment to the Infection Site and Improves Sepsis Outcome.
[The Role of Laboratory Medicine in Hematopoietic Stem Cell Transplantation "Echocardiogram"].
Serum Sickness
Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
Severe Acute Respiratory Syndrome
The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy.
Shock, Septic
Attenuated platelet aggregation in patients with septic shock is independent from the activity state of myosin light chain phosphorylation or a reduction in Rho kinase-dependent inhibition of myosin light chain phosphatase.
Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock.
Sick Sinus Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Skin Diseases
A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.
Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test.
Calcineurin antagonists differentially affect mediator secretion, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases from immunologically activated human basophils.
Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.
Calcineurin inhibitors for the treatment of skin disease: how do they work?
Calcineurin inhibitors: a novel approach to canine atopic dermatitis.
Can we teach old drugs new tricks?-Repurposing of neuropharmacological drugs for inflammatory skin diseases.
Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Editorial comments on this issue of the Journal.
Effect of pimecrolimus vs. corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function.
Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis.
Erosive Pustular Dermatosis of the Scalp. A Chronic Recalcitrant Dermatosis Developed upon CO(2) Laser Treatment.
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema.
Multiple labial melanotic macules occurring after topical application of calcineurin inhibitors.
Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Pimecrolimus in dermatology: atopic dermatitis and beyond.
Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro.
Potential new indications of topical calcineurin inhibitors.
Steroid-sparing properties of emollients in dermatology.
Successful treatment of nodular actinic reticuloid with tacrolimus ointment.
Systemic ciclosporin and tacrolimus in dermatology.
The Itch that… freckles? Development of lentigines in areas of resolved chronic atopic dermatitis.
The role of calcineurin inhibitors in the management of lichen sclerosus.
The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis.
The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation.
Topical calcineurin inhibitors for the treatment of vulvar dermatoses.
Topical treatment of perianal eczema with tacrolimus 0.1%
Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
[Antipruritic effects of pimecrolimus and tacrolimus]
[Topical treatment of bullous pemphigoid with tacrolimus. Case report with brief literature review]
[Topical treatment of vulvar lichen sclerosus with calcineurin inhibitors].
Skin Neoplasms
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.
Calcineurin inhibitor (CNI)-associated skin cancers: New insights on exploring mechanisms by which CNIs downregulate DNA repair machinery.
Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation.
Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study.
Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.
Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients.
Interventions to Prevent Nonmelanoma Skin Cancers in Recipients of a Solid Organ Transplant: Systematic Review of Randomized Controlled Trials.
Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults.
Long-Term Immunosuppression Management: Opportunities and Uncertainties.
Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Opposing roles for calcineurin and ATF3 in squamous skin cancer.
Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer.
Ras and TGF-? signaling enhance cancer progression by promoting the ?Np63 transcriptional program.
Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients.
Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair.
Skin cancer in organ transplant recipients: More than the immune system.
Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits.
The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients.
The effect of switching from calcineurin inhibitor to sirolimus on the incidence of skin cancers in kidney transplant recipients.
The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.
The protein phosphatase 6 catalytic subunit (Ppp6c) is indispensable for proper post-implantation embryogenesis.
The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis.
[Topical pimecrolimus and tacrolimus and the risk of cancer]
Sleep Apnea, Obstructive
Obstructive sleep apnea and intermittent hypoxia increase expression of dual specificity phosphatase 1.
Sleep Deprivation
Calcineurin contributes to spatial memory impairment induced by rapid eye movement sleep deprivation.
Small Cell Lung Carcinoma
Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer.
Key genes in lung cancer translational research: a meta-analysis.
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance.
[Expression and clinical significance of CIP2A in small cell lung cancer patients].
Smallpox
Overproduction, purification, and biochemical characterization of the dual specificity H1 protein phosphatase encoded by variola major virus.
Solitary Kidney
Patient and graft outcome in current era of immunosuppression: a single centre pilot study.
Spasm
Recent insights into the mechanisms, predisposing factors, and racial differences of coronary vasospasm.
Spinal Cord Injuries
Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury.
Critical role of regulator of calcineurin 1 in spinal cord injury.
FK506 treatment inhibits caspase-3 activation and promotes oligodendroglial survival following traumatic spinal cord injury.
PPP1CC is associated with astrocyte and microglia proliferation after traumatic spinal cord injury in rats.
The Emerging Roles of the Calcineurin-Nuclear Factor of Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases.
Spinal Cord Ischemia
[The effects of calcineurin inhibitors on neurologic and histopathologic outcome after transient spinal cord ischemia in rabbits]
Spinocerebellar Ataxias
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Unusual cerebral white matter change in a Chinese family with Spinocerebellar ataxia type 12.
Spondylitis, Ankylosing
Autoantibodies against Protein Phosphatase Magnesium-Dependent 1A as a Biomarker for Predicting Radiographic Progression in Ankylosing Spondylitis Treated with Anti-Tumor Necrosis Factor Agents.
Role of Protein Phosphatase Magnesium-Dependent 1A and Anti-Protein Phosphatase Magnesium-Dependent 1A Autoantibodies in Ankylosing Spondylitis.
The intracellular protein phosphatase magnesium-dependent 1A negatively regulates osteoclast commitment.
Squamous Cell Carcinoma of Head and Neck
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma.
DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma.
Gene amplification and overexpression of protein phosphatase 1alpha in oral squamous cell carcinoma cell lines.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Protein phosphatase-2A association with microtubules and its role in restricting the invasiveness of human head and neck squamous cell carcinoma cells.
Protein phosphatase-2A maintains focal adhesion complexes in keratinocytes and the loss of this regulation in squamous cell carcinomas.
Protein phosphatase-2A regulates endothelial cell motility and both the phosphorylation and the stability of focal adhesion complexes.
ST Elevation Myocardial Infarction
Evidence of increased platelet reactivity in the first six months after acute ST segment elevation myocardial infarction.
Staphylococcal Infections
Structure-Based Identification of a Potent Inhibitor Targeting Stp1-Mediated Virulence Regulation in Staphylococcus aureus.
Tacrolimus impairs Kupffer cell capacity to control bacteremia: why transplant recipients are susceptible to infection.
Starvation
A calcium signalling network activates vacuolar K+ remobilization to enable plant adaptation to low-K environments.
A yeast protein phosphatase related to the vaccinia virus VH1 phosphatase is induced by nitrogen starvation.
Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response.
Biochemical and molecular analysis of LePS2;1: a phosphate starvation induced protein phosphatase gene from tomato.
Calcineurin Silencing in Dictyostelium discoideum Leads to Cellular Alterations Affecting Mitochondria, Gene Expression, and Oxidative Stress Response.
Calcium channel regulator Mid1 links TORC2-mediated changes in mitochondrial respiration to autophagy.
Cdc14 phosphatase downmodulates ESCRT-0 complex formation on vacuolar membranes and microautophagy after TORC1 inactivation.
CNP-1 (ARRD-17), a Novel Substrate of Calcineurin, Is Critical for Modulation of Egg-Laying and Locomotion in Response to Food and Lysine Sensation in Caenorhabditis elegans.
Cytoplasmic dynein undergoes intracellular redistribution concomitant with phosphorylation of the heavy chain in response to serum starvation and okadaic acid.
Enzymatic and functional analysis of a protein phosphatase, Pph3, from Myxococcus xanthus.
Global identification of genes related to nutrient deficiency in intervertebral disc cells in an experimental nutrient deprivation model.
Inorganic phosphate as an important regulator of phosphatases.
Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB.
Molecular physiology of the neural circuit for calcineurin-dependent associative learning in Caenorhabditis elegans.
New regulator for energy signaling pathway in plants highlights conservation among species.
Protein phosphatase type-1 mRNA levels in response to starvation-refeeding and streptozotocin-diabetes.
Specific phosphoantibodies reveal two phosphorylation sites in yeast Pma1 in response to glucose.
The Crz1/Sp1 transcription factor of Cryptococcus neoformans is activated by calcineurin and regulates cell wall integrity.
The dual-specificity protein phosphatase Yvh1p regulates sporulation, growth, and glycogen accumulation independently of catalytic activity in Saccharomyces cerevisiae via the cyclic AMP-dependent protein kinase cascade.
The inhibitor-1 C terminus facilitates hormonal regulation of cellular protein phosphatase-1: functional implications for inhibitor-1 isoforms.
The S. cerevisiae nitrogen starvation-induced Yvh1p and Ptp2p phosphatases play a role in control of sporulation.
[CONTENT AND RESTORATION OF PHOSPHOPROTEIN PHOSPHOSERINE AND PHOSPHOPROTEIN PHOSPHATASE IN THE LIVER IN STARVATION AND SUBSEQUENT FEEDING OF ANIMALS.]
Status Epilepticus
A cellular mechanism for dendritic spine loss in the pilocarpine model of status epilepticus.
A significant increase in both basal and maximal calcineurin activity in the rat pilocarpine model of status epilepticus.
Effect of the calcineurin inhibitor FK506 on K(+)-Cl (-) cotransporter 2 expression in the mouse hippocampus after kainic acid-induced status epilepticus.
Increased calcineurin expression after pilocarpine-induced status epilepticus is associated with brain focal edema and astrogliosis.
Status epilepticus-induced changes in the subcellular distribution and activity of calcineurin in rat forebrain.
The Calcineurin Inhibitor FK506 Prevents Cognitive Impairment by Inhibiting Reactive Astrogliosis in Pilocarpine-Induced Status Epilepticus Rats.
The effects of calcineurin inhibitor FK506 on actin cytoskeleton, neuronal survival and glial reactions after pilocarpine-induced status epilepticus in mice.
Stevens-Johnson Syndrome
Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study.
Still's Disease, Adult-Onset
Calcineurin inhibitors for adult-onset Still's disease: a multicentre retrospective cohort study.
Stomach Neoplasms
Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines.
Comprehensive analysis of vascular endothelial growth factor-C related factors in stomach cancer.
Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis.
DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer.
Genetic variants in PPP2CA are associated with gastric cancer risk in a Chinese population.
Genetically engineered drug rhCNB induces apoptosis and cell cycle arrest in both gastric cancer cells and hepatoma cells.
Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Inhibiting PP2Ac? Promotes the Malignant Phenotype of Gastric Cancer Cells through the ATM/METTL3 Axis.
Loss of PPM1F expression predicts tumour recurrence and is negatively regulated by miR-590-3p in gastric cancer.
MAEL contributes to gastric cancer progression by promoting ILKAP degradation.
MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2.
microRNA-95 knockdown inhibits epithelial-mesenchymal transition and cancer stem cell phenotype in gastric cancer cells through MAPK pathway by upregulating DUSP5.
MiR-125b promotes cell migration and invasion by targeting PPP1CA-Rb signal pathways in gastric cancer, resulting in a poor prognosis.
Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Poor prognosis of phosphatase of regenerating liver 3 expression in gastric cancer: a meta-analysis.
Prognostic value of PPM1D in 800 gastric cancer patients.
Synergistic cytotoxic effect between serine-threonine phosphatase inhibitors and 5-fluorouracil: a novel concept for modulation of cytotoxic effect.
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
[The malignant phenotype of calcineurin B homologous protein 2 in gastric cancer and its clinical significance].
Stomatitis, Aphthous
Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.
Striatonigral Degeneration
Calcineurin immunoreactivity in striatonigral degeneration.
Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders.
Inhomogeneity of the putaminal lesion in striatonigral degeneration.
Subregional loss of putaminal efferents to the basal ganglia output nuclei may cause parkinsonism in striatonigral degeneration.
Stroke
Detailed in vitro pharmacological analysis of FK506-induced neuroprotection.
Enhanced platelet-derived microparticle formation is associated with carotid atherosclerosis in convalescent stroke patients.
Expression profile based gene clusters for ischemic stroke detection.
High level calcineurin activity predisposes neuronal cells to apoptosis.
Incidence, Risk Factors, and Outcomes of Stroke Following Cardiac Transplantation.
Influence of dual-specificity protein phosphatase 5 on mechanical properties of rat cerebral and renal arterioles.
Inpatient Neurologic Consultation in Solid Organ Transplant Patients.
Mitochondrial Protein PGAM5 Regulates Mitophagic Protection against Cell Necroptosis.
Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism.
Over-expression of DSCR1 protects against post-ischemic neuronal injury.
Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines.
[Kidney transplant: a mere stage of CKD?]
Subarachnoid Hemorrhage
Neuroprotective Effect of Protein Phosphatase 2A/Tristetraprolin Following Subarachnoid Hemorrhage in Rats.
Supranuclear Palsy, Progressive
Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci.
Surgical Wound Infection
Incidence and risk factors of incisional hernia formation following abdominal organ transplantation.
Syndactyly
Prevalence and associated phenotypes of DUSP6, IL17RD and SPRY4 variants in a large Chinese cohort with isolated hypogonadotropic hypogonadism.
Tachycardia, Ventricular
Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts.
Heart block in mice overexpressing calcineurin but not NF-AT3.
Tauopathies
An okadaic acid-induced model of tauopathy and cognitive deficiency.
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.
Memantine mediates astrocytic activity in response to excitotoxicity induced by PP2A inhibition.
Methionine-Mediated Protein Phosphatase 2A Catalytic Subunit (PP2Ac) Methylation Ameliorates the Tauopathy Induced by Manganese in Cell and Animal Models.
Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.
The protein phosphatase PP2A/B? binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: Implications for tauopathies.
Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy.
TDP-43 Proteinopathies
The phosphatase calcineurin regulates pathological TDP-43 phosphorylation.
Telangiectasis
P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Tension-Type Headache
Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms.
Teratocarcinoma
Cloning and expression of a cDNA encoding a novel protein serine/threonine kinase predominantly expressed in hematopoietic cells.
Identification of a third alternatively spliced cDNA encoding the catalytic subunit of protein phosphatase 2B beta.
Inhibition of protein phosphatase PPM1D enhances retinoic acid-induced differentiation in human embryonic carcinoma cell line.
Mammalian protein serine/threonine phosphatase 2C: cDNA cloning and comparative analysis of amino acid sequences.
Protein phosphatase X has been highly conserved during mammalian evolution.
Teratoma
Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratoma.
Tetanus
Enhanced spontaneous transmitter release at murine motor nerve terminals with cyclosporine.
Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
Protein kinase and phosphatase activity regulate the form of synaptic plasticity expressed.
Suppressive effect of preconditioning low-frequency stimulation on subsequent induction of long-term potentiation by high frequency stimulation in hippocampal CA3 neurons.
Tetany
Drug-induced alterations in Mg2+ homoeostasis.
Tetralogy of Fallot
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Thalassemia
The relation between mitogen activated protein kinase (MAPK) pathway and different genes expression in patients with beta Thalassemia.
Thrombasthenia
[Effect of the defect of integrin alpha II b beta 3 on the inside-out signal transduction in platelets]
Thrombocythemia, Essential
[The study of relationship between platelet function and thrombus in patients with essential thrombocythaemia]
Thrombocytopenia
Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Thrombophilia
Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem.
Thrombosis
Branched-Chain Amino Acid Catabolism Promotes Thrombosis Risk by Enhancing Tropomodulin-3 Propionylation in Platelets.
Comparison of denovo sirolimus vs. Calcineurin inhibitor immunosuppression regarding incidence of deep venous thrombosis and pulmonary embolism following renal transplantation.
Egyptian clinical practice guideline for kidney transplantation.
Gene polymorphism of platelet glycoprotein I balpha in Chinese patients with large- and small-artery subtypes of ischemic stroke.
Platelets and capillary injury in acute humoral rejection of renal allografts.
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients.
Safety of mTOR inhibitors in adult solid organ transplantation.
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19.
The catalytic subunit of protein phosphatase 1 gamma regulates thrombin-induced murine platelet alpha(IIb)beta(3) function.
[Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis.]
[Identifying the specific causes of kidney allograft loss: A population-based study].
[The study of relationship between platelet function and thrombus in patients with essential thrombocythaemia]
Thrombotic Microangiopathies
A case of thrombotic microangiopathy caused by oral contraceptives in a kidney transplant recipient.
Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report.
Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.
Conversion from calcineurin inhibitors to sirolimus in transplant-associated thrombotic microangiopathy.
De novo post-transplant thrombotic microangiopathy localized only to the graft in autosomal dominant polycystic kidney disease with thrombophilia.
De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.
De Novo Thrombotic Microangiopathy Immediately After Kidney Transplant in Patients Without Apparent Risk Factors.
De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection.
De Novo Thrombotic Microangiopathy in Renal Transplant Patients.
Diagnosis of de novo localized thrombotic microangiopathy by surveillance biopsy.
Everolimus worsening chronic proteinuria in patient with diabetic nephropathy post liver transplantation.
Glomerular mRNA expression of prothrombotic and antithrombotic factors in renal transplants with thrombotic microangiopathy.
Kidney Pathology after Hematologic Cell Transplantation-A Single-Center Observation Study of Indication Biopsies and Autopsies.
Living-Donor Kidney Transplant-Associated Thrombotic Microangiopathy Successfully Treated With Thymoglobulin: A Case Report.
No Relapse of Calcineurin Inhibitor-Associated Thrombotic Microangiopathy after Discontinuation of Eculizumab.
Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation.
Platelets and capillary injury in acute humoral rejection of renal allografts.
Rapamycin for refractory acute graft-versus-host disease.
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.
Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient.
Tacrolimus associated localized thrombotic microangiopathy developing in early stage after renal transplantation.
Tacrolimus-induced thrombotic microangiopathy: natural history of a severe, acute vasculopathy.
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation.
Thrombotic microangiopathy associated with tacrolimus in lung transplantation.
Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient.
Transplant-associated thrombotic microangiopathy and immune haematological complications following intestine-containing organ transplantation: experience from over 100 consecutive cases.
Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.
Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation.
Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report.
[The Role of Laboratory Medicine in Hematopoietic Stem Cell Transplantation "Echocardiogram"].
Thymoma
Activation of messenger-independent protein kinases in wild-type and phorbol ester-resistant EL4 thymoma cells.
Thymus Neoplasms
Cloning, tissue distribution, subcellular localization and overexpression of murine histidine-rich Ca2+ binding protein.
Thyroid Cancer, Papillary
MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6.
MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Thyroid Carcinoma, Anaplastic
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA.
NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26).
Thyroid Neoplasms
Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Correction to: Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
Long non-coding RNA HOTAIR/microRNA-761 sponge regulates PPME1 and further influences cell biological functions in thyroid carcinoma.
Regulator of calcineurin 1 modulates cancer cell migration in vitro.
Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Tinea
Clinical and mycological analysis of twenty-one cases of tinea incognita in the aegean region of Turkey: a retrospective study.
Genetic and Phenotypic analyses of Calcineurin A subunit in Arthroderma vanbreuseghemii.
Psoriasis-like tinea incognita: a case report and literature review.
Tinea corporis: an updated review.
Tinea Incognita following the Use of an Antipsoriatic Gel.
Tinea incognito due to Trichophyton mentagrophytes: case report.
Tinea incognito in Korea and its risk factors: nine-year multicenter survey.
[A tinea incognito case caused by Trichophyton rubrum with clinical and mycological cure and review of the literature]
Tremor
Completeness of reporting of adverse events in trials of maintenance immunosuppression in kidney transplantation: a systematic review.
Health-related quality of life outcomes after kidney transplantation.
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors.
Neurologic complications after liver transplantation.
Neurologic complications after solid organ transplantation.
Neurologic complications in renal transplantation.
Tacrolimus-Associated Psychotic Disorder: A Report of 2 Cases.
Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy.
Tremor induced by Calcineurin inhibitor immunosuppression: a single-centre observational study in kidney transplanted patients.
Unusual cerebral white matter change in a Chinese family with Spinocerebellar ataxia type 12.
[Neurological complications in renal transplant recipients]
Triple Negative Breast Neoplasms
Aurovertin B exerts potent antitumor activity against triple-negative breast cancer in vivo and in vitro via regulating ATP synthase activity and DUSP1 expression.
DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk.
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Silencing of DUSP6 gene by RNAi-mediation inhibits proliferation and growth in MDA-MB-231 breast cancer cells: an in vitro study.
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
The role of dual?specificity phosphatase 1 and protein phosphatase 1 in ?2?adrenergic receptor?mediated inhibition of extracellular signal regulated kinase 1/2 in triple negative breast cancer cell lines.
Tuberculosis
Abdominal tuberculosis in renal transplant recipient. Presentation of a case and literature review
An alternate conformation and a third metal in PstP/Ppp, the M. tuberculosis PP2C-Family Ser/Thr protein phosphatase.
Calcineurin Inhibitors and Variation in the Performance of Interferon-? Release Assays Used to Detect Tuberculosis Infection.
Egyptian clinical practice guideline for kidney transplantation.
Fever in a transplant recipient: think beyond infection.
First structural glimpse at a bacterial Ser/Thr protein phosphatase.
Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Phosphoprotein phosphatase of Mycobacterium tuberculosis dephosphorylates serine-threonine kinases PknA and PknB.
Phosphorylation of Mycobacterium tuberculosis Ser/Thr Phosphatase by PknA and PknB.
PknB kinase activity is regulated by phosphorylation in two Thr residues and dephosphorylation by PstP, the cognate phospho-Ser/Thr phosphatase, in Mycobacterium tuberculosis.
Protein Phosphatase, Mg2+/Mn2+-dependent 1A controls the innate antiviral and antibacterial response of macrophages during HIV-1 and Mycobacterium tuberculosis infection.
Serine/Threonine Protein Phosphatase PstP of Mycobacterium tuberculosis Is Necessary for Accurate Cell Division and Survival of Pathogen.
Targeting the messengers: Serine/threonine protein kinases as potential targets for antimycobacterial drug development.
The condensing activities of the Mycobacterium tuberculosis type II fatty acid synthase are differentially regulated by phosphorylation.
Treatment of tuberculosis with rifabutin in a renal transplant recipient.
[Advances in the study of Mycobacterium tuberculosis protein phosphatase and its inhibitors].
Tuberous Sclerosis
Identification of proteins interacting with the catalytic subunit of PP2A by proteomics.
Tumor Virus Infections
Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability.
Unverricht-Lundborg Syndrome
Advances in the genetics of progressive myoclonus epilepsy.
Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all.
Uremia
Relationship between the expression levels of CD61, CD63, and PAC-1 on platelet surface in peripheral blood and the transplanted kidney function.
Renal transplantation: basic concepts and evolution of therapy.
[Complications in kidney transplantation]
[The relationship between the peripheral blood of CD61, CD63, PAC-1 and the transplant kidney function]
Ureteral Obstruction
Norcantharidin inhibits renal interstitial fibrosis by downregulating PP2Ac expression.
Urinary Bladder Neck Obstruction
Calcineurin mediates bladder smooth muscle hypertrophy after bladder outlet obstruction.
Calcineurin Mediates Bladder Wall Remodeling Secondary to Partial Outlet Obstruction.
Urinary Bladder Neoplasms
CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.
Deciphering the Roles of Thiazolidinediones and PPAR? in Bladder Cancer.
Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells.
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
miR-186 downregulates protein phosphatase PPM1B in bladder cancer and mediates G1-S phase transition.
Oncogenic role of MIR516A in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy.
Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.
Targeting PPM1D by lentivirus-mediated RNA interference inhibits the tumorigenicity of bladder cancer cells.
Urinary Tract Infections
Calcineurin inhibitor Tacrolimus impairs host immune response against urinary tract infection.
Recent advances in new-onset diabetes mellitus after kidney transplantation.
Urolithiasis
Egyptian clinical practice guideline for kidney transplantation.
Extracorporeal shock wave lithotripsy of impacted radiolucent stone at the right pyeloureteric junction and oral dissolution therapy in a patient with transplanted liver: a case report.
Urologic Diseases
[Identifying the specific causes of kidney allograft loss: A population-based study].
Urticaria
Calcineurin inhibitors in chronic urticaria.
Uterine Cervical Neoplasms
Human papillomavirus (HPV) oncoprotein E6 facilitates Calcineurin-Nuclear factor for activated T cells 2 (NFAT2) signaling to promote cellular proliferation in cervical cell carcinoma.
Knockdown of Wip1 Enhances Sensitivity to Radiation in HeLa Cells Through Activation of p38 MAPK.
Long non-coding RNA ARAP1-AS1 promotes the proliferation and migration in cervical cancer through epigenetic regulation of DUSP5.
Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer.
Production of DUSP1 protein using the baculovirus insect cell expression system and its in vitro effects on cancer cells.
Synergistic cytotoxic effect between serine-threonine phosphatase inhibitors and 5-fluorouracil: a novel concept for modulation of cytotoxic effect.
Volume-sensitive KCI cotransport associated with human cervical carcinogenesis.
Uterine Neoplasms
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Uveitis
A Review of the Course and Treatment of Non-Infectious Uveitis during Pregnancy.
Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.
Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases.
The role of biologic agents in the management of non-infectious uveitis.
Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
[Systemic voclosporin for uveitis treatment]
Uveitis, Posterior
Mycophenolate mofetil use in the treatment of noninfectious uveitis.
Vaccinia
A protein phosphatase related to the vaccinia virus VH1 is encoded in the genomes of several orthopoxviruses and a baculovirus.
A Tyr/Ser protein phosphatase encoded by vaccinia virus.
A yeast protein phosphatase related to the vaccinia virus VH1 phosphatase is induced by nitrogen starvation.
Bacterial and viral protein tyrosine phosphatases.
Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR.
Fluorogenic peptide substrates for serine and threonine phosphatases.
Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.
Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54jnk.
Mutational and kinetic evaluation of conserved His-123 in dual specificity protein-tyrosine phosphatase vaccinia H1-related phosphatase: participation of Tyr-78 and Thr-73 residues in tuning the orientation of His-123.
Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability.
PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase.
The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro.
Tyrosine phosphorylation of VHR phosphatase by ZAP-70.
Vaccinia protein kinase 2: a second essential serine/threonine protein kinase encoded by vaccinia virus.
Vascular Diseases
Discovery and Characterization of Halogenated Xanthene Inhibitors of DUSP5 as Potential Photodynamic Therapeutics.
Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation.
Vascular System Injuries
Cellular mechanisms of vascular injury mediated by calcineurin inhibitors.
Vascular injury mediated by calcineurin inhibitors: contribution of rheological factors?
Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5'-monophosphate-activated protein kinase/mammalian target of rapamycin complex 1 pathway.
Vasculitis
Bacterial superantigen TSST-1 attenuates suppressive efficacy of glucocorticoids and calcineurin inhibitors against blastogenesis of peripheral blood mononuclear cells from patients with antineutrophil cytoplasmic antibody-associated vasculitis and nephrosis.
Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus.
Venous Thrombosis
Comparison of denovo sirolimus vs. Calcineurin inhibitor immunosuppression regarding incidence of deep venous thrombosis and pulmonary embolism following renal transplantation.
Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation.
Ventricular Dysfunction
A preliminary study of platelet hyperactivity in the chronic indeterminate phase of Chagas' disease.
Ventricular Fibrillation
Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts.
Vesico-Ureteral Reflux
Clinicopathological Analysis of Medullary Ray Injury in 1-Year Protocol Paediatric Renal Allograft Biopsies.
Vesicular Stomatitis
PGAM5-MAVS interaction regulates TBK1/ IRF3 dependent antiviral responses.
PPP6C Negatively Regulates STING-Dependent Innate Immune Responses.
Viremia
A single-center experience of overseas kidney transplant for immunologically high-risk patients.
Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor.
BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results.
Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.
Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature.
Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients.
Hepatitis C infection in liver transplantation.
Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction.
Natural history of hepatitis C and outcomes following liver transplantation.
Progression from Sustained BK Viruria to Sustained BK Viremia with Immunosuppression Reduction Is Not Associated with Changes in the Noncoding Control Region of the BK Virus Genome.
Resurgence of BK virus following Covid-19 in kidney transplant recipients.
[Treatment of recurrent HCV infection after liver transplantation]
[Treatment of recurrent HCV infection after liver transplantation].
[Treatment of recurrent hepatitis C infection after liver transplantation]
Virus Diseases
A case of thrombotic microangiopathy caused by oral contraceptives in a kidney transplant recipient.
Accompanying renal injuries did not impact graft survival in patients with transplant glomerulopathy.
Acute demyelinating polyneuropathy after lung transplantation: guillain-barré syndrome or tacrolimus toxicity?
An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome).
Anemia in solid organ transplantation.
Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha.
Cancer and mTOR inhibitors in Transplant Recipients.
Clinical-pathological correlations in post-transplant thrombotic microangiopathy.
Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.
CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
Comparison of expression profiles induced by dust mite in airway epithelia reveals a common pathway.
Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
Currently available useful immunohistochemical markers of renal pathology for the diagnosis of renal allograft rejection.
Diagnosis and prevention of chronic kidney allograft loss.
Dual Specificity Phosphatase 5 Is Essential for T Cell Survival.
DUSP1 regulates apoptosis and cell migration, but not the JIP1-protected cytokine response, during Respiratory Syncytial Virus and Sendai Virus infection.
Epigenome-wide effects of vitamin D on asthma bronchial epithelial cells.
Expression of calcineurin activity after lung transplantation: a 2-year follow-up.
Guillain-Barre syndrome: a typical paraneoplastic syndrome in a kidney transplant recipient with allograft renal cell carcinoma: a case report and review of the literature.
Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6.
Herpes viruses and tumours in kidney transplant recipients. The role of immunosuppression.
Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.
Measles Virus Infection Inactivates Cellular Protein Phosphatase 5 with Consequent Suppression of Sp1 and c-Myc Activities.
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.
Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation.
Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation.
PGAM5-MAVS interaction regulates TBK1/ IRF3 dependent antiviral responses.
PPM1D silencing by lentiviral-mediated RNA interference inhibits proliferation and invasion of human glioma cells.
Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor.
Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hematopoietic stem cell transplantation.
Risk assessment and management of post-transplant diabetes mellitus.
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report.
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management.
The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen.
The multiple functions of protein phosphatase 6.
The pathogenesis and treatment of chronic allograft nephropathy.
The utility of cytodiagnostic urinalysis as a tool to diagnose kidney allograft dysfunction in the era lymphocyte-depleting induction therapy.
Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
Thrombotic microangiopathy after kidney transplantation.
Vaccinia Virus Protein C6 Inhibits Type I IFN Signalling in the Nucleus and Binds to the Transactivation Domain of STAT2.
[Outcome of renal transplantation after tacrolimus switch to cyclosporine].
Vision Disorders
Posterior reversible encephalopathy syndrome in children with kidney disease.
Vitamin A Deficiency
Moderate maternal vitamin A deficiency alters myogenic regulatory protein expression and perinatal organ growth in the rat.
Vitamin D Deficiency
25-Hydroxy Vitamin D Deficiency Following Pediatric Hematopoietic Stem Cell Transplant.
CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health.
New-Onset Diabetes after Kidney Transplantation.
Prevalence of vitamin D deficiency in post renal transplant patients.
The Association of 25-Hydroxyvitamin D Levels with Late Cytomegalovirus Infection in Kidney Transplant Recipients: the Wisconsin Allograft Recipient Database (WisARD).
Vitiligo
308nm excimer lamp monotherapy for lip vitiligo-a short case series.
A multi-center, randomized, split face and/or neckcomparisonof 308-nm excimer laser and0·1%tacrolimus ointmentfor stable vitiligo, plus intramuscular slow releasing betamethasone for active vitiligo.
A pilot study of 1% pimecrolimus cream for the treatment of childhood segmental vitiligo.
A review of monochromatic excimer light in vitiligo.
Are vitiligo treatments cost-effective? A systematic review.
Childhood Vitiligo.
Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: A single blind, randomised clinical trial.
Consensus on the treatment of vitiligo - Brazilian Society of Dermatology.
Different Advanced Therapeutic Approaches to Treat Vitiligo.
Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis.
Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis.
Effectiveness of Topical Corticosteroid, Topical Calcineurin Inhibitors and Combination of Them in the Treatment of Vitiligo.
Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study.
Efficacy of the Topical Calcineurin Inhibitors Tacrolimus and Pimecrolimus in the Treatment of Vitiligo in Infants Under 2 Years of Age: A Randomized, Open-Label Pilot Study.
Efficacy of topical calcineurin inhibitors in vitiligo.
New treatment modalities for vitiligo: focus on topical immunomodulators.
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Pigmentation Disorders: Diagnosis and Management.
Pimecrolimus increases the melanogenesis and migration of melanocytes in vitro.
Potential new indications of topical calcineurin inhibitors.
Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
Successful Treatment of Vitiligo Associated with Vogt-Koyanagi-Harada Disease.
The effectiveness of topical calcineurin inhibitors comparing with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis.
The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs).
The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.
The rationality involved in the popular use of coffee (Coffea sp) and sunflower seed (Helianthus annuus) for the treatment of vitiligo: a case report.
Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo.
Topical pimecrolimus for skin disease other than atopic dermatitis.
Topical pimecrolimus in the treatment of vitiligo.
Topical treatment and combination approaches for vitiligo: new insights, new developments.
Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis.
Update on childhood vitiligo.
Update on skin repigmentation therapies in vitiligo.
Vitiligo, From Physiopathology to Emerging Treatments: A Review.
Vitiligo: an update on systemic treatments.
Vitiligo: An Updated Narrative Review.
Vulvar Lichen Sclerosus
An arm-based network meta-analysis on treatments for vulvar lichen sclerosus and a call for development of core outcome sets: Treatment options for vulvar lichen sclerosus.
Calcineurin antagonists in vulvar lichen sclerosus.
[Topical treatment of vulvar lichen sclerosus with calcineurin inhibitors].
Vulvitis
Anti-inflammatory treatment.
Successful treatment of plasma cell cheilitis with topical tacrolimus: Report of two cases.
Therapeutic efficacy of topical calcineurin inhibitors in plasma cell balanitis: case series and review of the literature.
WAGR Syndrome
Unique Utilization of a Phosphoprotein Phosphatase Fold by a Mammalian Phosphodiesterase Associated with WAGR Syndrome.
Warts
Induction of Suicidal Erythrocyte Death by Cantharidin.
The natural anticancer agent cantharidin alters GPI-anchored protein sorting by targeting Cdc1-mediated remodeling in endoplasmic reticulum.
Whooping Cough
A novel role for protein phosphatase 2A in receptor-mediated regulation of the cardiac sarcolemmal Na+/H+ exchanger NHE1.
Angiotensin II type 2 receptor stimulation of neuronal delayed-rectifier potassium current involves phospholipase A2 and arachidonic acid.
Exposure of astrocytes to thrombin reduces levels of the metabotropic glutamate receptor mGluR5.
Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview.
Imidazoline NNC77-0074 stimulates insulin secretion and inhibits glucagon release by control of Ca(2+)-dependent exocytosis in pancreatic alpha- and beta-cells.
Modulation by angiotensin II of isoproterenol-induced cAMP production in preglomerular microvascular smooth muscle cells from normotensive and genetically hypertensive rats.
Pertussis toxin modification of PC12 cells inhibits a protein phosphatase 2A-like phosphatase.
Regulation of dopamine D-receptor activation in vivo by protein phosphatase 2B (calcineurin).
Signaling pathways involved in DNA synthesis and migration in response to lysophosphatidic acid and low-density lipoprotein in coronary artery smooth muscle cells.
Synthetic peptides based on the calmodulin-binding domain of myosin light chain kinase inhibit activation of other calmodulin-dependent enzymes.
The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5.
The imidazoline NNC77-0020 affects glucose-dependent insulin, glucagon and somatostatin secretion in mouse pancreatic islets.
Tyrosine phosphorylation induced by cross-linking of Fc gamma-receptor type II in human neutrophils.
Williams Syndrome
Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway.
Wilms Tumor
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
Wolfram Syndrome
Identification and characterization of wolframin, the product of the wolfram syndrome gene (WFS1), as a novel calmodulin-binding protein.
Wound Infection
Nosocomial infection in kidney transplant recipients: a retrospective analysis of a single-center experience.
Xeroderma Pigmentosum
Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.
Zygomycosis
Emerging importance of infections due to zygomycetes in organ transplant recipients.